Synthesis, Surface Functionalization, and Biological Testing of Iron Oxide Nanoparticles for Development as a Cancer Therapeutic by Gilliland, Stanley E, III
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2015
Synthesis, Surface Functionalization, and Biological
Testing of Iron Oxide Nanoparticles for
Development as a Cancer Therapeutic
Stanley E. Gilliland III
Virginia Commonwealth University, gillilandse@mymail.vcu.edu
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Inorganic Chemistry Commons, Materials Chemistry Commons, and the
Nanomedicine Commons
© The Author
This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in
Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/4024
  
Stanley E. Gilliland III 2015 
All Rights Reserved
  
 
 
 
Synthesis, Surface Functionalization, and 
Biological Testing of Iron Oxide 
Nanoparticles for Development as a Cancer 
Therapeutic  
 
A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University. 
 
 
 
 
 
 
By 
Stanley Eugene Gilliland III 
Bachelor of Science 
James Madison University  
December 2015 
 
 
 
 
 
 
Director: Dr. Everett E. Carpenter 
Professor, Department of Chemistry 
Co-Director: Dr. Michael D. Shultz 
Research Biologist - McGuire VA Medical Center  
& Adjunct Faculty, Department of Chemistry 
 
 
 
 
 
 
Virginia Commonwealth University
i 
 
 
 
 
Richmond, Virginia 
December 2015 
  
Acknowledgment 
 While working towards my PhD in Nanoscience and Nanotechnology I received 
exceptional support, help and advice from numerous people. First, I would like to thank my 
beautiful wife Ruthie and our daughter Emily for their unwavering support and affection. Ruthie 
has always given me confidence to achieve my goals. Our daughter Emily was born in May 2013 
and has been a source of rejuvenation and laughter which has made the writing of this 
dissertation so much easier. I would also like to give thanks to my family that has always been 
encouraging and supportive in all of my life’s endeavors. 
 I have received invaluable advising for the Nanoscience and Nanotechnology PhD 
program, research, and career advice from Dr. Carpenter. Dr. Shultz, my co-advisor, has always 
been optimistic about all aspects of the research and has given great advice and inspiration for 
the research project and for career and life decisions. My committee members and the VCU 
Chemistry Department all deserve my appreciation for allowing me the opportunity to study and 
research this interesting topic. My lab mates ‘across town’ have always been helpful in my 
research and teaching me new research techniques. I would like to specifically thank Zach Huba 
for teaching me so many techniques, Dustin Clifford for helping with TEM imaging, and Sarah 
Smith for running and analyzing XPS data and running so many TGA samples. Lastly, I would 
like to thank the VCU Nanomaterials Core Characterization Facility and Hunter Holmes 
McGuire VA Medical center, as none of this research would have been possible without access 
to these facilities. 
 
 
 
 
 
   
ii 
 
 
 
 
 
 
 
Table of Contents 
 
 
 
List of Tables ................................................................................................................................. iv 
List of Figures ................................................................................................................................ vi 
List of Abbreviations ................................................................................................................... xiii 
Abstract ....................................................................................................................................... xvii 
 
Chapter 1: Introduction and Background ...................................................................................... 1 
1.1Radiofrequency Induced Hyperthermia: Treatment of Cancer ...................................... 1 
1.2 Néel and Brownian Relaxation Mechanisms ................................................................ 3 
1.3 Iron Oxide Nanoparticles for Magnetic Hyperthermia: Ideal Properties and 
Challenges to Overcome ................................................................................................7  
1.3.1 Colloidal Stability  ........................................................................................10 
1.3.2 Biological Challenges for Surface Functionalization  ..................................16 
1.3.3 Chemical Challenges for Surface Functionalization ....................................19 
1.4 Methods of Synthesizing Iron Oxides......................................................................... 20 
1.5 Benzyl Alcohol Synthesis of Metal Oxides ................................................................ 22 
1.6 Surface Functionalization of nanoparticles for Biological Applications .....................23 
1.6.1 Carboxymethylated Polyvinyl Alcohol Surface Functionalization ..............24 
1.6.2 Organosilane Surface Functionalization .......................................................24 
1.7 Project Overview .........................................................................................................26 
Chapter 2: Iron Oxide Nanoparticles ...........................................................................................28 
2.1 Iron Oxides in Nanotechnology ...................................................................................28 
2.2 Iron Oxide Crystal Structures ..................................................................................... 29 
2.2.1 Magnetite Crystal Structure ......................................................................... 30 
2.2.2 Maghemite Crystal Structure ....................................................................... 33 
2.2.3 Hematite Crystal Structure ........................................................................... 33 
2.2.4 Wüstite Crystal Structure ............................................................................. 34 
2.3 Magnetic Properties of Iron Oxide ............................................................................. 35 
Chapter 3: Benzyl Alcohol Synthesis of Iron Oxide Nanoparticles ........................................... 38 
3.1 Experimental Section .................................................................................................. 38 
3.1.1 Reagents, Materials, and Equipment ........................................................... 38 
3.1.2 Modified Seed Growth of Iron Oxide Nanoparticles ................................... 38 
3.2 Characterization Techniques ....................................................................................... 40 
3.2.1 X-ray Diffraction (XRD) ............................................................................. 40 
3.2.2 Dynamic Light Scattering (DLS) ................................................................. 42 
3.2.3 Vibrating Sample Magnetometry (VSM) ...................................................  46 
3.2.4 Thermal Gravimetric Analysis (TGA) ......................................................... 47 
3.2.5 Transmission Electron Microscopy (TEM) ................................................. 48 
3.2.6 Radiofrequency Heating .............................................................................. 48 
iii 
 
 
 
3.3 Results and Discussion ............................................................................................... 50 
3.3.1 Investigation of Synthesis Parameters ......................................................... 50 
3.3.2 Effect of Reaction Environment .................................................................. 56 
3.3.3 Effect of Reaction Time ............................................................................... 61 
3.3.4 Effect of Reaction Temperature ................................................................... 64  
3.3.5 Effect of Reaction Concentration................................................................. 70 
3.3.6 Examination of Radiofrequency Induced Heating Properties ..................... 77 
Chapter 4: Surface Functionalization of Benzyl Alcohol Synthesized Iron Oxide    
Nanoparticles ..............................................................................................................85 
4.1 Experimental Section .................................................................................................. 85 
4.1.1 Reagents, Materials, and Equipment ........................................................... 85 
4.1.2 Synthesis of Carboxymethylated Polyvinyl Alcohol (CMPVA) ................. 86 
4.1.3 Surface Functionalization with CMPVA ..................................................... 87 
4.1.4 Surface Functionalization with APTS or APTES ........................................ 88  
4.1.5 Surface Functionalization with GLYMO and Base Catalyzed Epoxide Ring 
Opening with Nucleophiles.......................................................................... 89 
4.1.6 EDC Coupling DOTA Chelate and Radiolabeling ...................................... 91 
4.2 Characterization Techniques ....................................................................................... 92 
4.2.1 Fourier Transform Infrared (FTIR) Attenuated Total Reflectance (ATR) 
Spectroscopy  ............................................................................................. 92 
4.2.2 X-ray Photoelectron Spectroscopy (XPS) ................................................... 93 
4.2.3 High-Performance Liquid Chromatography (HPLC) .................................. 93 
4.3 CMPVA Discussion .................................................................................................... 94 
4.3.1 Surface Functionalization and Optimization for Biostability ...................... 94 
4.4 Silane Surface Functionalization of Iron Oxide Nanoparticles ................................ 109 
4.5 Stability Assessment in Different Biologically Relevant Medium ........................... 131 
4.6 Iron Oxide Nanoplatform: Confirming Conjugation Potential with a   
Radiotherapeutic ........................................................................................................146 
Chapter 5: Biological Testing of Surface Functionalized Iron Oxide Nanoparticles ............... 154 
5.1 Experimental Section ................................................................................................ 154 
5.1.1 Reagents, Materials, and Equipment ......................................................... 154 
5.1.2 Tissue Culture and Cellular Uptake Studies .............................................. 155 
5.1.3 WST-1 Cell Proliferation Assays................................................................155 
5.1.4 U87MG Glioblastoma Tumor Implantation  ............................................. 157 
5.1.5 U87MG Glioblastoma Tumor Implantation  ..............................................158 
5.1.6 Radioactivity Dose Preparation and Survival Study .................................. 158 
5.1.7 Statistical Analysis ..................................................................................... 160 
5.2 Cellular Uptake, Proliferation, and IC50 investigation .............................................. 160 
5.3 Hyperthermia Cell Proliferation ............................................................................... 165 
5.4 Survival Study- Iron Oxide nanoparticle 
177
Lu Brachytherapy Investigation .......... 168 
Chapter 6: Conclusion ............................................................................................................... 174 
References .................................................................................................................................. 178 
Appendix .....................................................................................................................................199 
Vita ............................................................................................................................................. 214 
  
iv 
 
 
 
 
 
List of Tables 
 
 
 
Chapter 2. 
 
Table 2.1. The mineral name and formula for the sixteen known pure phase iron oxides 
subcategorized into iron oxide, iron hydroxide and iron oxide-hydroxide. 
Reproduced from 
1
 ......................................................................................................30 
 
Table 2.2. Properties of magnetite, maghemite, hematite and wüstite. Reproduced from 
1
 .........32 
 
Chapter 3. 
 
Table 3.1. Initial hydrodynamic diameters and PDI values for various v/v % concentration 
of TMAOH. ................................................................................................................45 
 
Table 3.2. The DLS determine hydrodynamic size, percent composition, and width of each 
peak for the size distribution by percent intensity and size distribution by 
percent volume for reaction A2-24(195)_B2-24(195). ..............................................53 
 
Table 3.3. Effect of various temperatures in reactions under nitrogen flow on nanoparticle 
properties ....................................................................................................................62 
 
Table 3.4. Effect of various temperatures in reactions open to air on nanoparticle properties .... 63 
 
Table 3.5. Effect of various concentrations of Fe(acac)3 on nanoparticle properties ...................66 
 
Table 3.6. Effect of various temperatures in the modified seed growth on nanoparticle 
properties ....................................................................................................................71 
 
Table 3.7. Effect of various Fe(acac)3 concentrations in the modified seed growth on 
nanoparticle properties ...............................................................................................75 
 
Table 3.8. Effect of various Fe(acac)3 concentrations, temperatures, and reaction 
environment on nanoparticle properties. Reactions are grouped by their 
reaction environment: nitrogen (blue) and open to air (green). .................................78 
 
Table 3.9. List of seed growth syntheses and nanoparticle properties used in the effect 
screening and predicted model ...................................................................................81 
 
v 
 
 
 
Table 3.10. Effect screening of crystallite size, hydrodynamic diameter, PDI, 
magnetization saturation, and volume CS/HS on RF heating ....................................82 
 
Table 3.11. ANOVA results for the predicted model effect of significant nanoparticle 
properties on RF heating. ...........................................................................................83 
 
Table 3.12. Parameter estimates for the model fit least squares of significant nanoparticle 
properties effecting RF heating ..................................................................................83 
 
Table 3.13. Predicted and actual RF heating values .....................................................................83 
 
Chapter 4. 
 
Table 4.1. Initial hydrodynamic diameters and PDI values for various v/v % concentration 
of TMAOH ................................................................................................................ 97 
 
Table 4.2. Values of nanoparticle properties calculated using crystallite and hydrodynamic 
diameter ....................................................................................................................103 
 
Table 4.3. Total number and surface area of nanoparticles in 10 mg are shown based on 
different crystallite and hydrodynamic diameters. The ratio of the number of 
CMPVA molecules to both nanoparticles and total surface area are also shown ....103 
 
Table 4.4. List of identifying FTIR-ATR peaks surface functionalized iron oxide 
nanoparticles .............................................................................................................118 
 
Table 4.5. DLS measurements of hydrodynamic diameter, polydispersity index, and Zeta 
potential for surface functionalized iron oxide nanoparticles ..................................125 
 
Table 4.6. List of first signs of instability of various surface functionalized iron oxide 
nanoparticles; indicated by a cloudy or precipitated solution ..................................133 
  
vi 
 
 
 
 
 
 
 
 
List of Figures 
 
 
Chapter 1. 
 
Figure 1.1. Illustration of Néel (A) and Brownian (B) mechanisms in response to an 
alternating current magnetic field. The dashed arrow represents either the 
internal magnetic spins (A) or the entire nanoparticle (B) rotating in response 
to a 180° magnetic field direction change ..................................................................4 
 
Figure 1.2. A) Electrostatic, B) steric, or C) electrosteric colloidal stabilization of 
nanoparticles provided by surface charge properties, surface ligands, or 
charged surface ligands respectively ........................................................................11 
 
Figure 1.3. Scheme of the electrostatic double layer of small positively charged solid 
particle in an ionic liquids. The double layer is comprised of the positively 
charged (blue circle with + inside) surface layer and the surrounding 
negatively charged (red circle with – inside) layer (Stern layer). This is 
encompassed by a diffuse layer of equal positive and negative charges (Guoy 
layer) .........................................................................................................................12 
 
Figure 1.4. Graph illustrating interparticle potentials for stable dispersions (solid line), 
flocculated  dispersions (dotted line), and aggregated dispersions (dashed line) .....14 
 
Chapter 2. 
 
Figure 2.1. Diagram showing the side view and top view of wüstite (a), magnetite (b), and 
hematite(c). Two top views are shown for magnetite and hematite to visualize 
the different layers of the crystal structure. From 
2
 ................................................. 31 
 
Figure 2.2. Representative hysteresis loop for single domain ferromagnetic (a) and 
superparamagnetic (b) crystals plotted as magnetization (M) versus magnetic 
field (H). MS, Mr, and Hc correspond to magnetization saturation, remnant 
magnetization, and coercive field respectively. From 
168
 ........................................ 36 
 
Chapter 3. 
 
Figure 3.1. XRD peaks of samples: N2-A2-24 (blue), A2-24 (red), and A2-24_B2-24 
(green). An offset of 100 count increments was used to clearly show each 
reactions pattern ........................................................................................................52 
 
vii 
 
 
 
Figure 3.2. The DLS hydrodynamic size measurements displayed in terms of percent 
intensity (A) and percent volume (B) for reaction A2-24(195)_B2-24(195). 
The Z-average hydrodynamic diameter was equal to 47.75 nm and the PDI 
was equal to 0.219.....................................................................................................53 
 
Figure 3.3. VSM measured hysteresis loop of TGA mass corrected (10.901 mg * 0.945164 
= 10.303 mg) A2-24(195)_B2-24(195) nanoparticles ..............................................54 
 
Figure 3.4. TGA of A2-24(195)_B2-24(195) nanoparticles revealing a final mass percent 
of 0.945164 at 400°C ................................................................................................55 
 
Figure 3.5. RF heating curves of water and iron oxide samples dispersed in 0.25% 
TMAOH. Prussian Blue assay determined the iron concentrations for 
deionized water (blue), A2-24 under nitrogen (green), A2-24 (red), A2-
24_B2-24 (purple), and A2-24(195)_B2-24(195) (black) to be 0, 14.48, 15.40, 
14.00, and 15.36 mg/mL respectively. Temperature was recorded every 1.4 
seconds in an alternating magnetic field set at 175.4 A for 600 seconds or until 
reaching approximately 70°C ...................................................................................56 
 
Figure 3.6. Heating curves for reaction of Fe(acac)3 in Benzyl Alcohol heated to 175°C 
under nitrogen (A), and air (B). Heating curves for reaction containing FeCl2, 
NaOH, and Benzyl Alcohol heated to 150°C under nitrogen flow (C), and air 
(D). For reactions under nitrogen the initial and final color changes are 
indicated with a gold and black square. Likewise, the color changes are 
indicated with a gold and black diamond for reactions open to air ..........................59 
 
Figure 3.7. XRD peak patterns for benzyl alcohol, FeCl2, and NaOH under nitrogen flow 
(blue), and open to air (red) offset by 5000 intensity counts. NaCl was 
indicated by peaks at 32.5 and 46.2 angles. It was determined that the reaction 
under nitrogen and open to air contained 71% and 77% NaCl respectively ............60 
 
Figure 3.8. LaMer growth model scheme, displaying the generation of monomers, self-
nucleation, and growth phases.  Adapted from 
3
 ..................................................... 65 
 
Figure 3.9. Proposed effect of increasing temperature and concentrations of precursor on 
LaMer growth model (blue). The red curve represents the proposed effects of 
increasing either temperature or concentration. The green curve represents the 
proposed effect of increasing both temperature and concentration ......................... 68 
 
Figure 3.10. Proposed effect of increasing temperature and concentrations of precursor on 
LaMer growth model (blue). The red curve represents the proposed effects of 
increasing both temperature and concentration. The green curve represents the 
proposed effect of increasing both temperature and concentration when a 
maximum generation of monomers has been reached resulting in prolonged 
nucleation ................................................................................................................. 69 
 
viii 
 
 
 
Figure 3.11. TEM bright field image A2-24_B2-24 nanoparticles dispersed with TMAOH. 
Image J software determined an average particle diameter of 15.28 ± 2.21 nm ......72 
 
Figure 3.12. Hysteresis curve for reaction A2-24(205)_B2-24(205). Inset shows the 
remnant magnetization and coercivity is non-zero ...................................................74 
 
Figure 3.13. Plots comparing nanoparticle properties with reactions under nitrogen and 
open to air indicated by blue diamonds and green triangles respectively. (A, 
B) Plots of crystallite size versus Ms and RF heating. (C, D) Plots of 
hydrodynamic diameter versus Ms and RF heating. (E) Plot showing Ms 
versus RF heating. (F) Plot of polydispersity index versus RF heating....................79 
 
Figure 3.14. Plots comparing PDI versus crystallite size (A) and hydrodynamic diameter 
versus crystallite size (B) for reactions under nitrogen and open to air 
indicated by blue diamonds and green triangles respectively ...................................80 
 
Figure 3.15. The actual vs predicted RF heating fit of the model of crystallite size, PDI, 
and volume CS/HS on RF heating ............................................................................82 
 
Chapter 4. 
 
Figure 4.1. The FTIR spectra shown as % transmittance vs wavenumber is shown with 
polyvinyl alcohol in blue, and carboxymethylated polyvinyl alcohol in red. 
Peaks at 1640, 1583 and 1417 indicate the presence of carboxylate anion and 
the peak at 1089 cm
-1
 indicates the ether group. Polyvinyl acetate presence 
was indicated by peak at 1730 cm
-1
. The disappearance of the 1730 cm
-1
 peak 
and appearance of peaks at 1600 and 1417 cm
-1
 are indicative of acetate 
groups being replaced by carboxylate ion groups in CMPVA .................................95 
 
Figure 4.2. DLS hydrodynamic size measurements at 4 steps throughout the surface 
functionalization process with CMPVA based on several TMAOH 
concentrations. The concentrations of TMAOH used were (A) 0.0625% 
TMAOH, (B) 0.125% TMAOH, (C) 0.25% TMAOH, and (D) 0.5%. The four 
steps when aliquots were taken are listed in order: before and after a 30k 
MWCO centrifuge filter and 1
st
 and 2
nd
 elution fractions from a PD-10 
desalting column. Small, medium, and large hydrodynamic diameters 
correspond to inadequately functionalized (red), adequately functionalized 
(blue), or aggregated nanoparticles (green) ..............................................................98 
 
Figure 4.3. Solutions of CMPVA (blue) and iron oxide nanoparticles with CMPVA (red) 
titrated with 6.25% TMAOH. Several markers indicate solution pH when 
TMAOH concentrations used in the DLS study were reached .................................99 
 
 
 
ix 
 
 
 
Figure 4.4. DLS hydrodynamic size measurements based on volume for different CMPVA 
concentrations based on total number of nanoparticles (A) (11.5 mg/mL 
CMPVA) or surface area (B) (16.6 mg/mL) in 10 mg of iron oxide 
nanoparticles at various steps in the clean-up process. Depending on the 
hydrodynamic size the volume population of nanoparticles were labelled as 
either functionalized (blue), partially functionalized (red), or aggregated 
(green) nanoparticles. The four steps when aliquots were taken are listed in 
order: before and after a 30k MWCO centrifuge filter and 1
st
 and 2
nd
 elution 
fractions from a PD-10 desalting column ...............................................................105 
 
Figure 4.5. FTIR-ATR spectra of A) iron oxide nanoparticles and B) water .............................107 
 
Figure 4.6. Normalized FTIR-ATR spectra of CMPVA iron oxide nanoparticle aqueous 
solution with water subtracted ................................................................................108 
 
Figure 4.7. DLS hydrodynamic diameter by volume percentage for CMPVA iron oxide 
nanoparticles ...........................................................................................................108 
 
Figure 4.8. Zeta potential measurement of CMPVA surface functionalized iron oxide 
nanoparticles .......................................................................................................... 109 
 
Figure 4.9. Visual aqueous stability assessment at pH=7.4 in presence of a magnet of 
several nucleophilic ligands used to open the GLYMO epoxy ring. Aqueous 
stability was indicated by a clear brown top solution as seen in Gly-FeOx and 
Ser-FeOx. From left to right: Lys-FeOx, Gln-FeOx, Gly-FeOx, Ser-FeOx, 
Arg-FeOx, and Cys-FeOx ...................................................................................... 111 
 
Figure 4.10. FTIR-ATR spectra with normalized percent transmittance for A) APTS-FeOx 
and B) APTES-FeOx with water subtracted .......................................................... 114 
 
Figure 4.11. FTIR-ATR spectra with normalized percent transmittance for A) Gly-FeOx 
and B) Ser-FeOx with water subtracted ..................................................................115 
 
Figure 4.12. FTIR-ATR spectra with normalized percent transmittance for A) EDA-FeOx 
and B) TEPA-FeOx with water subtracted .............................................................116 
 
Figure 4.13. FTIR-ATR spectra with normalized percent transmittance for A) ABA-FeOx 
and B) SAHBA-FeOx with water subtracted..........................................................117 
 
Figure 4.14. Normalized FTIR-ATR spectrum of GLYMO-FeOx (blue line) and SAHBA-
FeOx (red line). Epoxy ring opening with SAHBA is indicated by 
disappearance of peaks at 1250 and 740-850 cm
-1
 and appearance of peaks at 
1581 and 1416 cm
-1
 .................................................................................................118 
 
Figure 4.15. High-resolution Fe 3p XPS spectrum of FeOx nanoparticles without surface 
modification ............................................................................................................118 
x 
 
 
 
 
Figure 4.16. XPS survey spectrum, and high resolution Fe 2p, and O 1s spectra of FeOx 
nanoparticles without surface modification ............................................................120 
 
Figure 4.17. XPS high-resolution Si 2p, N 1s, and O 1s spectra of APTS-FeOx 
nanoparticles ...........................................................................................................122 
 
Figure 4.18. XPS high-resolution Si 2p, N 1s, and O 1s spectra of Ser-FeOx nanoparticles .....123 
 
Figure 4.19. XPS high-resolution Si 2p, N 1s, and O 1s spectra of Ser-FeOx nanoparticles .....123 
 
Figure 4.20. DLS measurements based on volume percent for A) APTS-FeOx and B) 
APTES-FeOx ..........................................................................................................125 
 
Figure 4.21. DLS measurements based on volume percent for A) Gly-FeOx and B) Ser-
FeOx ........................................................................................................................126 
 
Figure 4.22. DLS measurements based on volume percent for A) ABA-FeOx and B) 
SAHBA-FeOx .........................................................................................................127 
 
Figure 4.23. DLS measurements based on volume percent for A) EDA-FeOx and B) 
TEPA-FeOx ............................................................................................................127 
 
Figure 4.24. Zeta potential measurement of A) Gly-FeOx and B) Ser-FeOx nanoparticles ......129 
 
Figure 4.25. Zeta potential measurement of A) ABA-FeOx and B) SAHBA-FeOx 
nanoparticles ...........................................................................................................129 
 
Figure 4.26. Zeta potential measurement of A) APTS-FeOx and B) APTES-FeOx 
nanoparticles ...........................................................................................................130 
 
Figure 4.27. Zeta potential measurement of A) EDA-FeOx and B) TEPA-FeOx 
nanoparticles ...........................................................................................................131 
 
Figure 4.28. Time study of surface functionalized iron oxide nanoparticle stability in water 
(H2O) and 1x phosphate buffered saline (PBS). Clear, cloudy, or aggregated 
precipitations indicate stable, partially stable, or complete instability 
respectively .............................................................................................................134 
 
Figure 4.29. Time study of surface functionalized iron oxide nanoparticle stability in 0.5x 
PBS and 0.9% sodium chloride (saline). Clear, cloudy, or aggregated 
precipitations indicate stable, partially stable, or complete instability 
respectively .............................................................................................................136 
 
Figure 4.30. DLS hydrodynamic size measurements of APTS-FeOx (A) or APTES-FeOx 
(B) after 1 (Top) and 12 days (Bottom) ..................................................................137 
xi 
 
 
 
 
Figure 4.31. Time study of surface functionalized iron oxide nanoparticle stability in 
artificial cerebral spinal fluid (CSF). Clear, cloudy, or aggregated 
precipitations indicate stable, partially stable, or complete instability 
respectively .............................................................................................................138 
 
Figure 4.32. Time study of surface functionalized iron oxide nanoparticle stability in cell 
medium (CM) and human serum (HS). Clear, cloudy, or aggregated 
precipitations indicate stable, partially stable, or complete instability 
respectively .............................................................................................................140 
 
Figure 4.33. Dynamic light scattering hydrodynamic diameter measurement by volume for 
EDA-FeOx nanoparticles (A) and EDA-FeOx nanoparticles 12 days later (B) .....142 
 
Figure 4.34. Dynamic light scattering hydrodynamic diameter measurement by volume for 
TEPA-FeOx nanoparticles (A) and TEPA-FeOx nanoparticles 12 days later 
(B) ...........................................................................................................................142 
 
Figure 4.35. Time study of surface functionalized FeOx nanoparticle stability in water, 1x 
PBS, and 0.5x PBS at 3 weeks, 4 weeks, and 5 months. Clear, cloudy, or 
aggregated precipitations indicate stable, partially stable, or complete 
instability respectively ............................................................................................144 
 
Figure 4.36. Time study of surface functionalized FeOx nanoparticle stability in 0.9% 
NaCl, CSF, CM, and HS at 3 weeks, 4 weeks, and 5 months. Clear, cloudy, or 
aggregated precipitations indicate stable, partially stable, or complete 
instability respectively ............................................................................................145 
 
Figure 4.37. HPLC elution profiles of SAHBA-FeOx nanoparticles. The absorbance at 254 
nm (top) and radioactivity counts (bottom) are shown ...........................................147 
 
Figure 4.38. HPLC elution profiles of 
177
Lu-DOTA-SAHBA-FeOx post MCX column 
elution. The normalized absorbance at 254 nm (top) and radioactivity counts 
(bottom) are shown .................................................................................................148 
 
Figure 4.39. HPLC elution profiles of 
177
Lu-DOTA-SAHBA-FeOx post MCX and PD-10 
column elution. The absorbance at 254 nm (top) and radioactivity counts 
(bottom) are shown .................................................................................................149 
 
Figure 4.40. HPLC elution profiles absorbance at 245 nm of 
177
Lu-DOTA-SAHBA-FeOx 
final product after T0, T15, and T45 minutes of RF heating ..................................151 
 
Figure 4.41. HPLC elution profiles radioactivity counts of 
177
Lu-DOTA-SAHBA-FeOx 
final product after T0, T15, and T45 minutes of RF heating ..................................152 
 
 
xii 
 
 
 
Chapter 5. 
 
Figure 5.1. GBM-6 cellular uptake results for surface functionalized iron oxide 
nanoparticles; reported in units of percent uptake (purple) or pg of iron/cell 
(blue). EDA-FeOx and TEPA-FeOx uptake values are included in the inset 
figure with a larger y-axis .......................................................................................162 
 
Figure 5.2. Effect of surface functionalized nanoparticles on cell proliferation at 24 (blue) 
and 48 (purple) hours ..............................................................................................163 
 
Figure 5.3. Effect of varying concentrations of SAHBA-FeOx on cell proliferation at 24 
hours based on WST-1 (green) and cell titer blue (blue) assays used to 
determine IC50. The IC50 trend line is shown in black with open circles 
representing estimated y-values ..............................................................................165 
 
Figure 5.4. M059J cell uptake of CMPVA-FeOx (red) and PBS control (Blue) at 24 hours 
in terms of µg of iron (A), percent uptake (B), and pg of Fe/cell (C) ....................166 
 
Figure 5.5. RF hyperthermia effect on M059K survival as determined by colony assay. 
(Top) No particle (blue), particle (red), and extra particle (green) treatment 
groups survival are shown at 0, 10 and 15 minutes with a * indicating a 
significant difference determined by ANOVA and Dunnett two-sided post-hoc 
tests with a 0.05 significance level. (Bottom) The corresponding treatments 
measured RF hyperthermia over 15 minutes with dashed lines indicating 10 
and 15 minutes of heating .......................................................................................167 
 
Figure 5.6. HPLC of 
177
Lu-DOTA-SAHBA-FeOx final product. The absorbance at 254 nm 
(top) and radioactivity counts (bottom) are shown .................................................170 
 
Figure 5.7. HPLC of 
177
Lu-DOTA-CMPVA-FeOx final product. The absorbance at 254 
nm (top) and radioactivity counts (bottom) are shown ...........................................171 
 
Figure 5.8. Survival study using murine orthotopic xenograft model of glioblastoma 
multiforme (U87MG) treated with PBS (Black), FeOx (Blue), 
177
Lu-DOTA 
(Purple), 
177
Lu-DOTA-SAHBA-FeOx (Red), and 
177
Lu-DOTA-CMPVA-
FeOx (Green). Significantly different treatment groups from control are 
indicated by a * as determined by ANOVA and Dunnett two-sided post hoc 
test at a 0.05 significance level .............................................................................. 173 
 
 
 
  
xiii 
 
 
 
 
 
 
 
 
List of Abbreviations and Symbols 
 
 
(
𝚫𝑻
𝚫𝒕
) - Initial linear temperature increase per unit time 
⟨Γ ⟩- average decay rate 
𝟏
𝛕
- Effective relaxation time 
a-  Radius 
A- Amperes 
AH- Hamacker constant 
ABA- γ-aminobutryic acid 
AC- Alternating Current 
ANOVA- Analysis of variance 
APTS- (3-Aminopropyl)trimethoxy silane 
APTES- (3-aminominopropyl)triethoxysilane 
Arg- DL-arginine 
Asn- L-(+)-asparagine 
ATR- Attenuated total reflectance 
b- Full Width Half Maximum (FWHM) 
cH2O-  Specific heat capacity of water 
cnp- Specific heat capacity of nanoparticles 
CED- Convection enhanced delivery 
CM- Complete cell medium 
CMPVA- Carboxymethylated polyvinyl alcohol 
CSF- Artificial cerebral spinal fluid 
CVD- Chemical Vapor Deposition 
Cys- L-cysteine 
Db- Einstein’s Brownian diffusion coefficient 
Df- Diffusion coefficient 
dhkl- distance between atomic planes of lattice 
Dp- Particle Size 
dp- Depth of penetration 
DLS- Dynamic Light Scattering 
DLVO- Derjaguin, Landua, Verwey, and Overbeek 
DMEM- Eagle's minimal essential medium 
DOTA- S-2-(4-Aminobenzyl)-1,4,7,10-tetraazacyclododecane tetraacetic acid 
DPBS- Dulbecco’s phosphate buffered saline 
EA- Energy Barrier 
(
𝐄𝑨
𝒌𝑩𝐓
)-  Exponential term  
EDA- Ethylenediamine 
EDC- 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
xiv 
 
 
 
EPR- Enhanced Permeation and Retention 
EtOH- Ethanol 
eV- Electronvolt 
f- frequency 
FBS- Fetal bovine serum 
FCC- Face Centered Cubic 
Fe(acac)3- Iron (III) acetylacetonate 
FeCl2- Iron (II) Chloride 
Fe3O4- Magnetite 
FeOx- Iron Oxide 
FTIR- Fourier transform infrared 
g- Gram 
Gly- Glycine 
GLYMO- (3-Glycidyloxypropyl)trimethoxysilane 
Gln- L-glutamine 
H- Magnetic field strength 
HC- Coercivity 
HCl- Hydrochloric acid 
HPLC- High-performance liquid chromatography 
HS- Human serum 
HSD- Honest significant difference 
I- Current 
IACUC- Institutional Animal Care and Use Committee 
IC50- Half maximal inhibitory concentration 
ICP- Inductively coupled plasma 
ILP- Intrinsic Loss of Power 
IRE- Internal reflectance element 
K- Magnetocrystalline anisotropy constant 
K- Shape factor 
KB- Boltzmann constant 
kBT- Thermal energy 
L- Length of a coil 
Lys- DL-lysine monohydrochloride 
M- Magnetization 
mH2O- Mass of water 
mnp- Mass of nanoparticles 
MR- Remnant Magnetization 
MS- Magnetization Saturation 
MCLhkl- Coherently scattering domain that is perpendicular to the hkl plane 
MES- 2-(N-morpholino)ethanesulfonic acid 
MFH- Magnetic Fluid Hyperthermia 
MRI- Magnetic Resonance Imaging 
MWCO- Molecular weight cutoff 
n- Integer 
N- Number of turns in a coil 
n- Refractive index 
xv 
 
 
 
N2- Nitrogen 
NaHCO3- Sodium bicarbonate 
nm- Nanometer 
NaCl- Sodium Chloride 
NaOH- Sodium Hydroxide 
O- Oxygen 
OH- Hydroxide 
PBS- Phosphate buffered saline 
PDI- Polydispersity index 
PVA- Polyvinyl alcohol 
q- Magnitude of scattering wave 
RH- Hydrodynamic radius 
r- Distance between particles, center-to-center 
𝐫
𝐚
- Equilibrium separation distance 
RF- Radiofrequency 
S-NHS- N-hydroxysulfosuccinimide 
SAHBA- (S)-(-)-4-Amino-2-hydroxybutyric acid 
SAR- Specific Absorption Rate 
Ser- DL-serine 
Δt-  Change in time 
T- Temperature 
TB- Brownian relaxation time 
TM- Morin Temperature 
TN- Néel relaxation time 
TN- Néel Temperature 
TEM- Transmission Electron Microscopy 
TEPA- Tetraethylenepentamine 
TGA- Thermogravimetric analysis 
Thr- DL-threonine 
TMAOH- Tetramethylammonium hydroxide 
VC- Volume of the core particle 
VH- Hydrodynamic Volume 
VSM- Vibrating Sample Magnetometery 
W-  Watt 
X- Magnetic Susceptibility 
Δx- Extent of three dimensional Brownian motion displacement 
XRD- X-ray Diffraction 
γ-Fe2O3- Maghemite 
ε- Permittivity 
εo- Permittivity of free space 
εr- Relative permittivity 
ζ- Zeta potential 
η- Viscosity 
κ- Debye Hückel parameter 
𝟏
𝜿
 Double layer thickness 
θ- Incident Angle 
xvi 
 
 
 
θDLS- Range of scattering angle 
λ- Wavelength 
μ- Solution viscosity 
μ2- Variance of the decay rate distribution 
μB- Bohr magneton 
μL- Microliter 
μo- Permeability of free space 
τoEA- Pre-exponential factor 
ψA- Van der Waal attractive forces 
ψR- Van der Waal repulsive forces 
ψTOT- Total interparticle potential 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
Abstract 
 
 
 
SYNTHESIS, SURFACE FUNCTIONALIZATION, AND BIOLOGICAL TESTING OF 
IRON OXIDE NANOPARTICLES FOR DEVELOPMENT AS A CANCER 
THERAPEUTIC 
 
By Stanley Eugene Gilliland III, B.S., M.S. 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2015. 
Major Director: Dr. Everett E. Carpenter, Professor,  
Director of the Nanoscience and Nanotechnology Program, 
Director of the NCC 
Department of Chemistry 
Research Director: Dr. Everett E. Carpenter 
Professor, Department of Chemistry 
Research Co-Director: Dr. Michael D. Shultz 
Research Biologist - McGuire VA Medical Center  
& Adjunct Faculty, Department of Chemistry 
 
 
 
 
 Iron oxide nanoparticles are highly researched for their use in biomedical applications 
such as drug delivery, diagnosis, and therapy. The inherent biodegradable and biocompatible 
nanoparticle properties make them highly advantageous in nanomedicine. The magnetic 
properties of iron oxide nanoparticles make them promising candidates for magnetic fluid 
hyperthermia applications. Designing an efficient iron oxide nanoparticle for hyperthermia 
  
 
requires synthetic, surface functionalization, stability, and biological investigations. This 
research focused on the following three areas: optimizing synthesis conditions for maximum 
radiofrequency induced magnetic hyperthermia, designing a simple and modifiable surface 
functionalization method for specific or broad biological stability, and in vitro and in vivo testing 
of surface functionalized iron oxide nanoparticles in delivering effective hyperthermia or 
radiotherapy.   
The benzyl alcohol modified seed growth method of synthesizing iron oxide 
nanoparticles using iron acetylacetonate as an iron precursor was investigated to identify 
significant nanoparticle properties that effect radiofrequency induced magnetic hyperthermia. 
Investigation of this synthesis under atmospheric conditions revealed a combination of thermal 
decomposition and oxidation-reduction mechanisms that can produce nanoparticles with larger 
crystallite sizes and decreased size distributions.  
Nanoparticles were easily surface functionalized with (3-Glycidyloxypropyl)
trimethoxysilane (GLYMO) without the need for organic-aqueous phase transfer methods. The 
epoxy ring on GLYMO facilitated post-modifications via a base catalyzed epoxy ring opening to 
obtain nanoparticles with different terminal groups. Glycine, serine, γ-aminobutryic acid (ABA), 
(S)-(-)-4-amino-2-hydroxybutyric acid (SAHBA), ethylenediamine, and tetraethylenepentamine 
were successful in modifying GLYMO coated-iron oxide nanoparticles to provide colloidal and 
varying biological stability while also allowing for further conjugation of chemotherapeutics or 
radiotherapeutics. The colloidal stability of cationic and anionic nanoparticles in several 
biologically relevant media was studied to address claims of increased cellular uptake for 
cationic nanoparticles.  
  
 
The surface functionalized iron oxide nanoparticles were investigated to determine 
effects on cellular uptake and viability. In vitro tests were used to confirm the ability of iron 
oxide nanoparticles to provide effective hyperthermia treatment. S-2-(4-Aminobenzyl)-1,4,7,10-
tetraazacyclododecane tetraacetic acid (DOTA) was coupled to SAHBA and carboxymethylated 
polyvinyl alcohol surface functionalized iron oxide nanoparticles and radiolabeled with 
177
Lu. 
The capability of radiolabeled iron oxide nanoparticles for delivering radiation therapy to a 
U87MG murine orthotopic xenograft model of glioblastoma was initially investigated.
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Chapter 1: Introduction and Background 
 
 
 
1.1 Radiofrequency Induced Hyperthermia: Treatment of Cancer 
 
The hyperthermia treatment of cancer with magnetic particles was first introduced by 
Gilchrist in 1957.4 Hyperthermia can be subcategorized into three temperature ranges: mild 
hyperthermia, moderate hyperthermia, and thermoablation. Each of these has varying degrees of 
effects and can interact with different therapies.5,6 Increasing the body temperature above 37°C to 
non-lethal ranges of 39-42°C is referred to as mild hyperthermia and can increase drug perfusion 
and oxygenation which can sensitize cells to radiotherapy or chemotherapy.6-8 When the 
temperature is increased to moderate hyperthermia temperatures, 41-46°C, the heat stress will 
stimulates degradation of proteins, interferes with essential cell processes, and causes programed 
cell death or apoptosis.9-11 Further increase of temperature above 45°C is termed 
thermoablation.9,11-14 At these extreme temperatures cells will begin to die as a direct result of the 
temperature increase causing carbonization, coagulation and necrosis.9,11-14 In terms of heat 
sensitivity there has been no reported evidence of a difference between normal and cancerous 
tissue.15,16 However, due to the vasculature of cancerous tumors there are regions of low pH and 
hypoxia that sensitize tumors to hyperthermia at temperatures between 40-44°C.15 These levels 
of hyperthermia can be achieved utilizing magnetic particles in an external radiofrequency (RF) 
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alternating current (AC) magnetic field. Heating is produced by eddy currents, hysteretic heating, 
and dielectric losses, but the material characteristics and properties such as conductivity, size, 
and magnetic properties determine the extent of heating for a given magnetic field strength and 
frequency.4,5,17-20 Dielectric loss can damage tissue when high magnetic field strengths and 
frequencies are applied.4 To maximize the amount of hysteretic heating of the particles and limit 
unwanted damage to normal tissues it has been suggested that the frequency be kept below 100 
MHz as they have the required RF penetration with minimal RF absorption and are used in 
magnetic resonance imaging (MRI).21 The magnetic field strength and frequency product (Hxf) 
of 5×109 
𝐴
𝑚𝑠
 is considered the maximum threshold for safe heating of a human torso for 1 hour.22 
Above this threshold nonspecific and potentially detrimental eddy current heating can occur.22 In 
the treatment of smaller tissues of a healthy patient and depending on the location of the tumor 
the H×f product can be surpassed in some cases.22 Therefore, the goal of magnetic hyperthermia 
with particles has focused on maximizing achievable heating rates while minimizing the 
magnetic field strengths and/or frequencies required.22 The RF coil used within this research was 
designed so that small solution volumes in microcentrifuge tubes or similar containers could be 
easily heated. Reports have indicated that there is a linear relationship between increased heating 
and H×f values, however these higher H×f values require the time of heating to be reduced to 
limit possible detrimental side effects or patient discomfort.23The RF heating values reported in 
this work were conducted under 1.01x10
10
 
𝐴
𝑚𝑠
 H×f values. This was deemed to be acceptable for 
in vitro and small animal in vivo studies.24 Additionally, the heating times used were well below 
one hour.  
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1.2 Néel and Brownian Relaxation Mechanisms  
Since Gilchrist’s research there has been a significant change in magnetic particle based 
hyperthermia. Multi-domain particles have been replaced by the use of superparamagnetic 
nanomaterials. Nanoparticles small size lends them a tremendous advantage in navigating the 
complexities of biological systems. Superparamagnetic nanoparticles are beneficial because of 
their greater efficiency of absorbing the applied radiofrequency to generate heat.5 The ability to 
generate more heat with lower required power reduces the nonspecific heating of normal tissue 
that may occur with prolonged treatment times. 
Néel and Brownian relaxation mechanisms are responsible for producing heat in 
superparamagnetic nanoparticles exposed to a RF alternating current (AC) magnetic field. When 
an AC magnetic field is applied, the superparamagnetic nanoparticles will adjust the magnetic 
moment orientation to match the direction of the applied field. This reorientation results from 
either rapid alteration of magnetic moment directions within the crystal lattice (Néel mechanism) 
(Figure 1.1 A) or by the nanoparticle physically rotating to align the internal magnetic moments 
with the external magnetic field (Brownian mechanism) (Figure 1.1 B).9,25,26 The Néel 
mechanism is also referred to as internal heating; as heat is first generated by internal friction 
between the crystal lattice and the rotating magnetic spins and is then lost as thermal energy to 
the surrounding medium.25,26 More specifically, the Néel mechanism produces heat when the AC 
magnetic field provides a sufficient amount of energy for the dipole to overcome an energy 
barrier and alter directions.25,27 The volume of the nanoparticle and the magnetocrystalline 
anisotropy are determining factors of the energy barrier.25,27 Equation 1a shows the relationship 
between the magnetocrystalline anisotropy constant (K), volume of the core particle (Vc), and the 
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energy barrier (EA). The Brownian mechanism generates and releases mechanical heat generated 
from friction  
 
Figure 1.1. Illustration of (A) Néel and (B) Brownian mechanisms in response to an alternating 
current magnetic field. The dashed arrow represents either the internal magnetic spins (A) or the 
entire nanoparticle (B) rotating in response to a 180° magnetic field direction change.  
 
between the rotating nanoparticle and solution.25,26 The amount of friction is dependent upon the 
viscosity of the solution.25,26 Heat is generated simultaneously by both mechanisms at all relevant 
superparamagnetic nanoparticle sizes.17,18,25,28-31  Depending on the crystallite size of the 
nanoparticle one mechanism will have a faster relaxation time and is thus the dominate source of 
heating.17,18,25,28-31 The effective relaxation time (1/τ) (Equation 1b) is used to describe the 
combination of heating mechanisms. Néel heating is dominant at smaller nanoparticle sizes. For 
example, this heating mechanism dominates below 15-16 nanometers (nm) for iron oxide (FeOx) 
nanoparticles. In the equation for Néel relaxation time (τN)
28 (Equation 1c) it can be seen that 
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below 8 nm crystallite diameters the Néel relaxation time is dictated by the pre-exponential term 
(τ𝑜E𝐴) and at crystallite diameters between 8 and 15-16 nm the relaxation time is dictated by the 
exponential term (
E𝐴
𝑘𝐵T
).17,27,29,32,33 Above 15-16 nm crystallite diameters the Brownian relaxation 
time (τB)
28,34 (Equation 1d)  is much faster than Néel relaxation time and becomes 
dominant.17,29,32,33 The Brownian relaxation time depends on the medium viscosity (η), 
hydrodynamic volume of the particle (Vh), and inversely on temperature (T) and Boltzmann 
constant (kB). 
𝐸𝐴 = KV𝑐      (1a) 
1
τ
=  
1
τ𝑁
 + 
1
τ𝐵
      (1b) 
τ𝑁 = τ𝑜E𝐴exp (
E𝐴
𝑘𝐵T
)     (1c) 
τ𝐵 =
3ηVℎ
𝑘𝐵T
      (1d) 
From Equations 1a-d it becomes apparent that the heating mechanisms are determined by 
nanoparticle size, crystal structure, polydispersity, shape, and magnetocrystalline anisotropy.25,26 
When a large size distribution is used (large polydispersity) heat will be generated by a varying 
degree of combined heating mechanisms and is typically unfavorable.25 
 The ability to quantifiable measure and compare the effectiveness of hyperthermia 
between nanoparticles is important. In 1993 Jordan et al. attempted this through the use of 
determining what they termed the specific absorption rate (SAR).17 However, SAR values are 
often misunderstood or improperly determined and lead to improperly reporting the efficiency of 
magnetic nanoparticles.23 The SAR equation (Equation 2a) has since been expanded to 
normalize SAR values depending on the magnetic field strength and frequency of the coil 
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used.23,35 The new equation is referred to as effective SAR (Equation 2b) or intrinsic loss of 
power (ILP) (Equation 2c).23,35,36 
 
𝑆𝐴𝑅 =
𝑐
𝑚𝑛𝑝
(
Δ𝑇
Δ𝑡
)      (2a) 
      𝐸𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒 𝑆𝐴𝑅 =
𝑐𝐻2𝑂𝑚𝐻2𝑂+𝑐𝑛𝑝𝑚𝑛𝑝
𝑚𝑛𝑝
(
Δ𝑇
Δ𝑡
) (
1
𝐻𝑎𝑝𝑝𝑙𝑖𝑒𝑑
2 ×𝑓
)     (2b) 
 𝐼𝐿𝑃 =
𝑆𝐴𝑅
𝐻𝑎𝑝𝑝𝑙𝑖𝑒𝑑
2 ×𝑓
      (2c) 
In Equations 2a-c, specific heat capacity of water and nanoparticles are denoted 𝑐𝐻2𝑂 and 𝑐𝑛𝑝 
with units of  (
W×s
g×K
), mass of total nanoparticles and water are denoted mnp and  𝑚𝐻2𝑂, initial 
linear increase in temperature per unit time is denoted (
Δ𝑇
Δ𝑡
) in units of (
K
s
), magnetic field 
strength is H in units of (
A
m
), and AC magnetic field frequency (f) in units of kHz.29,31 From 
Equations 1 and 2 it has been determined that to maximize energy absorption and thus produce 
the most efficient heating, the crystallite size and monodispersity must be controlled.20,37  
 Additional benefits of switching to nanoparticles include more uniform heating, 
decreased invasiveness, and reduced chances of causing adverse damage to surrounding normal 
tissue.5 The superparamagnetism of these small nanoparticles are additionally useful as they lose 
their magnetism when the external magnetic field is removed.38 This is essential in biological 
applications as magnetic aggregation of stable nanoparticles are less likely to occur which 
prolongs the blood circulation time.38 The advent of nanomedicine has allowed for numerous 
new targeting strategies specifically for cancer cells to provide confined local heating while 
limiting invasiveness.5,9,20,39,40 The extraordinary advantages of nanoparticle hyperthermia are 
responsible for the vast amount of recent literature and research being conducted on magnetic 
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hyperthermia treatment of cancer. Several issues that must be addressed for successful clinical 
implementation of magnetic nanoparticle hyperthermia include increasing ILP values, biological 
stability, blood circulation, and cellular uptake while minimizing immunogenicity and 
toxicity.22,24,25,41 Maximizing ILP values is essential to lower the required amount of nanoparticles 
for effective heating. However, there is evidence that hyperthermia without detectable 
temperature increases can provide sufficient treatment of cancer.25,42,43  This gives evidence to 
suggest that SAR and ILP values are often misleading and may not always indicate the best 
magnetic hyperthermia.25 Biocompatible nanomaterials with biologically suitable surface 
modifications may offer the best chance of addressing the current challenges of transitioning 
more nanoparticle hyperthermia into clinical trials. 
   
1.3 Iron Oxide Nanoparticles for Magnetic Hyperthermia: Ideal 
Properties and Challenges to Overcome 
Nanomaterials have remained an important research area in nanomedicine. 
Biocompatible nanomaterials make excellent nanomedicine therapeutics, such as magnetic fluid 
hyperthermia. For example, FeOx is a biocompatible material with RF induction heating 
potential that allow for its application in magnetic fluid hyperthermia (MFH).
25,38,41,44
 FeOx 
nanoparticles can be cleared from the body by opsonization or through degradation via the 
body’s metabolism forming iron ions that are then used by erythrocytes to form hemoglobin.45,46 
Biocompatible FeOx nanoparticles can furthermore act as a theranositc agent
47-50
 by providing 
therapy via magnetic fluid hyperthermia
41,51,52
 and diagnosis in the form of magnetic resonance 
imaging.
51,53
 FeOx nanoparticles are one of the only US FDA approved nanoparticles for their 
use as MRI contrast agents
54
 of the liver and as iron supplements
55-57
. In Germany, aminosilane 
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functionalized superparamagnetic FeOx nanoparticles are already being investigated for 
glioblastoma and prostate cancer treatment with MFH at the clinical level.
39,52,58
 
MFH research using FeOx nanoparticles has revealed that the optimal crystallite size is 
15-16 nm with minimal size distribution.
29,59
 Within this size range Néel relaxation is still 
dominant, but has a fast Brownian relaxation time as well which results in the best theoretical 
superparamagnetic heating.
13
 Crystallite sizes above 16 nm that have dominant Brownian heating 
usually have less effective heat generation.
13
 Hyperthermia is not a new medical procedure and 
can be delivered via thermoseeds, water bath, microwave, infrared or ultrasound radiation.
25,60
 
However, nanoparticle delivered MFH offers the ability to less invasively deliver effective MFH 
to smaller cancerous regions.
25,60
 Nanoparticles offer a unique solution to the problem that some 
conventional drugs have with regards to being ineffective due to poor solubility or 
bioavailability.
61
 Due to their small size nanoparticles can in some cases cross biological 
membrane barriers such as mucus membranes or the absorptive epithelium in the small 
intestine.
62,63
 Additionally, surface modifiable nanoparticle can be used as a nanoplatform or a 
nanocarrier to deliver a surface conjugated drug or drugs to the target of interest by either passive 
or active uptake.
64,65
 Active uptake can be facilitated by surface functionalized targeting ligands 
that can direct nanoparticles to overexpressed targets in cancerous tissues.
63,66
 An additional 
benefit of FeOx nanoparticles is that they are inherently biodegradable. This means that once the 
drug has been delivered the nanoparticles can be easy cleared from the body or metabolized. 
Also, due to the size range of superparamagnetic nanoparticles they can be passively uptaken by 
cancerous tissue through the enhanced permeation and retention (EPR) effect.
25,67
 
Research on nanomaterials for biological applications continues to suffer from a lack of 
broad stability and/or ease of surface functionalization, which impedes the advancement of many 
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synthesized nanoparticles into actual nanomedical applications.  Moreover, the definition of 
stability is often misused or misleading when claiming a “stable” nanomaterial surface 
functionalization. True stability is very complex and can be defined in regards to colloidal, 
chemical, physical, pharmaceutical, and/or biological stability.
68
 For efficient magnetic 
hyperthermia stability should be defined as a combination of the above listed stability terms. The 
colloidal stability can most simply be defined as having higher repulsive forces than attractive 
forces with respect to solid nanoparticles dispersed in an aqueous medium (colloid). The 
pharmaceutical stability refers to how long the solution is physically and chemically stable, and 
can effectively deliver a pharmaceutical dose. Chemical and physical stability refers to the 
protection against factors such as temperature, pH, humidity, etc. that may alter the nanoparticle 
composition or render the nanoparticle inert. With respect to biological stability this refers to 
overcoming attractive forces that may arise from immersion into different biological 
environments where counter ions, proteins, pH, and other molecules vary.  
An alarming number of studies on nanoparticles rely on the assumption that a surface 
coating will provide the required colloidal stability to properly investigate certain parameters of 
interest. It should be noted that nanoparticles displaying colloidal stability upon synthesis or after 
surface functionalization may aggregate and precipitate in when introduced to different 
biologically relevant medium or biological environments. This can drastically alter or affect the 
results of biological testing and investigations. Therefore, it is vital to understand what 
constitutes a stable nanoparticle solution, the biological and chemical challenges of surface 
functionalizing nanoparticles for stability, and ideal biological and chemical properties of surface 
functionalized nanoparticles for nanomedical applications. These topics will be covered in the 
following subsections. 
 10 
 
1.3.1 Colloidal Stability 
 Nanoparticles small size lends them a tremendous advantage in navigating the 
complexities of biological systems. However, nanoparticles exhibit a greater propensity to 
aggregate in aqueous solutions, than their bulk counterparts, due to surface properties, 
interactions between nanoparticles, and size.69 Aggregation must be addressed to achieve 
colloidal stability in buffered or saline based medium which is paramount to permit sterile 
filtration (or other sterilization methods; for example sterile buffer exchange) before use with in 
vitro studies or in vivo administration.  Additionally, without proper colloidal stability in 
biologically relevant medium the nanoparticles may aggregate or interact unfavorably when 
administered in vitro or in vivo.66,70 Colloidal stability in buffered solutions is also necessary for 
reactions involving conjugation to biological targets, such as proteins and antibodies, and for 
other reactions such as radiolabeling and chelation. Nanoparticles that do not possess intrinsic 
colloidal stability cannot be used effectively in biomedical applications, but colloidal stability 
can be provided by functionalizing the surface with hydrophilic ligands.70-72 
 Nanoparticle surface functionalization is most often used to overcome nanoparticles 
greater tendency to aggregate. The small size of nanoparticles and Brownian motion offers a 
simple explanation for nanoparticles propensity to aggregate.69 In Equations 3a and 3b we can 
see the relationship between particle size (dp) and extent of three dimensional Brownian motion 
displacement (Δx).69 Where Db is Einstein’s Brownian diffusion coefficient, Δt is change in time, 
T is temperature, kB is Boltzmann’s constant, and μ is the solution viscosity. 
   𝛥𝑥 = √6𝐷𝑏𝛥𝑡     (3a) 
 𝐷𝑏 =
𝑘𝐵𝑇
3𝜋𝜇𝑑𝑝
      (3b) 
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Equation 3b clearly shows that as particle size decreases the displacement due to Brownian 
motion increases. This results in a greater chance for aggregation between nanoparticles due to 
Van der Waal attraction forces.69 More precisely, there usually exists a relatively strong 
attraction between solid phase nanoparticles that are dispersed in an aqueous phase.69,73 This 
attractive force can result in aggregation.69,74 While the size of nanoparticles offers a simple 
explanation for greater aggregation probability, factors such as surface charge and chemistry can 
also influence aggregation tendency, further complicating obtaining colloidal stability. 
Therefore, the surface modification must sufficiently increase van der Waal repulsion to prevent 
aggregation and achieve colloidal stability.72,73 Surface ligands can provide nanoparticles with 
steric, electrostatic, or electrosteric stability.72,75 These types of stability are shown in Figure 1.2.  
 
Figure 1.2. A) Electrostatic, B) steric, or C) electrosteric colloidal stabilization of nanoparticles 
provided by surface charge properties, surface ligands, or charged surface ligands respectively. 
 
Electrostatic stability prevents aggregation due to charged nanoparticle surfaces that repel 
neighboring nanoparticles with greater force as they approach.73 An electrostatic double layer, 
shown in Figure 1.3, forms due to counter ions in solution being attracted to the charged surface 
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forming the ‘diffuse layer’ and repelling nanoparticles with the same ‘surface layer’.76 The 
surface and diffuse layers are also termed Stern and Guoy layers respectively. Addition of 
surface ligands to the nanoparticle can also provide steric stability. Steric repulsion is provided 
by the steric hindrance of the ligands and is determined by how dense and compressed the 
ligands can pack as the nanoparticles approach.73 Surface ligands with charged functional groups 
utilize both steric and electrostatic stabilization to prevent aggregation and are often referred to 
as electrosteric stabilization.73 
 
 
Figure 1.3. Scheme of the electrostatic double layer of small positively charged solid particle in 
an ionic liquids. The double layer is comprised of the positively charged (blue circle with + 
inside) surface layer and the surrounding negatively charged (red circle with – inside) layer 
(Stern layer). This is encompassed by a diffuse layer of equal positive and negative charges 
(Guoy layer). 
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The stabilization distance provided by the electrostatic double layer is typically between 1-100 
nm for colloids and is compacted as the concentration of ionic electrolytes increases.74,76 The 
formed layer of counter ions has a certain thickness (1/κ) or is inversely proportional to the 
Debye Hückel parameter (κ) which is dependent upon concentration of ions and the interaction 
between charged surfaces and ions.74,76 Therefore, factors such as concentration of counter ions, 
and nanoparticle surface charges as well as the size of nanoparticles can play a crucial role in 
colloidal stability.73 This offers a simple explanation for the nanoparticle instability upon transfer 
from water to biological medium such as PBS that contain higher ion concentrations. A model 
that is most commonly used to describe the repulsive force generated due to the electrostatic 
interactions is the Derjaguin, Landua, Verwey, and Overbeek (DLVO) model.69,77-80 In this model 
several simplifications are used, mainly the co-ions, counter ions, and nanoparticle surface 
charges are represented as spheres that interact through short range potentials and Coulomb 
interactions.73,80 The change of energy as charged nanoparticles approach each other is 
quantitated within the DLVO model and relates to the extent of stability.73,80 The double layer 
thickness is used to calculate the amount of Coulomb repulsion between approaching 
nanoparticles.73,80 The DLVO theory can be simply stated as the total interparticle potential 
(ΨTOT) which is the combination of overlapping electrostatic double layers providing repulsive 
forces (ΨR) and  van der Waal attractive forces (ΨA), shown in Equation 4a.
73,80 The simplified 
equations for van der Waal attractive forces and repulsive forces are shown in Equations 4 b 
and c. The equation for attractive forces is simplified by assuming particles are of identical 
radius (a) and that the radius of particles is much greater than the distance between particles, 
center-to-center (r).73,80 Likewise the equation for repulsive forces can be simplified by assuming 
the radius of particles and zeta potential (ζ)  are identical.73 The Hamacker constant (AH) 
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describes the forces between two particles in solution and the interaction between the surface of 
the nanoparticle and solution medium.73  
  Ψ𝑇𝑂𝑇 = Ψ𝐴 + Ψ𝑅      (4a) 
  Ψ𝐴 = −
𝐴𝐻𝑎
12𝑟
            (4b) 
  Ψ𝑅 = 2πεaζ
2ln (1 + 𝑒−𝜅𝑎)            (4c) 
It should be noted that the attractive force decreases drastically as the distance between 
nanoparticles increases (1/r
2
) and that the attractive force exists over larger distances compared 
to the repulsive forces.74,80 This can be represented by graphing r/a vs. interparticle potentials 
(Figure 1.4) where a positive potential represents repulsive forces and a negative potential 
represents an attractive force.  
 
Figure 1.4. Graph illustrating interparticle potentials for stable dispersions (solid line), 
flocculated dispersions (dotted line), and aggregated dispersions (dashed line). 
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For stable dispersions (Figure 1.4 solid line) the particles repel nanoparticles effectively at all 
distances.74 Particles that are starting to flocculate or are starting to aggregate (Figure 1.4 dotted 
line) have greater attractive forces at certain distances (r/a) which is termed the equilibrium 
separation distance.74 Unstable particles (Figure 1.4 dashed line)  that do not have sufficient 
repulsive forces will have very large attractive forces as they approach and will irreversibly 
aggregate and precipitate.74 This exemplifies why nanoparticles can be dispersed in solutions, but 
may require stabilization by means such as surface modifications to attain colloidal stability.75 
Dynamic light scattering (DLS) is a useful characterization tool that can determine the zeta 
potential of the nanoparticles and assess the stability of the nanoparticles in solution. 
 There are numerous different strategies for functionalizing the surface of FeOx 
nanoparticles to provide colloidal stability. Such strategies include modifying the surface with 
hydrophilic biomolecules, small molecules, dendrimers, surfactants, or polymers.71 In addition to 
the electrostatic forces provided by the surface ligands, the stability is also due to an osmotic and 
elastic involvement.61,81-85 When two nanoparticles with a surface coating approach each other the 
increase in concentration of surface ligands will cause water to enter the volume and force the 
nanoparticles apart to restore osmotic equilibrium.81-84 Additionally, when the nanoparticles are 
in a confined area the surface ligands will have an reduction in conformational entropy which 
will ultimately repel the particles to increase entropy.81-84 Once colloidal stability is achieved, it 
should be assessed in multiple biologically relevant media since colloidal stability in water or 
phosphate buffered saline (PBS) may not translate to stability when introduced to the biological 
environment of interest. 
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 Effective use of nanoparticles for treatment of cancer requires colloidal stability. 
However, there are several additional factors that need to be addressed when choosing and 
designing a surface functionalization strategy. These challenges can be subcategorized into 
biological and chemical challenges of modifying the surface of nanoparticles. 
 
1.3.2 Biological Challenges for Surface Functionalization 
  FeOx nanoparticles without post-modifications are generally not stable in biological 
conditions. Additionally, nanoparticles can exhibit low probability of reaching the desired target, 
non-specific interactions with proteins that can cause aggregation, adsorption of opsonins leading 
to phagocytosis and subsequent clearance from the body, and toxicity issues.61,63 To prolong the 
circulation time and enhance passive uptake the optimal surface functionalized nanoparticle size 
should be between 30-100 nm.61,86 Below this size range the nanoparticles are susceptible to 
leakage into the blood capillaries and above this size they become more likely to be opsonized 
and cleared by macrophages.61,86,87 The ideal surface ligand should therefore provide colloidal 
stability in biological media  while maintaining a small size to increase circulation time and 
enhance cellular uptake probability. It is also advantageous in radiofrequency magnetic 
hyperthermia to choose a surface functionalization that can be easily conjugate additional 
therapeutics, diagnostics, and targeting ligands to aid in delivery, treatment, and/or diagnosis. 
The biological concerns and requirements are addressed in further detail below.  
 Opsonization is the process by which opsonin tags a foreign object for phagocytosis and 
clearance from the body.46 A potential way to overcome the challenge of avoiding opsonization 
is to use a surface functionalization technique using polymers.46 Utilizing these biomolecules 
could prevent opsonization by mimicking biology to create ‘stealth’ like properties for the 
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nanoparticle.61,81,88 Stealth property of some nanoparticles refers to a surface coating that 
increases the circulation time allowing for a greater chance of passive targeting by reduce protein 
adsorption and recognition by opsonin.61,81,88 This is especially important in cancer treatment 
since some tumors are known to have leaky vasculature, as a result of reduced lymphatic 
drainage and increased angiogenesis, which improves the accumulation of nanoparticles in these 
regions.61,63  The intercellular junctions of normal tissue is typically less than 10 nm reducing the 
potential for nanoparticles to accumulate.61 In comparison it has been reported that tumor 
intercellular spaces can range from 0.5-2.5 μm.89,89,90 The passive uptake resulting from both 
leaky vasculature and increased intercellular spaces is termed the enhanced permeation and 
retention (EPR) effect. Nanoparticles in the size range of about 20-150 nm can take advantage of 
the EPR effect most efficiently.63 
 While passive targeting via the EPR effect increases the accumulation of nanoparticles in 
tumors as compared to normal tissue it should not be exclusively relied upon. For this reason the 
ability for further conjugation of targeting moieties, therapeutics, and/or diagnostic agents is 
highly advantageous for medical applications. Addition of targeting moieties such as ligands, 
proteins, or antibodies facilitates active accumulation of nanoparticles by targeting 
overexpressed receptors on tumor cells.63,66,91,92 One popular way of conjugating targeting 
moieties is to use 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) coupling to form an 
amide bond between a carboxyl group and a primary amine.93 This method is beneficial as 
amines and carboxyl groups aid in providing aqueous stability and are typically found on surface 
functionalizations used for biological stability.93 Additionally, targeting biomolecules typically 
contain a primary amine and/or carboxyl group. 
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 Another significant biological challenge that nanomaterials face is accurate assessment of 
stability. Nanoparticles’ colloidal stability must be assessed not only in water and PBS, but also 
in biologically relevant medium before conducting any in vitro experiments, such as uptake or 
toxicity. This is important as colloidal instability due to the introduction of nanoparticles into cell 
medium can drastically alter results.66,94 When the nanoparticles are introduced to cell culture 
medium, blood, cerebral spinal fluid, or other medium, aggregation can result. This can be 
caused by differences in pH, ion concentrations, or presence of interacting or adsorbing proteins. 
Instability due to aggregation reduces the circulation time and prevents the nanoparticles from 
reaching or remaining at the region of interest.66 Aggregation can also decrease cellular uptake 
and internalization, or drastically reduce the effectiveness of targeting.61,66 In some cases 
adsorption can lead to recognition by the immune system leading to clearance from the body. It 
is therefore very important that the biological stability of the surface functionalized FeOx 
nanoparticles be investigated in several relevant media such as complete tissue culture medium, 
cerebral spinal fluid, and human serum. For the treatment of glioblastoma multiform (GBM) it is 
important to modify the surface for stability in cerebral spinal fluid. This can be tested by using 
artificial cerebral spinal fluid (CSF). Additionally, the use of convection enhanced delivery 
(CED) reduces the need for active targeting as the nanoparticles are directly administered at the 
tumor site. The use of CED also reduces the issue of nanoparticles crossing the blood brain 
barrier.  
 Toxicity is another biological obstacle that must be kept in mind when modifying the 
surface of the nanoparticles.63 It has been suggested that cationic surface functionalizations can 
improve the cellular uptake, however there is some evidence that suggests potential toxicity due 
to surface functionalizations containing positive amine groups.63,95,96 The charge of the surface 
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modification is thought to not only affect cellular uptake of nanoparticles, but also where the 
nanoparticles localize within the cell.95,96 Cellular toxicity can be significantly affected by where 
a nanoparticle localizes.95,96 Therefore the possible tradeoff between potential toxicity and 
potential increased cellular uptake must be considered for specific applications. 
 In conclusion factors such as charge, size, chemical composition, and toxicity must all be 
considered when designing a nanoparticle surface for biological stability and targeting of 
cancerous cells. Further understanding of factors that influence biological stability and the ability 
to produce stable nanoparticle solutions in a broad range of medium is paramount in progressing 
nanomedical agents into the clinic. Ideally, surface functionalized nanoparticles will provide 
protection against clearance and aggregation as they interact with different biological 
environments, exhibit low toxicity, and offer potential for further conjugation of targeting 
ligands and/or additional therapeutic or diagnostic agents.  
  
1.3.3 Chemical Challenges for Surface Functionalization 
 When choosing a surface functionalization strategy the chemical challenges of 
functionalizing the surface must also be considered and addressed. The nanoparticles surface 
chemistry can pose several challenges to surface modification. Such chemical issues to be 
avoided include use of toxic chemicals, difficult surface functionalization methods, and large 
surface functionalizations that cannot be sterile filtered.  Other challenges include washing and 
isolating the surface functionalized nanoparticles, and retaining colloidal stability when 
conjugating additional targeting ligands or drugs. 
 Washing and isolating the stable surface functionalized nanoparticles is vital to remove 
unreacted ligands, chemicals, and partially or incomplete surface functionalized nanoparticles. 
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This becomes extremely necessary if toxic chemicals are used or toxic byproducts are present 
during surface functionalization. Additionally it is important to be able to buffer exchange the 
nanoparticles directly into different biologically relevant medium without the need to completely 
dry the nanoparticles. Often when surface functionalized nanoparticles are dried to a powder the 
surface chemistry is altered or even removed resulting in colloidal instability upon resuspension. 
 Difficult surface functionalizations are frequently required to obtain colloidal stability in 
water or PBS. The nanoparticles that usually require these difficult methods are synthesized by 
organic methods which result in only organic media stability. For these nanoparticles a phase 
transfer process is generally required to transition the nanoparticle from organic stability to 
aqueous stability. Facilitating this transition requires a mixture of organic and aqueous phases 
with a surface functionalization or stabilizer. The two phases are allowed to separate and then the 
nanoparticles in the aqueous phase are extracted. Additional steps must then be taken to ensure 
complete removal of these organic chemicals. If the chemical, polymer, or molecule used to 
modify the surface is soluble in the organic phase then removal of the chemical, polymer, or 
molecule is easily done by washing with the organic phase. Synthetic approaches with facile 
surface functionalization methods without the need for potentially toxic organic chemicals are 
highly sought after.  
   
1.4 Methods of Synthesizing Iron Oxides 
 There is a plethora of synthetic methods reported in the literature including mechanical 
alloying or ball milling
97-99
, electron beam lithography
100
, laser pyrolysis
101-105
, electrospray
106
, 
and gas-phase deposition
107
.
51
 It is desirable to avoid these synthetic methods for FeOx 
nanoparticles used in hyperthermia because these methods are often complex and/or do not have 
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sufficient nanoscale size control. Synthetic methods that produce more applicable nanoparticles 
for hyperthermia include aqueous co-precipitation
108-113
, sol-gel
114
, hydrothermal reaction
115
, 
flow injection synthesis
116
, microemulsion
117
, chemical vapor deposition (CVD)
118,119
, 
glycol
53,120-122
, thermal decomposition(83-86), and sonochemical syntheses
123
.
27,124,125
  Co-
precipitation of iron salts is mentioned in spite of its sufficient lack of size distribution control 
because it produces nanoparticles that have some degree of water stability without post-
modification steps.
27,126
  
 Thermal decomposition synthesis of FeOx nanoparticles are worthy of particular 
emphasis. This method is extremely versatile and the size and morphology can be controlled.
27
 
Synthesis parameters of time, reactant concentration, ratios of reactants, temperature, intrinsic 
solvent or iron precursor properties, and seed growth techniques can be utilized to obtain 
morphology and size control.
27,127
 Utilizing non-polar solvents is beneficial to obtain highly 
crystalline FeOx nanoparticles with tunable size, narrow size distribution and facile scale-up 
potential. To produce 15 nm crystallite sizes, with non-polar solvents, the nanoparticles must be 
synthesized with seed growth steps that require multiple solvents, capping agents, and/or 
intermediate wash steps.
128,129
 However, the downside of non-polar solvent use is that they 
require difficult or complex phase transfer steps to obtain aqueous dispersions and stability. It is 
crucial that a biologically stable colloidal solution of nanoparticle be easily obtain by post-
synthetic methods such as surface functionalization. The importance of biological stability and 
conjugation potential of targeting ligands provided by surface functionalization is critical for 
FeOx nanoparticles for use in MFH or nanomedical applications especially where targeting to 
tumor cells is required.
39,40,130
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1.5 Benzyl Alcohol Synthesis of Metal Oxides  
 Benzyl alcohol, a polar solvent, provides the benefits of non-polar solvent synthetic 
methods of control of size, high crystallinity, narrow size distribution, and potential facile scale-
up with the added benefit of being more easily surface functionalized for the required biological 
stability post synthesis.
131
 Size control has been achieved for crystalline titania nanoparticles 
synthesized with benzyl alcohol from titanium tetrachloride by modifying the reaction 
temperature and precursor concentrations.
132
 Scale-up was demonstrated in recent reports of 
benzyl alcohol synthesis with vanadium and tungsten chlorides to produce gram quantities.
133
 
Thermal decomposition of iron (III) acetylacetonate (Fe(acac)3) in benzyl alcohol has several 
benefits. Benzyl alcohol is simultaneously acting as a solvent, capping agent, and reducing agent 
to synthesize FeOx nanoparticles. Furthermore, when the reaction is carried out under the 
presence of air the reduction of Fe(acac)3 is increased due to increased oxidation of benzyl 
alcohol to benzaldehyde.
94
 The oil of plants naturally contain benzyl alcohol.
134
 Commercial 
applications have been found for benzyl alcohol in products such as cosmetics products
135
, 
injectable drug preservative
134
, and as fragrance and flavor additives
135-137
.  
 Over 35 metal oxides have been synthesized using benzyl alcohol and metal precursor 
salts such as alkoxides, acetates, acetylacetonates, and halides.
138-143
 Literature reports relatively 
few benzyl alcohol synthesis studies of FeOx nanoparticles especially using Fe(acac)3 as a metal 
precursor.
138,139
 FeOx has been synthesized in a microwave mediated benzyl alcohol synthesis 
with the metal precursor Fe(acac)3 which had the benefits of producing highly crystalline 
nanoparticles very rapidly (5 minutes), but only 5 nm crystallite sizes were obtainable.
139
 A more 
complicated benzyl alcohol synthesis with Fe(acac)3 was recently done using an autoclave 
method and requiring a glovebox, and heating in a furnace for two days to obtain 15-25 nm 
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crystallite sizes.
143
 A simple, well controlled and understood benzyl alcohol reaction that 
produces 15-16 nm crystallite sizes is highly desirable. Therefore, a simple benzyl alcohol 
synthesis under nitrogen and atmospheric conditions was used to gain mechanistic insight into 
the benzyl alcohol Fe(acac)3 synthesis of FeOx nanoparticles. Initial studies will be used to 
acquire enhanced control over crystallite size and size distribution that is vital for increasing the 
effectiveness in radiofrequency hyperthermia. 
 
1.6 Surface Functionalization of nanoparticles for Biological 
Applications 
 The initial stability of FeOx nanoparticles depends on whether they were synthesized by 
an aqueous or organic method. Aqueous synthesis such as co-precipitation typically results in 
some degree of aqueous stability. Organic synthesis such as thermal decomposition of Fe(acac)3 
results in stability in organic solvents and requires difficult phase transitions to modify the 
surface for aqueous stability.144 However, organic synthesis is favored for producing FeOx 
nanoparticles where precise control of size and size distribution is required. FeOx nanoparticles 
synthesized by the benzyl alcohol modified seed growth synthesis have the advantages of 
organic synthesis of tunable size and size distribution and can be easily surface functionalized for 
aqueous stability without complicated phase transfer processes.94 There is an ever increasing 
demand for surface functionalizations that provide true biologically relevant colloidal stability 
despite the numerous reported methods in literature.124 Typical surface functionalizations have 
terminal amine and/or carboxyl groups to provide stability and have the added benefit of further 
conjugation of targeting ligands, chelates, or radiolabels.94,124,145 Some examples of commonly 
used surface functionalizations for biological stability include use of polymers or organosilanes. 
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1.6.1 Carboxymethylated Polyvinyl Alcohol Surface Functionalization 
 Polyvinyl alcohol can be carboxymethylated to form carboxymethylated polyvinyl 
alcohol (CMPVA) a biodegradable, cheap, and hydrophilic biopolymer.130 The carboxyl groups 
of CMPVA interact strongly with the surface of FeOx.131 The carboxyl groups that do not 
interact with the surface provide the colloidal and biological stability as well as sites for further 
conjugation of targeting ligands, therapeutic and/or diagnostic agents. One possible disadvantage 
of using CMPVA is that the length of the polymer increases the possibility of bridging and/or 
multiple nanoparticles adsorbing the same polymer which will ultimately lead to clusters of 
stable nanoparticles or instability. Large stable clusters of nanoparticles are undesirable as this 
can potentially affect the cellular uptake, blood circulation time, and increase the chance of 
becoming opsonized. 
 
1.6.2 Organosilane Surface Functionalization 
 Organosilanes offer the advantage of protecting the surface of FeOx from undesirable 
reactions and are often used to provide stability based on the terminal functional group of the 
organosilane.146-148  Two of the more commonly used organosilanes for FeOx surface 
functionalization include (3-Aminopropyl)trimethoxy silane (APTS) and (3-
aminominopropyl)triethoxysilane (APTES). These organosilanes offer an efficient and easy 
method to modifying the surface of FeOx nanoparticles through a silanization reaction resulting 
in a Fe-O-Si bond and a silica shell around each nanoparticle.124,149 The resulting modified 
surface contains terminal amine groups giving the nanoparticles a positive zeta potential at 
neutral pH.146 More specifically the charge of the nanoparticles offers stabilization through an 
electrostatic double layer and steric hindrance of the organosilane.73-76 The number of silica shells 
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that form in addition to how quickly and effectively the silanization occurs depends on several 
factors such as time, pH, temperature, hydrolysis rate, concentration and type of catalyst 
used.124,149,150 There is a plethora of reported methods for APTS or APTES surface 
functionalization of FeOx nanoparticles, however few have sufficiently been optimized or 
characterized to properly show biologically relevant stability or extent of silanization.149 
Additionally, the methods employed will need to be modified or optimized depending on the 
FeOx nanoparticle synthesis used. 
 Another organosilane of particular interest is (3-Glycidyloxypropyl)trimethoxysilane 
(GLYMO) which contains a terminal three membered epoxy ring that can be used to easily alter 
the chemistry at the surface. The epoxide ring initially prevents aqueous stability after 
silanization, but also hinders the possibility of creating additional silane shells, and bridging or 
coating of multiple nanoparticles. Through the use of acid or base-catalyzed epoxy ring opening 
reactions aqueous stability can be achieved by coupling different biomolecules containing an 
amine group or strong nucleophile.151 When selecting an appropriate biomolecule it is 
advantageous to select one with only one reactive site to prevent possible bridging or cross 
linking between nanoparticles. This bridging would result in larger hydrodynamic diameters, 
wider size distributions, and ultimately aggregation and precipitation. Overall, modifying the 
surface of FeOx nanoparticles with GLYMO grants the ability to conjugate a wide array of 
biomolecules providing and even tuning the colloidal stability for specific biological 
environments.  
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1.7 Project Overview 
 Herein, the research into FeOx nanoparticles for radiofrequency induced magnetic 
hyperthermia treatment of cancer is split into three main objectives. The first objective was to 
design and optimize the benzyl alcohol synthesis of FeOx nanoparticles with ideal properties for 
hyperthermia applications. The second objective was to devise and tailor a simple surface 
functionalization strategy suitable for biological applications with further conjugation potential. 
The third objective was to conduct biological tests to determine the nanoparticles efficacy in for 
biological applications including RF hyperthermia and brachytherapy delivery.  
 Chapter 1 introduced the relevant and essential background information to understand 
radiofrequency induced magnetic hyperthermia. More specifically this chapter discussed the 
plethora of FeOx nanoparticle synthesis and surface functionalization strategies that are suitable 
for RF hyperthermia applications. The challenges and ideal properties of surface 
functionalization for translation to biological applications are also discussed. 
 In Chapter 2 the different FeOx nanoparticles are introduced. The numerous applications 
for FeOx nanoparticles and the different crystal structures are briefly reviewed with focus on the 
inverse spinel crystal structure of magnetite and maghemite ordinarily used in magnetic RF 
hyperthermia. 
 In Chapter 3 the results and discussion from the investigation into synthetic parameters of 
the benzyl alcohol synthesis are presented. Emphasis is placed on altering the reaction 
environment, concentration, and temperature to optimize the resulting FeOx nanoparticle 
properties. LaMer growth and Ostwald ripening principles are used to speculate on the observed 
effects of reaction parameters on nanoparticle properties. For further optimization and control of 
nanoparticle properties a modified seed growth method is investigated. The complex interactions 
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between reaction parameters and nanoparticle properties, as well as between nanoparticle 
properties and RF heating are analyzed using JMP effect screening models. 
 Chapter 4 presents the ease of surface functionalization for FeOx nanoparticles 
synthesized by the benzyl alcohol method. The surface functionalization with CMPVA, APTS, 
APTES, and GLYMO are discussed with emphasis on the stability properties in different 
biologically relevant media. The GLYMO modification with different amino acid and 
nucleophiles is investigated to obtain a method that allows for tailoring of stability properties. 
Additionally, the CMPVA-FeOx and SAHBA-FeOx nanoparticles are further functionalized 
with a DOTA chelate and radiolabeled with 
177
Lu to confirm their use as a nanoplatform. 
Chapter 5 presents biological testing of surface functionalized FeOx nanoparticles. In 
vitro cellular uptake, proliferation, and hyperthermia test results are presented and discussed. An 
initial in vivo survival study using a murine orthotopic xenograft model of glioblastoma 
multiforme is used to investigate the efficacy of CMPVA-FeOx and SAHBA-FeOx nanoparticles 
to deliver brachytherapy. 
Chapter 6 concludes the dissertation with a brief summary of important findings. The 
combination of investigating synthetic methods, surface functionalization strategies, and 
biological testing in this project will be extremely beneficial to gain knowledge applicable to 
magnetic hyperthermia applications, nanotechnology, and nanomedicine. The work herein will 
be beneficial and intriguing to experts in areas of material synthesis, surface coating technology, 
medicine, physics, radiology, molecular biology, and other disciplines.   
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Chapter 2: Iron Oxide Nanoparticles 
 
 
 
2.1 Iron Oxides in Nanotechnology 
 Nanotechnology, especially FeOx nanoparticles, can be utilized in countless ways. FeOx 
nanoparticles are useful materials in biosensors,
152-156
 high density information data storage,
157-
160
 catalysts,
124,157,161-163
 magnetic sensors,
164-167
 and permanent magnets.
159,160,168,169
 FeOx 
nanoparticles with specific surface functionalizations have proven very useful in biosensing 
applications using diagnostic magnetic resonance (DMR) technology to detect cells and 
biomolecules such as DNA, pathogens, mRNA, proteins, drugs, and tumors.
156
 Understanding 
and manipulation of magnetocrystalline anisotropy of FeOx has given rise to innovative ways to 
magnetically store information data.
158
 The high surface area to volume ratio property of 
nanoparticles has led to a significant interest in utilizing FeOx nanoparticles for catalysts and 
magnetic sensors.
161
 Additionally, catalysts and magnetic sensors benefit from nanoparticles 
stability, selectivity, and increased efficiency as compared to bulk sized materials.
161
 The 
magnetic properties of FeOx nanoparticles are often sought after because they can be 
magnetically extracted and recycled after use as catalysts, biosensors, or in other 
applications.
156,161
 Significant amounts of research time have been invested into creating 
permanent magnets and finding new applications for them. Permanent magnet materials combine 
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the ideal properties of a soft magnet’s large coercivity property and a hard magnet’s large 
magnetization saturation property by exchange coupling.
160
 FeOx nanoparticles are extremely 
advantageous in biotechnology and nanomedicine as they can be used in both theranostics and 
diagnostics. Diagnostically they are used as magnetic resonance imaging contrast agents due to 
their strong T2-weighted and T2* image improvement.
28,170,171
 FeOx nanoparticles continue to be 
rigorously investigated to find new and better applications and improve their efficacy in 
applications such as magnetic hyperthermia where their superparamagnetic behavior, size, 
biocompatibility, and inherent imaging capabilities are utilized.
29,44,170,172-174
 
 
2.2 Iron Oxide Crystal Structures 
 Iron oxides in nature typically consist of iron (II) and/or iron (III) cations and certain 
oxygen containing anions.
125,175,176
 Iron oxides can be referred to as oxides, hydroxides, or oxide-
hydroxides depending on if the crystal structure contains O
2-
 and/or OH
-
 anions. The term iron 
oxide is often used as an encompassing term of the many different iron oxides, hydroxides, or 
oxide-hydroxides.
125
 Stoichiometry and crystal structures differences have been used to identify 
the sixteen known pure phase iron oxides.
1,125,175
 Table 2.1 lists the known iron oxides and are 
subcategorized into iron oxides, iron hydroxides, and iron oxide-hydroxides.
1
 In the following 
sections hematite, wüstite, maghemite, and magnetite crystal structures are briefly introduced. 
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Table 2.1. The mineral name and formula for the sixteen known pure phase iron oxides 
subcategorized into iron oxide, iron hydroxide and iron oxide-hydroxide. Reproduced from 
1
. 
Iron Oxide 
Mineral Name Formula 
Wüstite FeO 
Magnetite Fe3O4 
Hematite α-Fe2O3 
β-Maghemite β-Fe2O3 
Maghemite γ-Fe2O3 
ε-maghemite ε-Fe2O3 
High pressure iron oxide Fe4O5 
Iron Hydroxide 
Mineral Name Formula 
Iron(II) hydroxide Fe(OH)2 
Bernalite (Iron(III) hydroxide) Fe(OH)3 
Iron Oxide-Hydroxide 
Mineral Name Formula 
Goethite α-FeOOH 
Akaganéite β-FeOOH 
Lepidocrocite γ-FeOOH 
Feroxyhyte δ-FeOOH 
High Pressure FeOOH FeOOH 
Ferrihydrite Fe5HO8•4H2O approx. 
Schwertmannite Fe16O16(OH)y(SO4)z•nH2O 
Green Rusts Fex
3+
Fey
2+
(OH)3x+2y-z(A
-
)z ; A
-
=Cl
- 
,1/2SO4
2-
,CO3
2- 
 
2.2.1 Magnetite Crystal Structure 
 Magnetite is the preferred crystal structure for magnetic fluid hyperthermia. 
The inverse spinel structure of magnetite is depicted in Figure 2.1
2
.
1,28,157,175,177,178
 The inverse 
spinel crystal structure consists of 32 oxygen atoms close packed in a face centered cubic (FCC) 
orientation with iron ions located within 16 of the 32 octahedral holes and 8 of the 64 tetrahedral 
holes.
28,177
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in  
Figure 2.1. Diagram showing the side view and top view of wüstite (a), magnetite (b), and 
hematite(c). Two top views are shown for magnetite and hematite to visualize the different layers 
of the crystal structure. From 
2 
 
The magnetite inverse spinel crystal structure contains eight Fe
2+
 and eight Fe
3+
 ions the 
octahedral vacancies, and eight Fe
3+
 ions in the tetrahedral vacancies.
28,175,177
 The magnetite 
inverse spinel formula is therefore Fe3O4 or Fe
3+
(Fe
2+
Fe
3+
)O4.
28,175,177
 The octahedral and 
tetrahedral holes make up the sublattices within the oxygen FCC lattice. The ferrimagnetism 
intrinsic to magnetite results from the coupling between the iron ions.
175,177
 More specifically, we 
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can see that from Hund’s rule that Fe2+ and Fe3+ have magnetic moments of 4 and 5 Bohr 
magnetons (μB) respectively.
177
 Magnetite has a  calculated μB=4.07 per formula unit which is 
much closer to the 4 μB of Fe
2+
.
177,178
 This can be explained due to the antiferromagnetic 
arrangement of the Fe
3+
 in the octahedral and tetrahedral vacancies leaving the Fe
2+
 ions as the 
significant contributor to the magnetization.
177,178
 In summary, the ferrimagnetic property is a 
result of the difference in Bohr magnetons of each iron ion, the arrangement between the two 
sublattices, and the unequal Fe
2+
 and Fe
3+
 amounts. The properties of magnetite, maghemite, 
Wüstite, and hematite are summarized in Table 2.2.
1
 
  
Table 2.2. Properties of magnetite, maghemite, hematite and wüstite. Reproduced from 
1
. 
Mineral Name Magnetite Maghemite Hematite Wüstite 
 
Cubic Cubic or 
tetragonal 
Rhombohedral 
hexagonal 
Cubic 
Cell Dimensions 
(nm) 
a= 0.8396 a= 0.83474 a= 0.50356 
c= 1.37489 
a= 0.4302-0.4275 
Formula units, per 
unit cell, Z 
8 8 6 4 
Density (g/cm
3
) 5.18 4.87 5.26 5.9-5.99 
Octahedral 
occupancy 
- - 2/3 - 
Color Black Reddish-brown Red Black 
Hardness 5.5 5 6.5 5 
Magnetism 
Ferrimagnetic Ferrimagnetic Weekly ferromagnetic 
or antiferromagnetic 
Antiferromagnetic 
Currie (Néel) 
Temperature (K) 
850 820-986 956 203-211
1) 
Melting point (°C) 1583-1597  1350 1377 
Boiling point (°C) 2623   2512 
1) Néel Temperature 
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2.2.2 Maghemite Crystal Structure 
 Maghemite also displays an inverse spinel crystal structure and is more 
thermodynamically favored than magnetite.
1,2,157,179,180
 The properties of maghemite are 
summarized in Table 2.2.
1
 It is important to note that maghemite is a ferrimagnet and has a 
reddish-brown color. This color helps to first distinguish it from magnetite as the two inverse 
spinel structures cannot be differentiated by powder XRD. The metastable maghemite, γ-Fe2O3, 
cubic unit cell can be stoichemetrically written as (Fe
3+
)8[Fe
3+
5/61/6]16O32 where  indicates a 
cation vacancy and the tetrahedral and octahedral positions are indicated by () and [] 
respectively.
1,175,179,180
 Maghemite can be obtained from heating magnetite in organic compounds 
which causes the Fe
2+
 cations to become oxidized and result in some cation vacancies.
175,180,181
 
At high temperatures, around 400°C depending on crystallinity and size the crystal structure of 
maghemite can be converted to the more thermodynamically favored hematite crystal 
structure.
1,180
 
 
2.2.3 Hematite Crystal Structure 
 The red colored ferromagnetic iron oxide, hematite (α-Fe2O3), is nature’s most abundant 
iron oxide.
1,157,180,181
 Figure 2.1 depicts hematite’s crystal structure which is similar to 
rhombohedral corundum.
1,2
 Properties of hematite are summarized in Table 2.2.
1
 It has a 
rhombohedrally centered hexagonal close packed crystal structure with  two-thirds of the 
octahedral sites filled with Fe
3+
 ions.
1,157,180
 Hematite’s weak ferromagnetic state is due to the 
magnetic spins being canted about 5° at temperatures between the Morin Temperature (TM) and 
the Néel Temperature (TN).
180
 The ferromagnetism of hematite transitions to antiferromagnetism 
below TM=260 K, and to paramagnetism above TN=950 K.
180
 Hematite is the most 
 34 
 
thermodynamically favored structure of all the iron oxides and so under the correct conditions 
magnetite, maghemite, etc. will all undergo oxidation and/or rearrangement to hematite.
180,181
 
 
2.2.4 Wüstite Crystal Structure 
 Wüstite has a similar crystal structure to that of sodium chloride (NaCl) where the Fe
2+
 
ions exist in octahedral sites of the oxygen anions closed packed FCC lattice.
1
 The crystal 
structure is shown in Figure 2.1 and the summarized properties are listed in Table 2.2.
1
 
Interestingly this crystal structure is only formed at temperatures exceeding 843K and the 
stoichiometric formula is Fe1-xO because of 5-15% oxidation of Fe
2+
 ions to Fe
3+
 ions.
175,182
 The 
amount of oxidation is dependent upon the temperature and partial pressure of oxygen.
175,182
 
Below 843K this crystal structure will disproportionate to more thermodynamically favored 
states of Fe metal and Fe3O4.
1
 
  
2.3 Magnetic Properties of Iron Oxide 
The magnetic, biodegradable and biocompatible properties of magnetite (Fe3O4) and 
maghemite (γ-Fe2O3) make them the most desirable FeOx nanoparticles for magnetic 
hyperthermia.
9,25,28,183
 Bulk FeOx particles are comprised of multi-domain particles, but as the 
size is decreased into the nanometer region the FeOx nanoparticles will behave as single-domain 
particles and eventually superparamagnets. For example it has been estimated that below 166 nm 
diameter the particles will behave as single-domain particles.
160
 Likewise, magnetite has a 
theoretical multi-domain to single-domain transition at approximately 80-100 nm.
184,185
 Further 
reduction in diameter below approximately 20-30 nm the nanoparticles will start to display 
superparamagnetism depending on the crystal structure.
184
 Multi-domain particles will not be 
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discussed in detail as these are above the desirable size range for efficient magnetic 
hyperthermia. 
Superparamagnetism is an interesting phenomenon that arises in certain magnetic 
materials when the size is sufficiently small. The non-interacting magnetic moments of 
superparamagnets will respond to thermal fluctuations when the thermal energy (KBT) is greater 
than the anisotropic energy.
124,159,169
 When the thermal energy exceeds the anisotropic energy the 
individual magnetic moments will alter directions in response to thermal fluctuations.
169
 The 
nanoparticles magnetic spin direction will eventually reach an equilibrium comparable to thermal 
equilibrium.
169
 It should be noted that the size limit of superparamagnetism depends on the 
material of interest and is termed the superparamagnetic limit.
28,124
 Superparamagnets exhibit 
very large saturation magnetization and susceptibility values as a result of considering the 
nanoparticles total magnetic moments (as high as 10
4
-10
5
 Bohr magnetons) instead of the 
individual magnetic moment of a single atom.
28,169
 A representative hysteresis loop for a 
superparamagnet is shown in Figure 2.2. The negligible coercivity and magnetic remanence can 
be seen in the hysteresis curve in Figure 2.2. Coercivity refers to force required in terms of 
magnetic field strength required to return the magnetization to zero.
28,124,169
 Magnetic remanence 
defines the residual magnetism that remains after the magnetic field is removed.
28,124,169
 These 
properties make FeOx superparamagnets ideal candidates for use in biological applications such 
as magnetic hyperthermia as they will not exhibit magnetization after removal of the externally 
applied magnetic field. Additionally, when the radiofrequency alternating current magnetic field 
is applied the nanoparticles will rapidly respond to changes in the applied external magnetic 
field. The negligible remnant magnetization is important to mention as this reduces the 
probability of aggregation due to room temperature magnetism between nanoparticles.
28,124
 It 
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would be advantageous to use metallic nanoparticles instead of oxide nanoparticles because of 
their higher magnetization values, however they are generally toxic and not applicable in medical 
applications.
124
 
 
 
Figure 2.2. Representative hysteresis loop for single domain ferromagnetic (a) and 
superparamagnetic (b) crystals plotted as magnetization (M) versus magnetic field (H). MS, Mr, 
and Hc correspond to magnetization saturation, remnant magnetization, and coercive field 
respectively. From 168 
 
Single-domain particles in the nanorange, outside of the superparamagnetic size range, 
are also useful in biomedical applications. Single-domain particles do not have domain walls and 
therefore exhibit large magnetic coercivities. 
124,159,169
 Also, these single-domain particles have a 
net magnetic spin direction.
124,159,169
 The lack of domain walls is due to the unfavorable 
magnetostatic energy at such small volumes.
159
 External magnetostatic energy is allowed rather 
than creating energetically unfavorable domain walls.
124
 Therefore, when the size of the particle 
increases it will eventually become energetically favorable to create multiple walls resulting in 
multi-domain particles.
124,159
 At these larger sizes several factors determine the size and shape of 
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the domains; these include anisotropy, energy of exchange and magnetostatic interactions.
159
 It is 
worth mentioning that the coercivity can be increased with differing shape anisotropy of single-
domain particles.
124   
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Chapter 3: Benzyl Alcohol Synthesis of Iron Oxide 
Nanoparticles 
 
 
 
3.1 Experimental Section  
 3.1.1 Reagents, Materials, and Equipment 
All chemicals and materials were used as received.  Tetramethylammonium hydroxide 
(TMAOH) solution (Alfa Aesar, 25% w/w aq.), iron (III) acetylacetonate (Fe(acac)3) (Acros 
Organics, 99+%), benzyl alcohol (Alfa Aesar, 99%), copper TEM grids (Ted Pella Inc., 200 
mesh Formvar carbon type B), Fe inductively coupled plasma (ICP) standard (Alfa Aesar, Iron, 
plasma standard solution, Specpure®, Fe 1000 µg/mL), hydrochloric acid solution (HCl) 
(Electron Microscopy Sciences, 2%), potassium ferrocyanide aqueous solution (Prussian Blue) 
(Electron Microscopy Sciences, 2%), two-neck 100 mL round bottom flask (Chemglass), coil 
style reflux condenser (Chemglass), and acetone (Fisher Scientific, ACS grade) 
 
 3.1.2 Modified Seed Growth of Iron Oxide Nanoparticles 
 Synthesis of FeOx nanoparticles in benzyl alcohol was conducted under nitrogen flow or 
open to air in a two-neck 100 mL round bottom flask (Chemglass) equipped with a coil style 
reflux condenser (Chemglass). The volume of benzyl alcohol (Alfa Aesar, 99%) for all reactions 
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was 20 mL. Iron (III) acetylacetonate (Fe(acac)3) (1, 2, 3, 4, or 6 g) (Acros Organics, 99+%) was 
dissolved in benzyl alcohol with vigorous magnetic stirring and then immediately heated to 
reflux or a set temperature. In the nitrogen syntheses, nitrogen was initially bubbled in the benzyl 
alcohol and Fe(acac)3 for 30 minutes prior to heating. After the solution color changed from a 
dark red to black, the reaction was carried out for 2 or 24 hours. At the end of the reaction, the 
round bottom flask was removed from heat and stirred for 15 minutes while cooling. Acetone 
(Fisher Scientific, ACS grade) was then used to precipitate and wash the FeOx nanoparticles 
with magnetic extraction. This wash step was repeated 3-5 times with intermittent and brief 
sonication (Cole Parmer, Ultrasonic Cleaner 8892) between wash steps. The nanoparticles were 
then dried down to a powder with nitrogen flow. 
 The modified seed growth procedures followed the procedure as stated above, but after 
the 24 hour reaction an additional amount of Fe(acac)3 (1, 2, 3, 4, or 6 g) was added as a dry 
powder directly to the hot reaction. Reaction was then carried out for an additional 24 hours 
before removal from heat. The nanoparticles were then precipitated, washed, magnetically 
extracted, and dried as stated above. 
 The heating mantle (Thermoscientific, electrothermal heating mantle) used in initial 
studies was replaced with a silicone oil bath (Alfa Aesar) with the temperature controlled by a 
magnetic stirring hot plate (VWR, VMS-C7) equipped with a temperature control unit (VWR, 
VT-5 S40) to better and more precisely control the temperature. The maximum heating ramp rate 
was used for either the heating mantle or silicon oil bath and hotplate setup. The temperature and 
color of the solution was observed and documented every 60 seconds in the initial heating to 
reflux or set temperature. This was important to determine important temperature thresholds such 
as when high levels of nanoparticles were forming indicated by a solution color change to black. 
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3.2 Characterization Techniques 
 3.2.1 X-ray Diffraction (XRD) 
 Determining the crystal structure of a material by x-ray diffraction (XRD) 
characterization is advantageous as it is a non-destructive technique.1,186-189  XRD utilizes x-rays 
that will interact with the sample and form a diffraction pattern that is used in determining the 
bulk crystalline structure.188,189 More specifically, electromagnetic radiation in the form of x-rays 
are used to analyze the arrangement of the atoms within a crystal. Typically the wavelength (λ) 
of the x-rays is approximately 0.1 nm as this wavelength is similar to the crystal’s interatomic 
distance resulting in elastically scattered x-rays.1,188-190 The constructive and destructive 
interference of scattered x-rays produces a diffraction pattern that is unique to different crystal 
structures of crystalline materials.1,188,189 The atoms in a crystalline material are consistently 
arranged resulting in the incident x-rays elastically scattering at specific angles and interatomic 
lattice distances which causes constructive interference in specific directions.1,188 Bragg’s law 
(Equation 5) states  the distance between atomic planes of the lattice (dhkl) and the incident 
angle (θ), specific to an incident x-ray wavelength (λ) spaced at integer multiples (n) of the path 
difference where constructive interference of elastically scattered x-rays occur.1,188 
𝑛𝜆 = 2𝑑ℎ𝑘𝑙 sin θ     (5) 
The resultant XRD pattern’s peak positions are used to determine the lattice parameter, size, and 
symmetry.188 Additionally, the peak intensities are useful in determining the organization of 
atoms.188 The database of known crystallography data can be searched to find similar XRD 
patterns and thus verify the crystal structure of a material of interest.188 Powder XRD is very 
useful for the characterization of crystalline nanomaterials. This technique exploits the large 
number of crystals present in a powder and allows the incident x-ray to interact with the material 
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at numerous orientations or angles at the same time.189 A diffractometer investigates all possible 
crystal orientations of the powder by analyzing the resultant diffraction cones of the powder 
sample which are used to determine the diffraction pattern.189 It is important to note that 
magnetite and maghemite crystal structures are indistinguishable by XRD.1 
 The crystallite size of nanoparticles can also be determined by analyzing the XRD line 
broadening with the Scherrer formula (Equation 6).1 The Scherrer formula relates the corrected 
peak width at an angle in the XRD measurement to the crystallite size, but will underestimate the 
smaller crystallite sizes when multiple crystallites are present.1 In other words, the formula is 
biased towards larger crystallite size when the mean crystallite size is determined from the 
coherently scattering domain perpendicular to the hkl plane (MCLhkl).
1 This is due to larger 
crystallites more intensely scattering x-rays. 
𝑀𝐶𝐿ℎ𝑘𝑙 =  
𝐾𝜆
𝑏 cos 𝜃
      (6) 
The formula uses the shape factor (K), full width half maximum (FWHM) of the measured peak 
(b), and wavelength of the x-ray (λ).1 The instrument error is accounted for by subtracting the 
instrument width from the value of b.  
A PANalytical X'Pert Pro Materials Research Diffractometer was used to obtain powder 
XRD patterns. The sample was prepared by drying the material to a powder with nitrogen and 
mild grinding to acquire a fine powder that was then transferred to a low background silicon 
disk. The material was scanned at 20-80° 2θ using a Cu Kα x-ray source.  X’Pert High Score 
Plus software was used to analyze the pattern and calculate the crystallite size based on 
diffraction peak broadening using the Scherrer formula. Several of the peaks in the XRD pattern 
were used to calculate crystallite size and standard deviation. 
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 3.2.2 Dynamic Light Scattering (DLS) 
Characterizing nanoparticles in solution provides useful information about hydrodynamic 
size, size distribution, diffusion coefficients, and surface charge. Dynamic light scattering (DLS) 
is a technique that can be used to rapidly assess these properties of a nanoparticle solution 
without destroying the nanoparticles.191,192 DLS requires a stable colloidal suspension for best 
results. DLS utilizes a monochromatic light source to probe the colloidal suspension and record 
the time variation of the intensity of the light scattered by diffusing nanoparticles throughout a 
solution.191,192 The intensity at two specific time points are correlated by the intensity 
autocorrelation function.192 Since, the colloidal nanoparticles have kinetic energy the diffusion 
coefficient can be measured.191 The intensity of scattered light at certain angles over time is 
related to the diffusion of the nanoparticles throughout the solution.191 Therefore, it is important 
to know the viscosity, refractive index, and temperature of the solution being analyzed to 
effectively characterize nanoparticles using DLS. The hydrodynamic diameter and size 
distribution in terms of polydispersity index (PDI) values are calculated from the measured 
diffusion coefficients.192 In Equation 7, the magnitude of the scattering wave (q) is calculated 
using the range of scattering angles (θDLS), wavelength of the incident light (λ), and refractive 
index of the solution (n).191 
𝑞 = (
4𝜋𝑛
𝜆
) 𝑠𝑖𝑛 (
𝜃𝐷𝐿𝑆
2
)              (7) 
The hydrodynamic radius (RH) is calculated using the Stokes-Einstein equation shown in 
Equation 8 where the following abbreviations are used: T is the solution temperature, KB is 
Boltzmann constant, and η is the medium viscosity.191,192 Thus it can be seen that the 
hydrodynamic radius is directly related to the diffusion coefficient (Df).
191 
𝐷𝑓 =  
𝐾𝐵𝑇
6𝜋𝜂𝑅𝐻
      (8) 
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Next, the size distribution is calculated, in terms of the PDI, using the average decay rate (⟨Γ ⟩) 
and the variance of the decay rate distribution (μ2) (Equation 9).
191 
𝑃𝐷𝐼 =
μ2
〈Γ〉2
      (9) 
Absolute monodispersity is highly improbable, therefore the correlation function calculated ⟨Γ ⟩ 
and q values can be used to obtain an average hydrodynamic radius (Equation 10).191 Depending 
on the instrument used, a weighted function can be used to calculate the summation of all 
possible decay rates for each nanoparticle to determine a size distribution.192 The size distribution 
determined using a weighted average should be considered “semi-quantitative” representation of 
the size distribution and not an exact size distribution.192 
𝑅𝐻 =  
𝐾𝐵𝑇
6𝜋𝜂〈Γ〉
𝑞2     (10) 
The DLS data can be presented based on the number, volume, or intensity of 
nanoparticles because the data is an average of the nanoparticles in solution. Larger nanoparticles 
more intensely scatter light than smaller nanoparticles causing a bias towards larger 
nanoparticles when the results are presented as intensity. For nanoparticles in solution, it is better 
to analyze the data presented based on number or volume of nanoparticles rather than intensity as 
this is a more indicative of the actual hydrodynamic diameter. Hydrodynamic diameter is also 
useful in determining the surface functionalization thickness on nanoparticles. This is 
accomplished by measuring the nanoparticles before and after surface functionalization and 
subtracting the non-surface functionalized nanoparticles. However, the nanoparticle surface and 
the surface functionalization ligands may interact with water differently and thus skew the 
thickness measurement.  
Zeta potential (ζ) determined by dynamic light scattering is often used to characterize the 
electro-kinetic phenomenon of the stabilization offered by the double layer. This measurement 
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utilizes electrophoresis, the movement of charged particles in response to an external applied 
electric field, to calculate the mobility which is the velocity divided by the field intensity.73 When 
spherical nanoparticles are sufficiently small (where κa is small enough that spherical 
nanoparticles can be considered a point charge) and are measured at low electrolyte 
concentrations and potentials the Hückel-Onsager equation (Equation 11) can be used to relate 
electrophoretic mobility (μE) to zeta potential.
73 The value of κa is a dimensionless term that 
represents the thickness of the double layer and nanoparticle radius respectively.73 The viscosity 
(η) of the solution and permittivity (ε) also play key roles in determining the electrophoretic 
mobility. The permittivity is a combination of permittivity of free space (ε0) and relative 
permittivity (εr) and is shown in Equation 12. 
𝜇𝐸 =
𝜀𝜁
6𝜋𝜂
       (11) 
ε = 4πε0ε𝑟      (12) 
For particles too large to use the Hückel equation, a generalized equation (Equation 13) is used 
instead to relate electrophoretic mobility and zeta potential. 
𝜇𝐸 =
𝜀𝜁
6𝜋𝜂
𝑓(𝜅𝑎)      (13) 
A Malvern Zetasizer Nano-ZS (Malvern Instruments, U.K.) was used to analyze the 
hydrodynamic diameter, polydispersity index, and zeta potential of FeOx nanoparticles and 
surface functionalized FeOx nanoparticles at ambient conditions. This instrument uses a He-Ne 
laser (633 nm, max 4 mW) light source. For initial hydrodynamic diameter and PDI 
measurements the FeOx nanoparticles at a concentration of 20 mg/mL were dispersed by 
sonication for 180 minutes in a 0.25% tetramethylammonium hydroxide (TMAOH) solution. 
Next, the solution was incubated at room temperature overnight and then a 1 mL 1:100 dilution 
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with water was made for DLS analysis. These samples were transferred to a low volume 
disposable cuvette and DLS was run 5 times with each run containing 11 measurements. For zeta 
size measurements the surface functionalized nanoparticles were concentration and pH matched 
and then loaded into a folded capillary zeta cell (Malvern Instruments, U.K.) prewashed with 
ethanol and water to remove any contaminants.  
Several concentrations of TMAOH solution were used to disperse the FeOx nanoparticles 
to verify that the hydrodynamic diameter was not significantly altered by the TMAOH 
concentration. Additionally, this is important because different concentrations of TMAOH may 
be required to efficiently disperse different sizes of nanoparticles. FeOx nanoparticles produced 
by a modified seed growth method were dispersed in several TMAOH concentrations and their 
hydrodynamic size and PDI values were measured using DLS, the results are shown in Table 
3.1. 
 
Table 3.1. Initial hydrodynamic diameters and PDI values for various v/v % concentration of 
TMAOH. 
% TMAOH 
Hydrodynamic 
Diameter (nm) 
PDI
a
 
0.0625 25.99 0.38 
0.125 29.96 0.363 
0.25 23.61 0.39 
0.5 26.12 0.41 
a
Polydispersity Index (PDI) determined by DLS. 
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 3.2.3 Vibrating Sample Magnetometry (VSM) 
The magnetic properties of FeOx nanoparticles can be determined from vibrating sample 
magnetometry (VSM) determined hysteresis loop. A hysteresis loop is produced by loading a 
sample of known mass into a magnetometer and measuring the magnetization as the external 
magnetic field applied is increased from zero to a set magnetic field where the magnetization 
reaches a maximum or becomes saturated.1,189 Once the magnetization saturation is reached for 
the positive external magnetic field, the direction of external magnetic field is then reversed to 
reach a “negative” magnetization saturation and reversed a second time to the original “positive” 
magnetic field direction to complete the hysteresis loop.1,189 A representative hysteresis loop for 
superparamagnetic and ferromagnetic materials determined by VSM is displayed in Figure 2.2. 
Several important properties can be discerned from the shape, height, and width of the hysteresis 
loop. These properties include magnetization saturation (Ms), initial magnetic susceptibility (X), 
remnant magnetization (Mr), and coercivity (Hc). The magnetization saturation refers to the 
magnetization where all of the magnetic moments are oriented in the same direction of the 
externally applied magnetic field.1,189 Furthermore, the magnetization will not increase above the 
magnetization saturation when the external magnetic field is increased.1,189 The initial linear 
increase of the magnetization when the external magnetic field is increased from 0 is used to 
calculate the initial magnetic susceptibility. When the external magnetic field (H) is returned to 0 
any remaining magnetization is termed the remnant magnetization.1,189  The coercivity or 
coercive field refers to the magnetic field required to force the magnetization back to 0 or 
demagnetize the material after magnetization.1,189 It is important to note that for FeOx 
nanoparticles the presence of ferrimagnetic magnetite and maghemite will overpower the 
magnetism of other iron oxides detected.1  
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VersaLab 3 Tesla Cryogen-Free Vibrating Sample Magnetometer (Quantum Design) was 
used to probe the iron oxide materials and determine their magnetic properties. VSM sample 
capsule (Quantum Design) were loaded with 5-15 mg of dry FeOx powder and scanned for an 
offset of 35 mm. Next, the moment versus field measurements were recorded at a purged 
pressure of <50 Torr, sweep rate of 150 Oersted/second (Oe/s), and scanned in 5 quadrants from 
0 Oe to 15,000 Oe (Hmax) to -15,000 Oe (Hmin) without automatic centering. The hysteresis 
curve was examined to determine the magnetization saturation and was mass corrected using 
thermogravimetric analysis (TGA) in units of emu/g. 
 
 3.2.4 Thermal Gravimetric Analysis (TGA) 
Thermal gravimetric analysis (TGA) characterization is beneficial in determining the 
weight loss of a material as the temperature is increased.1 This technique can be used to correct 
the mass of impurities within a sample such as water, organic compounds, excess chemicals, 
surface functionalities, etc. in dry FeOx nanoparticles. Sample preparation for TGA involves first 
calibrating the tare weight of the TGA pan with a highly sensitive balance and then loading a 
sample (laden weight) on to the TGA pan and recording the sample weight as the temperature is 
increased at rates of 2-10 °C/min.1 The amount of mass lost is expressed as mass percent loss and 
can be used to correct the mass of sample used in techniques such as VSM where the mass of the 
magnetic material is critical to determine magnetization in terms of emu/g. 
A Q5000 TGA instrument (TA Instruments) was used to perform TGA and mass correct 
samples of FeOx nanoparticles. The platinum TGA pans were loaded with 5-50 mg of dry FeOx 
nanoparticles, under a nitrogen flow rate of 25 mL/min, and the temperature was ramped at 10 
°C/min from room temperature to 150°C and held isothermal for 15 minutes. This was followed 
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by additional temperature increase to 400°C at 10 °C/min and held isothermal for 60 minutes. 
 
 3.2.5 Transmission Electron Microscopy (TEM) 
Direct imaging of nanoparticles with atomic scale resolution can be performed with 
transmission electron microscopy (TEM) which uses a beam of electrons to acquire the 
image.192,193 TEM uses an electron beam gun to produce a beam of electrons that will probe a 
sample.193 The transmitted electron beam is dependent upon the amount of diffraction, the atomic 
number of the material, and phase contrast.193 To enhance the contrast and gain higher resolution 
images the sample stage should have different properties than the sample being analyzed.192,193 
A Zeiss LIBRA® 120 PLUS TEM was used to acquire bright field TEM images of the 
FeOx nanoparticles. Sample preparation was done by drying a drop of dilute FeOx nanoparticles 
(20 mg/mL) in 0.25% TMAOH solution on copper TEM grids (Ted Pella Inc., 200 mesh 
Formvar carbon type B). For CMPVA-FeOx the cleanup, desalting, and centrifuge filters were 
all done as described above prior to TEM sample preparation. Image J software was used to 
analyze the TEM images and calculate the nanoparticle size. 
 
 3.2.6 Radiofrequency Heating 
FeOx nanoparticle heating characteristics were investigated with a 1.2-2.4 kW EasyHeat 
induction heating system with a coil designed at a set point of 200 Ampere (A) to run at 1222 
watt (W) and frequency (f) of 269 kHz to produce an alternating magnetic field with a magnetic 
field strength (H) of 37.4 kA/m at 175.4 A. Other magnetic field strengths were used for small 
time length investigations of heating nanoparticles in cells. Ampere’s law can be used to 
calculate the magnetic field strength (H) (Equation 14) produced by a coil with length (L), and 
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number of turns (N), in a magnetic field (B), current (I) and using the permeability of free 
space(µo.).
194
  
BL =  µoNIo       (14) 
 The magnetic field strength is related to the magnetic field as shown in Equation 15.
189
 
By substituting Equation 14 into Equation 15 we can approximate the magnetic field strength 
produced inside the coil (Equation 16). The coil used in these studies had 8 turns (N=8) and a 
length of 0.0375 m (L=0.0375 m) which corresponds to H= 37.4 kA/m at 175.4 A.  
B =  µoH             (15) 
H =  
N
𝐿
Io           (16) 
 An OpSens fiber optic temperature sensor measured the in situ nanoparticle solution 
temperature when RF AC magnetic fields were applied. SoftSens software was used to record 
temperature every 1.4 seconds. The RF heating of 3 mL of 0.25% TMAOH aqueous FeOx 
nanoparticle (20 mg/mL) solution was used to compare the RF heating rates of samples at 175.4 
A and H=37.4 kA/m over 600 seconds. All solutions were corrected for potential convective 
heating by measuring a control 3 mL sample of water under identical conditions. The initial 
linear increase of temperature per unit time (dT/dt) of the water control (0.549°C/min) was 
subtracted from the initial linear increase of all TMAOH nanoparticle samples tested. 
 The RF heating data collected must be corrected based on iron concentration to more 
accurately compare samples. The iron concentration was determined using a Prussian blue assay. 
A serial dilution of Fe inductively coupled plasma (ICP) standard (Alfa Aesar, Iron, plasma 
standard solution, Specpure®, Fe 1000 µg/mL) was used to build a standard curve as measured 
by UV-Vis absorbance assay (λ=685 nm) using a Nanoquant plate reader (Tecan).  As prepared 
RF heating FeOx TMAOH nanoparticle solutions were diluted 1:100 and 2.14 μL of 70% nitric 
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acid (BDH Chemicals) was added to 30 μL of the diluted sample. This sample was heated at 
90°C  for 1 hour. The dissolved FeOx sample (10 μL) was added to 1 μL of 20% potassium 
ferrocyanide (Prussian blue) aqueous solution (Electron Microscopy Sciences, 20%) and 0.5 μL 
of 20% HCl solution (Electron Microscopy Sciences, 20%). After 15 minutes of incubation at 
room temperature the UV-Vis absorbance was measured at λ=685 nm.  
 
3.3 Results and Discussions 
 3.3.1 Investigation of Synthesis Parameters 
 Magnetic fluid hyperthermia requires a specific crystallite size with minimal size 
distribution to obtain the most efficient nanoparticle heating effect. To improve and optimize the 
benzyl alcohol synthesis of FeOx nanoparticles several reaction parameters were investigated. 
The parameters of interest are concentration, temperature, and addition of extra iron precursor 
(modified seed growth). The reaction concentration was modulated by concentration of iron 
precursor in a constant 20 mL volume of benzyl alcohol. The reaction parameters and 
nanoparticle properties were analyzed using JMP software’s effect screening to ascertain trends 
of reaction parameters upon the resultant nanoparticle properties. 
 A naming system was used to track of the large number of reaction conditions performed. 
The first and second additions of Fe(acac)3 are denoted as “A” and “B” and separated with an 
underscore. The gram amount of Fe(acac)3 added to the 20 mL of benzyl alcohol are listed 
immediately following A and B. The length of time, in hours, the reaction was carried out is 
listed as “-X” for both A and B additions. Temperature is listed in parenthesis for reactions 
where precise control of temperature was investigated. When temperature is not listed the 
reaction was heated to reflux using a heating mantle that was shown to have similar temperatures 
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and rate of reflux. For example a reaction carried out in 20 mL of benzyl alcohol with 2 g of 
Fe(acac)3 added initially and heated at 175°C for 24 hours and followed by an addition of 2 g of 
Fe(acac)3 and heated at 175°C for an additional 24 hours is named A2-24(175)_B2-24(175). For 
reactions that were carried out under nitrogen flow the reaction name begins with a “N2”. A 
reaction of 20 mL of benzyl alcohol with 2g of Fe(acac)3 added initially and reacted at 205°C for 
24 hours is named N2-A2-24(205). 
Characterization of nanoparticles was done using XRD, DLS, VSM corrected by TGA, 
and RF heating measurements to identify their crystallite size, hydrodynamic diameter and PDI 
values, saturation magnetization, and RF heating capabilities for internal comparisons. 
Nanoparticles were first characterized by XRD to verify the nanoparticles are indeed FeOx and 
to calculate the crystallite size. The XRD patterns for FeOx nanoparticles produced by reactions 
N2-A2-24, A2-24, and A2-24_B2-24 are displayed in Figure 3.1. It is not necessary to show all 
of the XRD patterns as they all indicate FeOx. It is important to reiterate that XRD cannot 
distinguish between magnetite and maghemite.  
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Figure 3.1. XRD peaks of samples: N2-A2-24 (blue), A2-24 (red), and A2-24_B2-24 (green). An 
offset of 100 count increments was used to clearly show each reactions pattern. 
 
Next, it is important to examine the hydrodynamic diameter and determine the size distribution 
in terms of PDI values with DLS. These measurements are very useful in determining how the 
reaction conditions affected the resultant nanoparticle. Figure 3.2 and Table 3.2 respectively 
show the DLS determined hydrodynamic diameter and peak data for reaction A4-24(195)_B4-
24(195). Figure 3.2 displays the DLS pattern based on percent intensity and percent volume to 
show that intensity results are biased towards larger sizes. It is important to note that the results 
based on intensity are biased towards larger sized nanoparticles as they will more intensely 
scatter the light. Therefore, the results based on volume were used when reporting the 
hydrodynamic diameter as it more accurately represents the total population of nanoparticles. 
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Figure 3.2. The DLS hydrodynamic size measurements displayed in terms of percent intensity 
(A) and percent volume (B) for reaction A2-24(195)_B2-24(195). The Z-average hydrodynamic 
diameter was equal to 47.75 nm and the PDI was equal to 0.219.  
 
Table 3.2. The DLS determine hydrodynamic size, percent composition, and width of each peak 
for the size distribution by percent intensity and size distribution by percent volume for reaction 
A2-24(195)_B2-24(195). 
Size Distribution by Percent Intensity 
  Hydrodynamic Diameter (nm) % Intensity Width (nm) 
Peak 1 47.08 86.8 14.31 
Peak 2 313.3 13.2 95.5 
Peak 3 0 0 0 
Size Distribution by Percent Volume 
  Hydrodynamic Diameter (nm) % Volume Width (nm) 
Peak 1 37.52 99.3 11.26 
Peak 2 328.1 0.7 109.5 
Peak 3 0 0 0 
 
The magnetic properties of the nanoparticles were next investigated with VSM and weight 
corrected using TGA. The hysteresis curve from VSM and mass percent loss over time from 
A
B
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TGA is shown in Figure 3.3 and Figure 3.4 respectively. The TGA determined weight loss was 
between 94.6% and 85.9% for all samples. The VSM determined MS values were between 48.54 
and 57.69 emu/g for samples synthesized under nitrogen and were between 55.5 and 84.57 
emu/g for samples synthesized under atmospheric conditions. 
 
Figure 3.3. VSM measured hysteresis loop of TGA mass corrected (10.901 mg * 0.945164 = 
10.303 mg) A2-24(195)_B2-24(195) nanoparticles.  
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Figure 3.4. TGA of A2-24(195)_B2-24(195) nanoparticles revealing a final mass percent of 
0.945164 at 400°C. 
 
RF heating measurements were calculated from fiber optic temperature collected data for 
concentration matched TMAOH FeOx nanoparticle solutions. Sample heating curves for 
deionized water, N2-A2-24, A2-24, A2-24_B2-24, and A2-24(195)_B2-24(195) reactions are 
shown in Figure 3.5. Prussian blue assay was used to normalize the concentrations of iron for 
internal comparisons. Altering the synthetic parameters we were able to obtain RF heating 
measurement between 0.01 and 5.55 [°C/min]/mg. 
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Figure 3.5. RF heating curves of water and FeOx samples dispersed in 0.25% TMAOH. Prussian 
Blue assay determined the iron concentrations for deionized water (blue), A2-24 under nitrogen 
(green), A2-24 (red), A2-24_B2-24 (purple), and A2-24(195)_B2-24(195) (black) to be 0, 14.48, 
15.40, 14.00, and 15.36 mg/mL respectively. Temperature was recorded every 1.4 seconds in an 
alternating magnetic field set at 175.4 A for 600 seconds or until reaching approximately 70°C. 
 
 3.3.2 Effect of Reaction Environment 
 Initial benzyl alcohol synthesis reactions were carried out under nitrogen flow. Thermal 
decomposition of Fe(acac)3 or iron carboxylate salts are most commonly reported in literature as 
using nitrogen or argon flow.
51,131,143,144,195-198
 The reaction N2-A2-24 produced nanoparticles 
with 6.5 ± 1.2 nm crystallite sizes based on the Scherrer formula for calculating crystallite sizes 
from line broadening of peaks in the XRD pattern shown in Figure 3.1. Characterization with 
VSM and corrected by TGA revealed the Ms= 53.39 emu/g. DLS revealed a hydrodynamic 
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diameter of 23.23 nm and a PDI of 0.351. This crystallite size is well below the desired 15-16 
nm crystallite of ideal FeOx nanoparticles for RF induced hyperthermia. It should be noted that 
there is not a clear relationship between crystallite and hydrodynamic sizes, but the primary goal 
was to produce nanoparticles with the ideal crystallite size and low size distribution for 
maximum RF heating. Benzyl alcohol can be oxidized to benzaldehyde and further oxidized to 
benzoic acid at temperatures below the thermal decomposition temperatures as seen in glycol 
syntheses of metal and metal oxide nanoparticles.
53,120-122,199
 Based on this information our 
hypothesis was that by running the reaction open to air we could facilitate the production of 
larger crystallite sizes. To investigate formation of nanoparticles at lower temperatures based on 
the added oxidation mechanism, the reactions were monitored every minute while the reaction 
was heated to its final temperature. This revealed that reactions open to air had reflux drips 
starting at approximately 178°C and increasing as the temperature approached 205°C indicating 
the formation of benzaldehyde (boiling point = 178.1°C).
200
 The oxidation of benzyl alcohol to 
benzaldehyde suggests that a reduction of Fe(acac)3 may also be occurring at these temperatures. 
The addition of a second mechanism of formation of monomers and nuclei starting at 
temperatures below thermal decomposition could allow for better separation of nucleation and 
growth phases leading to larger crystallite sizes.
37
 Additionally, the formation of monomers and 
nuclei occurring at the lower temperatures due to an oxidation reduction mechanism occur when 
the temperature ramp rate is still high which would also lead to larger separation of nucleation 
and growth leading to larger crystallite sizes.
37
 Carrying out the reaction open to air (A2-24) 
resulted in FeOx nanoparticles with 8.33 ± 0.393 nm crystallite sizes (Figure 3.1), Ms of 70.839 
emu/g, hydrodynamic diameter of 13.64 and PDI of 0.703. This reaction is crucial as it 
demonstrates the ability to produce larger crystallite sizes and more crystalline nanoparticles by 
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only changing the reaction environment. The PDI value suggests a broad size distribution which 
may be narrowed by altering the other reaction parameters. In an attempt to elucidate why larger 
crystallites were formed the reaction color changes and corresponding temperatures were 
recorded every minute as the temperature was initially increased. The thermal decomposition of 
Fe(acac)3  depends on the solvent it is dissolved in, but is generally reported to occur around 
170-180°C.
201
 As seen in Figure 3.6 the color change from dark red to black indicating 
nanoparticle formation occurred at lower temperatures and earlier in the reaction when the 
reaction was carried out under air (Figure 3.6B). The solution for reaction under nitrogen 
remained dark red until 31 minutes in to the reaction at a temperature of 174.4°C and turned 
completely black at 40 minutes. The solution for reaction open to air, however first started to 
change colors after only 20 minutes at 169.4°C and became completely black after 30 minutes of 
reaction. This corroborates the hypothesis that the presence of oxygen allows for the generation 
of monomers and nuclei at lower temperatures and earlier in the reaction due to a possible 
oxidation reduction mechanism.  
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Figure 3.6. Heating curves for reaction of Fe(acac)3 in Benzyl Alcohol heated to 175°C under 
nitrogen (A), and air (B). Heating curves for reaction containing FeCl2, NaOH, and Benzyl 
Alcohol heated to 150°C under nitrogen flow (C), and air (D). For reactions under nitrogen the 
initial and final color changes are indicated with a gold and black square. Likewise, the color 
changes are indicated with a gold and black diamond for reactions open to air.  
 
To verify that benzyl alcohol is reducing the iron precursor, Fe(acac)3 was replaced with glycol 
reagents, FeCl2 and sodium hydroxide (NaOH).
53,120,122,199
 XRD confirmed that these reactions 
carried out under nitrogen and air still produced FeOx (Figure 3.7) and further indicated that an 
additional mechanism is responsible for the formation of  FeOx nanoparticles in benzyl alcohol 
since thermal decomposition did not occur in the FeCl2, NaOH, and benzyl alcohol reaction.  
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Figure 3.7. XRD peak patterns for benzyl alcohol, FeCl2, and NaOH under nitrogen flow (blue), 
and open to air (red) offset by 5000 intensity counts. NaCl was indicated by peaks at 32.5 and 
46.2 angles. It was determined that the reaction under nitrogen and open to air contained 71% 
and 77% NaCl respectively. 
 
The reaction color and temperatures were also recorded for the FeCl2, NaOH, and benzyl alcohol 
reactions carried out open to air and under nitrogen flow (Figure 3.6C and D). Reaction under 
nitrogen flow first changed colors at 99.3°C and was completely black at 132.7°C, while the 
reaction open to air had an initial color change at 90.8°C and was completely black at 127.7°C. 
This further corroborates the hypothesis that the benzyl alcohol synthesis open to air produces 
larger crystallite sizes by facilitating earlier generation of monomers and nuclei and thus a better 
separation of nucleation and growth. Based on this mechanistic insight, the remaining synthesis 
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reactions were primarily run open to air and reaction parameters were changed to gain larger 
crystallite sizes and smaller size distributions.  
 
 3.3.3 Effect of Reaction Temperature 
 Increasing temperature of the reaction was hypothesized to further increase the crystallite 
size based on recent reports that higher temperatures were required for sustained crystallite 
growth.
121,202
 The heating mantle was replaced with a silicon oil bath to more efficiently control 
the temperature. Additionally, the reflux of the benzyl alcohol solution was shown to start as low 
as 178°C as benzaldehyde was most likely formed. Therefore, using the heating mantle to reach 
reflux temperatures in air was most likely occurring at approximately 178°C and not at the 
boiling point of benzyl alcohol (205°C).
200
 Increasing the temperature to 205°C was 
hypothesized to further increase the crystallite size. Nitrogen reactions with varying reaction 
temperatures were used as comparisons to reactions open to air to further elucidate the reaction 
mechanisms occurring and to better determine other effects such as magnetization saturation 
changes. 
 Nitrogen synthesis reaction temperatures were varied between 150-205°C and the 
resultant nanoparticle properties are shown in Table 3.3. In addition to the reaction changing 
color at later time points and at higher temperatures when compared to reactions open to air, the 
nitrogen reaction did not contain reflux drips at 205°C. The absence of reflux drips suggests that 
the oxidation and reduction of benzyl alcohol and Fe(acac)3 is not occurring when reacted under 
nitrogen flow. Furthermore, this confirms that the primary mechanism of generation of 
monomers and nuclei is due to thermal decomposition. Without reduction of Fe
3+
 to Fe
2+
 the 
magnetite crystal structure is unlikely to form. This is validated by the lower magnetization 
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saturation values of 48.54-57.69 emu/g exhibited by nanoparticles produced under nitrogen flow. 
This result is in accordance with the lower magnetization saturation values of maghemite  as 
compared to magnetite in bulk and nanomaterials.
203
 
  
Table 3.3. Effect of various temperatures in reactions under nitrogen flow on nanoparticle 
properties.  
Reaction 
Magnetization 
(emu/g)
a 
RF Heating 
([
o
C/min]/mg)
b 
Crystallite 
size (nm) 
Hydrodynamic 
Diameter (nm) 
PDI
c
 
N2-A2-24 53.39  6.47 ± 1.17 23.23 0.351 
N2-A2-24(150) 48.54* 0.01 5.65 ± 0.76 13.02 0.372 
N2-A2-24(175) 57.69 0.04 6.06 ± 0.52 11.51 0.306 
N2-A2-24(195) 57.09* 0.02 6.3 ± 0.89   
N2-A2-24(205) 57.56* 0.05 11.3 ± 0.73 38.48 0.152 
a
mass unit indicates grams of FeOx nanoparticles corrected by TGA. 
b
mass unit indicates milligrams of Fe determined by Prussian blue assay. 
c
Polydispersity Index (PDI) determined by DLS. 
*VSM data was corrected using 0.88 percent weight of sample 
 
 
 
For the nitrogen syntheses the crystallite size only changed when the reaction reached 205°C, 
however the magnetization was only 57.56 emu/g suggesting that mainly maghemite was 
present. While larger nanoparticle sizes were obtainable by the nitrogen synthesis the 
nanoparticles most likely consisted of the less magnetic maghemite crystal structure. 
 Higher magnetization saturation values and crystallite sizes were obtainable at lower 
temperatures with the reactions open to air, as seen in Table 3.4. The larger magnetization 
saturation values at lower temperatures strongly suggests the presence of magnetite and offers 
additional evidence that a redox mechanism plays a significant role in the production of FeOx 
nanoparticles. The size distribution as indicated by PDI was much lower for reactions at 205°C. 
The trend of decreasing PDI as temperature increased was also seen for reactions under nitrogen 
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flow; however the larger magnetization saturation values and crystallite sizes make the FeOx 
nanoparticles synthesized open to air much more advantageous. 
 
Table 3.4. Effect of various temperatures in reactions open to air on nanoparticle properties.  
Reaction 
Magnetization 
(emu/g)
a 
RF Heating 
([
o
C/min]/mg)
b 
Crystallite 
size (nm) 
Hydrodynamic 
Diameter (nm) 
PDI
c
 
A2-24 70.839 0.17 8.8 ± 0.61 13.64 0.703 
A2-24(125) - - - - - 
A2-24(150) 55.50 0.06 6.2 13.58 0.589 
A2-24(175) 70.91 0.14 8.9 ±1.39 12.45 0.61 
A2-24(195) 74.32 0.18 8.1 ± 0.59 13.3 0.65 
A2-24(205) 73.36* 2.76 14.1 ± 0.80 24.53 0.275 
a
mass unit indicates grams of FeOx nanoparticles corrected by TGA. 
b
mass unit indicates milligrams of Fe determined by Prussian blue assay. 
c
Polydispersity Index (PDI) determined by DLS. 
*VSM data was corrected using 0.925 percent weight of sample  
 
 
 
It should be noted that reaction A2-24 was most comparable to reactions A2-24(175) and A2-
24(195) confirming that the heating mantle had inefficient control of temperature that may have 
fluctuated between these temperatures. The larger PDI values of these reactions were attributed 
to an overlap between thermal decomposition and redox of benzyl alcohol and Fe(acac)3. 
Comparing the RF heating capabilities of FeOx nanoparticles produced by reactions under 
nitrogen flow or open to air reveals drastically higher heating capabilities. This is attributed to 
the larger crystallite sizes; however the RF heating may be limited by the lower magnetization 
saturation values for nitrogen reactions. More specifically, the reaction open to air with 
MS=70.91 emu/g had an RF heating rate almost three times as high as the largest crystallite FeOx 
achieved with nitrogen reactions. The larger crystallite sizes for reactions open to air is explained 
by the LaMer growth model, where reduction of Fe
3+
 to Fe
2+ 
produces the first nuclei at lower 
temperatures and then the reaction exhibits a large influx of new monomers as the reaction 
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reaches higher temperatures where both thermal decomposition and redox reactions occur. This 
large influx of monomers leads to a burst nucleation even and is quickly depleted to begin 
growth on the nuclei. Since there are two “stages” where monomers and nuclei are formed there 
is also a higher resultant size distribution, but this also leads to larger crystallite sizes. At 205°C 
the temperature ramp rate is very high and passes through the beginning of the redox and thermal 
decomposition mechanisms creating a large number of monomers which in turn causes a quicker 
burst nucleation leading to smaller size distributions. 
 The effect of temperature on nanoparticle characteristics revealed several interesting 
conclusions. Reactions open to air produce larger crystallite sizes at lower temperatures due to 
the added redox mechanisms and lower temperature refluxing due to the formation of 
benzaldehyde. Through modulation of the temperature the added redox mechanism of reactions 
open to air can be taken exploited to more efficiently tune the crystallite size and size distribution 
of nanoparticles. This is possible due to the better separation of nucleation and growth and burst 
nucleation process that occurs in the reactions open to air.  
  
 3.3.4 Effect of Reaction Concentration 
 According to LaMer growth methodology the iron precursor concentration can also be 
modulated to increase the production of monomers and further shorten the burst nucleation event 
leading to larger crystallite sizes. Increasing reactant precursor concentrations has been reported 
to increase the overall particle size.
204
 The LaMer growth model (Figure 3.8) is useful in 
interpreting results of changing reaction parameters. The production of nanoparticles can be split 
into three main sections including generation of monomers, self-nucleation, and growth. In the 
benzyl alcohol reaction the monomers are generated from thermal decomposition and reduction 
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of Fe(acac)3. When the concentration of monomers is sufficiently high, termed the concentration 
minimum for nucleation (Cmin
nu
), self-nucleation will begin. In the self-nucleation phase the 
concentration of monomers will be rapidly depleted and will switch to the growth phase when 
the concentration is decreased below the Cmin
nu
.
3,205
 Theoretically the concentration of monomers 
can approach but never reach the critical limiting supersaturation or the concentration maximum 
of nucleation (Cmax
nu
). This is because as the critical limiting supersaturation is approached the 
rate of nucleation exponentially increases and will overcome even the largest rate of generation 
of monomers.
3,205,206
 The rate of generation of monomers controls the maximum monomer 
concentration that can be reached or how quickly the nucleation step will occur, since the 
nucleation rate increases exponentially until it becomes effectively  
 
Figure 3.8. LaMer growth model scheme, displaying the generation of monomers, self-
nucleation, and growth phases.  Adapted from 
3
.  
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infinite at the critical limiting supersaturation concentration.
3
 The ramification of this is that 
faster generation of monomers will lead to quicker “burst” nucleation events which will decrease 
the size distribution of nuclei leading into the growth phase.
3,205
 The growth phase is controlled 
by either diffusion of monomers to the surface of nuclei or reaction rate of monomers onto the 
surface of nuclei depending on which process is rate limiting.
207
 Growth will continue until the 
monomer concentration is depleted to the solubility concentration of monomers (CS).
3,205
 At this 
point Ostwald ripening will occur where smaller nanoparticles are dissolved to grow on the 
energetically favored larger nanoparticles.
208,209
 If the nanoparticles are monodisperse when 
Ostwald ripening begins more polydisperse nanoparticles will be created. Alternatively if the 
nanoparticles are polydisperse they will become more monodisperse by Ostwald ripening. 
 The effect of reaction concentration was investigated to further increase the crystallite 
size of the FeOx nanoparticles. To investigate this parameter the Fe(acac)3 was increased from 2 
grams to 4 and 6 grams in reactions (A2-24, A4-24 A6-24). However, this resulted in no 
significant change in crystallite size for these reactions (Table 3.5).  
Table 3.5. Effect of various concentrations of Fe(acac)3 on nanoparticle properties.  
Reaction 
Magnetization 
(emu/g)
a 
RF Heating 
([
o
C/min]/mg)
b 
Crystallite 
size (nm) 
Hydrodynamic 
Diameter (nm) 
PDI
c
 
A2-24 70.84 0.17 8.8 ± 0.61 13.64 0.703 
A4-24 68.99 0.13 8.3 14.68 0.2 
A6-24 68.25 0.22 7.9 16.5 0.164 
A2-24(205) 73.36* 2.76 14.1 ± 0.80 24.53 0.275 
A4-24(205) 73.07* 1.86 11.7 ± 0.73 22.85 0.269 
A6-24(205) 69.93* 0.85 8.2 ± 1.56 23.9 0.512 
a
mass unit indicates grams of FeOx nanoparticles corrected by TGA. 
b
mass unit indicates milligrams of Fe determined by Prussian blue assay. 
c
Polydispersity Index (PDI) determined by DLS. 
*VSM data was corrected using 0.925 percent weight of sample 
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Interestingly, the hydrodynamic diameter increased (13.64 nm, 14.68 nm, and 16.5 nm) and the 
size distribution decreased (PDI= 0.703, 0.2, 0.164) when the reactant concentration was 
increased in agreement with the reported LaMer growth model.
3,205,206
 More specifically the 
hydrodynamic size increased due to the growth phase switching from being limited by diffusion 
to limited by reaction. When growth is limited by diffusion the monomers will have sufficient 
time to react in the proper orientation which results in crystalline growth. However, when growth 
is limited by reaction the monomers will not always orient in a way suitable for crystalline 
growth, thus more amorphous growth will occur. With more amorphous growth the nanoparticles 
will have larger nanoparticle sizes and smaller crystallite sizes. At these temperatures the 
increase of concentration increases the generation of monomers resulting in more monodisperse 
nanoparticles.  
 The same set of reactions was also investigated at 205°C to determine if the same trend 
occurred when more precise temperature control was present. The higher temperature greatly 
increases the generation of monomers leading to larger crystallite sizes as seen in the previous 
section. Increased temperatures will also increase the rate of nucleation and the 
diffusion/reaction growth mechanisms. Figure 3.9 depicts the theorized effect of increasing both 
temperature and concentration on the LaMer growth model. It was thought that the combined 
increase in temperature and concentration would result in even faster generation of monomers. 
This is represented by a steeper slope in the generation of monomers phase. Interestingly, 
increased concentration of Fe(acac)3 at 205°C resulted in a decreasing crystallite size (14.1 ± 
0.80 nm to 11.7 ± 0.73 nm to 8.2 ± 1.56 nm) while the hydrodynamic diameter was constant. The 
PDI was only increased when the concentration was increased to 6 g and is consistent with 
growth limited by reaction leading to larger size distributions.
207
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Figure 3.9. Proposed effect of increasing temperature and concentrations of precursor on LaMer 
growth model (blue). The red curve represents the proposed effects of increasing either 
temperature or concentration. The green curve represents the proposed effect of increasing both 
temperature and concentration.  
 
 Based on the results of A6-24(205) an alternative explanation using LaMer growth 
method was rationalized. In this reaction, the generation of monomers may have reached a limit 
where further increases in temperature or precursor concentrations may not increase the rate of 
monomer generation. Instead the nucleation event could possibly be prolonged if the rate of 
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monomer generation has indeed reached a maximum. This theorized effect is shown in Figure 
3.10 (green curve).  
 
Figure 3.10. Proposed effect of increasing temperature and concentrations of precursor on 
LaMer growth model (blue). The red curve represents the proposed effects of increasing both 
temperature and concentration. The green curve represents the proposed effect of increasing both 
temperature and concentration when a maximum generation of monomers has been reached 
resulting in prolonged nucleation.  
 
Prolonging the nucleation event would lead to broader size distributions, more nuclei, and 
smaller particle sizes. More nuclei with a large concentration of monomers would lead to 
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increased amorphous growth due to growth limited by reaction. This theory is in accordance with 
the results observed for A6-24(205) which has approximately the same hydrodynamic size (23.9 
nm), but a much smaller crystallite size (8.2 ± 1.56 nm) and larger size distribution (PDI= 
0.512). 
 Based on these results of increasing concentration of Fe(acac)3 and temperature, the 
optimum starting amount of Fe(acac)3 for achieving the largest crystallite sizes is 2 g. The 
combined increase in reaction temperature and iron precursor for benzyl alcohol synthesis can be 
rationalized by the LaMer growth model where increasing temperature and/or precursor 
concentration increases the rate of monomer generation. The largest crystallite size of 14.1 ± 
0.80 was achieved in reaction A2-24(205). Since a potential limit was reached for rate of 
monomer generation at these conditions a modified seed growth method was used in attempts to 
further increase the crystallite size and decrease size distribution for maximum RF heating 
potential. 
 
 3.3.5 Effect of Parameters: Modified Seed Growth 
 Seed growth methods have been used to further increase the size of nanoparticles, but 
often require cooling or aging steps followed by washing and drying the nanoparticles to produce 
a powder often referred to as “seeds”.129,210,211 Next, the seeds are re-dispersed in the solvent 
with additional iron precursor prior to carrying out the reaction. A modified seed growth method 
was developed in attempts to increase the crystallite size and decrease the size distribution to 
produce optimum nanoparticle properties for RF hyperthermia. Instead of following traditional 
seed growth methods the nanoparticle “seeds” are not washed and dried to a powder, but are kept 
at elevated reaction temperatures and additional iron precursor (second addition) is added as a 
 71 
 
dry powder. This was done to keep the reaction at suitable temperatures for high rates of 
monomer generation that will then nucleate and grow on the seeds. 
 The A2-24 reaction was used as the first half of the modified seed reaction to discern how 
different temperatures and concentrations of second additions affect the resultant nanoparticle 
properties. These reactions are listed in Table 3.6. 
 
Table 3.6. Effect of various temperatures in the modified seed growth on nanoparticle properties. 
Reaction 
Magnetization 
(emu/g)
a 
RF Heating 
([
o
C/min]/mg)
b 
Crystallite 
size (nm) 
Hydrodynamic 
Diameter (nm) 
PDI
c
 
A2-24 
 
70.839 0.170 8.8 ± 0.61 13.64 0.703 
A2-24(175) 70.91 0.14 8.9 ± 1.39 12.45 0.61 
A2-24(195) 74.32 0.18 8.1 ± 0.59 13.3 0.65 
A2-24(205) 73.36 2.76 14.1 ± 0.80 24.53 0.275 
A2-24_B2-24 75.7 2.536 14.4 ± 2.42 28.93 0.148 
A2-24_B2[cool addition]-24 72.488 0.670 9.5 ± 0.71 20.76 0.252 
A2-24(175)_B2-24(175) 77.89 1.004 11.6 ± 1.01 24.53 0.404 
A2-24(185)_B2-24(185) 77.249 1.068 11.2 ± 0.94 23.11 0.395 
A2-24(195)_B2-24(195) 78.202 4.041 14.9 ± 0.74 37.52 0.219 
A2-24(205)_B2-24(205) 77.77 
 
5.55 19.5 ± 1.06 44.63 0.265 
a
mass unit indicates grams of FeOx nanoparticles corrected by TGA. 
b
mass unit indicates milligrams of Fe determined by Prussian blue assay. 
c
Polydispersity Index (PDI) determined by DLS. 
*VSM data was corrected using 0.925 percent weight of sample 
 
 
 The modified seed growth using the heating mantle (A2-24 and A2-24_B2-24) resulted in 
larger crystallite size (8.8 ± 0.61 vs. 14.4 ± 2.42) and drastically reduced PDI values (0.703 vs. 
0.148). Transmission electron microscopy (TEM) was used to directly image the morphology of 
the FeOx nanoparticles (Figure 3.11). 
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Figure 3.11. TEM bright field image A2-24_B2-24 nanoparticles dispersed with TMAOH. 
Image J software determined an average particle diameter of 15.28 ± 2.21 nm.  
 
The “hot” addition of iron precursor at the second addition step provides a burst nucleation event 
producing nuclei that will be dissolved to grow on the thermodynamically favored larger seed 
nanoparticles. This is also in accordance with Ostwald ripening resulting in a decrease in size 
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distribution.
208,209
 Reaction A2-24_B2[cool addition]-24 was used to corroborate the “hot” addition 
effect of lower size distribution by reducing the temperature to 30°C prior to the second addition 
of Fe(acac)3. Indeed, the hot addition facilitates larger crystallite growth (14.4 ± 2.42 vs. 9.5 ± 
0.71 nm) with lower size distribution (PDI= 0.148 vs. 0.252). More specifically, the hot addition 
facilitates a faster generation rate of monomers. 
 Temperature was shown to play a significant role in increasing the crystallite size and 
decreasing polydispersity for reactions without a seed growth step. Temperature was therefore 
investigated to determine the effect in the modified seed growth. Reactions A2-24(175)_B2-
24(175), A2-24(185)_B2-24(185), A2-24(195)_B2-24(195), and A2-24(205)_B2-24(205) were 
carried out and their characteristics are shown in Table 3.6. A2-24(175)_B2-24(175) reaction 
was used as the starting comparison point for temperature investigation. The crystallite size 
changed from 11.6 ± 1.01 nm in reaction A2-24(175)_B2-24(175) to 11.2 ± 0.94 at 185°C, 14.9 
± 0.74 at 195°C and 19.5 ± 1.06 at 205°C. The temperature at 185°C did not change the 
crystallite size which is thought to be explained by insufficient increase in temperature to cause a 
significant change in the nucleation event. The decrease in size distribution for the modified seed 
growth at their respective temperatures was thought to be facilitated by the second addition of 
iron precursor resulting in Ostwald ripening focusing the size distribution. Interestingly, the 
modified seed growth reaction at 205°C had a crystallite size of 19.5 ± 1.06 and the highest RF 
heating value 5.55 [oC/min]/mg even though the RF heating capabilities are theorized to 
exponentially decay above 15-16 nm. The theoretic decrease in RF heating above 15-16 nm is 
for superparamagnetic nanoparticles only, therefore the theoretic RF heating decrease may not be 
seen as the nanoparticles above 15-16 nm are most likely switching to single domain particles. 
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Further analysis of the VSM hysteresis curve for A2-24(205)_B2-24(205) (Figure 3.12) reveals 
some remnant magnetization indicating presence of single domain particles.  
 
 
Figure 3.12. Hysteresis curve for reaction A2-24(205)_B2-24(205). Inset shows the remnant 
magnetization and coercivity is non-zero. 
 
Since the crystallite size determined by XRD is biased towards larger sizes, it is entirely possible 
that the majority number population of nanoparticles have crystallite sizes closer to 15-16 nm. 
Using the specific heat of water cH2O = 4.18 
𝑊𝑠
𝑔𝐾
 as a close approximation of the true specific heat 
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of the nanoparticle solution, the SAR value was calculated to be 1,175.56 
𝑊
𝑔
. The SAR value was 
normalized using the H = 37.4 
𝑘𝐴
𝑚
 and f = 270 kHz of the coil used to calculate the ILP value of 
3.1127 
𝑛𝐻𝑚2
𝑘𝑔
. Commercially available synthetic ferrofluids are reported to have ILP values of 
0.15-3.12 
𝑛𝐻𝑚2
𝑘𝑔
.
23
 
 Next, changes in iron precursor concentration effect in the modified seed growth method 
were investigated. To do this both first and second additions of Fe(acac)3 were increased. It was 
thought that the size distribution could be lowered while maintaining the larger crystallite sizes 
achieved by increasing the temperature. Table 3.7 lists the reactions where concentration and 
temperature were changed for the modified seed growth reactions. 
 
Table 3.7. Effect of various Fe(acac)3 concentrations in the modified seed growth on 
nanoparticle properties. 
Reaction 
Magnetization 
(emu/g)
a 
RF Heating 
([
o
C/min]/mg)
b 
Crystallite 
size (nm) 
Hydrodynamic 
Diameter (nm) 
PDI
c
 
A2-24(195)_B2-24(195) 78.202 4.04 14.9 ± 0.74 37.52 0.219 
A2-24(205)_B2-24(205) 77.77 
 
5.55 19.5 ± 1.06 44.63 0.265 
A4-24(195)_B2-24(195) 75.12* 3.13 14.95 ± 2.03 29.5 0.36 
A4-24(195)_B4-24(195) 76.56* 4.48 13.4 ±1.61 31.94 0.121 
A4-24(205)_B4-24(205) 73.76 2.74 12.4 ± 1.11 26.67 0.146 
A4-24(195)_B6-24(195) 76.09 3.43 15.2 ± 1.50 26.6 0.112 
A4-24(205)_B6-24(205) 84.57 3.14 15.3 ± 2.45 28.2 0.14 
A6-24(195)_B2-24(195) 72.27 2.71 11.4 ± 1.25 43.89 0.305 
A6-24(195)_B4-24(195) 73.29 2.88 12.9 ± 0.92 23.5 0.176 
A6-24(195)_B6-24(195) 75.1* 2.58 14.1 ±0.98 26.19 0.231 
a
mass unit indicates grams of FeOx nanoparticles corrected by TGA. 
b
mass unit indicates milligrams of Fe determined by Prussian blue assay. 
c
Polydispersity Index (PDI) determined by DLS. 
*VSM data was corrected using 0.925 percent weight of sample 
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 Increasing the concentration of the first addition, A4-24(195)_B2-24(195), produced 
nanoparticles with similar crystallite sizes of 14.95 ± 2.03 nm, but with a higher PDI value of 
0.36. This is an important reaction as the RF heating rate was decreased even though the 
crystallite size was very similar. This is most likely due to the larger PDI value. Increasing the 
concentration at the second addition was thought to be crucial to utilize Ostwald ripening to 
minimize the size distribution.
208,209
 When the second addition is lower than the first addition 
there may not be sufficient added monomers to facilitate size distribution focusing and/or retain 
crystalline growth. This can be seen when comparing reactions A4-24(195)_B2-24(195) and A4-
24(195)_B4-24(195). In reaction A4-24(195)_B2-24(195) the second addition of only 2 g 
resulted in more crystalline growth (14.95 ± 2.03 crystallite size and 29.5 nm hydrodynamic 
size) compared to reaction A4-24(195)_B4-24(195) having more amorphous growth (13.4 ±1.61 
crystallite size and 31.94 nm hydrodynamic size). The more amorphous growth is consistent with 
the theory of growth limited by reaction. The lower PDI value of 0.121 for reaction A4-
24(195)_B4-24(195) (compared to 0.36) most likely explains the higher measured RF heating 
rate of 4.48 [oC/min]/mg. Size distribution narrowing by increasing the second addition 
concentration can be explained by having a sufficiently high concentration of monomers where 
both seeds and newly formed nanoparticles will have an equal number of monomers in their 
diffusion layer.
212
 When this happens the smaller nanoparticles will grow at a faster rate and 
“catch up” to the larger seed nanoparticles that are growing; this process reduces the surface 
energy which is energetically favored.
212,213
 This means that when larger nanoparticles are 
produced after the first addition a higher concentration of monomers is required to maintain 
crystal growth and to reduce the size distribution. Even further reduction in size distribution with 
more crystalline growth was observed for reaction A4-24(195)_B6-24(195). Similar trend is seen 
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for reactions A6-24(195)_B4-24(195), and A6-24(195)_B6-24(195) when comparing to reaction 
A6-24(195)_B2-24(195). 
 
 3.3.6 Examination of Radiofrequency Induced Heating Properties 
 All of the benzyl alcohol reactions were compiled into Table 3.8 to assess the effects of 
nanoparticle characteristics and synthetic parameters on RF heating rate. Table 3.8 was sub 
categorized by color with nitrogen reactions listed in blue and reactions open to air in green. This 
color scheme coincides with the colors used in Figure 3.13 A-F to graphically compare the 
nanoparticle characteristics. Several interesting trends can be seen in these comparisons. 
 First, the reactions open to air all had higher Ms values between 70-85 emu/g except for 
reaction A2-24(150), whereas the nitrogen reactions were in the range of 48-58 emu/g, (Figure 
3.13 A,C,E). Thus, the presence of air during the reaction leads to higher magnetization 
saturation values and possibly magnetite instead of maghemite crystal structures. It is important 
to point out the Ms value differences as the RF heating is highest for reactions open to air as seen 
in Figure 3.13 E. 
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Table 3.8. Effect of various Fe(acac)3 concentrations, temperatures, and reaction environment on 
nanoparticle properties. Reactions are grouped by their reaction environment: nitrogen (blue) and 
open to air (green). 
Reaction Magnetization 
(emu/g)
a 
RF Heating 
([
o
C/min]/mg)
b 
Crystallite 
size (nm) 
Hydrodynamic 
Diameter (nm) 
PDI
c
 
N2-A2-24 53.39  6.47 ± 1.17 23.23 0.351 
N2-A2-24(150) 48.54* 0.01 5.65 ± 0.76 13.02 0.372 
N2-A2-24(175) 57.69 0.04 6.06 ± 0.52 11.51 0.306 
N2-A2-24(195) 57.09* 0.02 6.3 ± 0.89   
N2-A2-24(205) 57.56* 0.05 11.3 ± 0.73 38.48 0.152 
A2-24 70.839 0.170 8.8 ±0.61 13.64 0.703 
A2-24(125) - - - - - 
A2-24(150) 55.50 0.06 6.2 13.58 0.589 
A2-24(175) 70.91 0.689 
 
8.9 ±1.39 12.45 0.61 
A2-24(195) 74.322 0.175 8.1 ± 0.59 13.3 0.65 
A4-24 68.99 0.134 8.3 14.68 0.2 
A6-24 68.25 0.219 7.9 16.5 0.164 
A2-24(205) 73.09 2.76 14.1 ± 0.80 24.53 0.275 
A4-24(205) 73.79 1.86 11.7 ± 0.73 22.85 0.269 
A6-24(205) 71.19 0.85 8.2 ± 1.56 23.9 0.512 
A2-24_B2-24 75.7 2.536 14.4 ± 2.42 28.93 0.148 
A2-24_B2[cool addition]-24 72.488 0.670 9.5 ± 0.71 20.76 0.252 
A2-24(175)_B2-24(175) 77.89 1.004 11.6 ± 1.01 24.53 0.404 
A2-24(185)_B2-24(185) 77.249 1.068 11.2 ± 0.94 23.11 0.395 
A2-24(195)_B2-24(195) 78.202 4.041 14.9 ± 0.74 37.52 0.219 
A2-24(205)_B2-24(205) 77.77 5.55 19.5 ± 1.06 44.63 0.265 
A4-24(195)_B2-24(195) 75.12* 3.13 14.95 ± 2.03 29.5 0.36 
A4-24(195)_B4-24(195) 76.56* 4.48 13.4 ±1.61 31.94 0.121 
A4-24(205)_B4-24(205) 73.76 2.74 12.4 ± 1.11 26.67 0.146 
A4-24(195)_B6-24(195) 76.09 3.43 15.2 ± 1.50 26.6 0.112 
A4-24(205)_B6-24(205) 84.57 3.14 15.3 ± 2.45 28.2 0.14 
A6-24(195)_B2-24(195) 72.27 2.71 11.4 ± 1.25 43.89 0.305 
A6-24(195)_B4-24(195) 73.29 2.88 12.9 ± 0.92 23.5 0.176 
A6-24(195)_B6-24(195) 75.1* 2.58 14.1 ±0.98 26.19 0.231 
A2-2_B2-24 76.1 0.211 9.3 ± 0.45 20.07 0.373 
A2-2_B4-24 72.18 0.212 9.8 ± 1.33 17.72 0.304 
A2-2_B6-24 75.56 0.639 10.5 ± 1.02 19.42 0.368 
a
mass unit indicates grams of FeOx nanoparticles corrected by TGA. 
b
mass unit indicates milligrams of Fe determined by Prussian blue assay. 
c
Polydispersity Index (PDI) determined by DLS. 
*VSM data was corrected using 0.925 and 0.88 percent weight of samples in air and under nitrogen 
respectively 
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Figure 3.13. Plots comparing nanoparticle properties with reactions under nitrogen and open to 
air indicated by blue diamonds and green triangles respectively. (A, B) Plots of crystallite size 
versus Ms and RF heating. (C, D) Plots of hydrodynamic diameter versus Ms and RF heating. (E) 
Plot showing Ms versus RF heating. (F) Plot of polydispersity index versus RF heating. 
 
 Next, there is a strong trend between crystallite size and RF heating. This was expected 
based on previously reported literature. Similarly there is a correlation between hydrodynamic 
diameter and RF heating, however it is hard to determine if this is a real trend or just due to the 
hydrodynamic diameter increasing as crystallite size increases. The linear correlation between 
hydrodynamic diameter and crystallite size can be seen in Figure 3.14 B. There potentially exists 
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an optimal crystallite to hydrodynamic size ratio for RF heating based on being able to provide 
maximum heat loss to surrounding solution. Figure 3.14 A indicates no clear correlation 
between crystallite size and size distribution. Therefore, the trend of increasing RF heating as 
size distribution decreases is most likely real. Overall, the effect of crystallite size, hydrodynamic 
diameter, and size distribution appear to have the most impact on RF heating. 
  
 
Figure 3.14. Plots comparing PDI versus crystallite size (A) and hydrodynamic diameter versus 
crystallite size (B) for reactions under nitrogen and open to air indicated by blue diamonds and 
green triangles respectively.  
 
 Based on these initial comparisons JMP software was used to screen the effects and 
determine which nanoparticle properties are significantly affecting RF heating. JMP software 
was also used to further elucidate the reaction parameters that significantly affect nanoparticle 
properties. All of the reactions open to air were used for effect screening. After determining 
which nanoparticle properties significantly affect the RF heating rates, a model was created and 
tested to determine its effectiveness in predicting RF heating based on nanoparticle properties. 
Likewise, models were created to determine nanoparticle properties based on reaction 
parameters. 
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  The effects of crystallite size, hydrodynamic diameter, PDI, magnetization saturation, 
and ratio of crystallite size to hydrodynamic diameter determined by volume (Volume CS/HS) 
on RF heating were analyzed for the seed growth syntheses listed in Table 3.9. The effect 
screening table is shown in Figure 3.9. Analysis of variance determined that crystallite size, PDI, 
and volume CS/HS were all significant (Table 3.11). Crystallite size had the most significant 
effect on RF heating. A model was created using least squares and emphasis on effect leverage 
of the significant nanoparticle properties to estimate the resultant RF heating. The ANOVA had a 
significance of <0.0001 indicating that the 3 nanoparticle properties did have a significant effect 
on the RF heating. The actual predicted fit plot is shown in Figure 3.15 and has an R
2
 value of 
0.95. The parameter estimates (Table 3.12) were used to formulate Equation 17 to predict RF 
heating, where CS and HD are crystallite size and hydrodynamic diameter. Crystallite size, 
volume CS/HS, and PDI had prob>t values of <0.0001, 0.0002, and 0.0002 respectively. 
 
Table 3.9. List of seed growth syntheses and nanoparticle properties used in the effect screening 
and predicted model. 
 
Crystallite 
Size 
Hydrodynamic 
Diameter PDI Ms 
RF 
Heating CS/HS 
Volume 
CS/HS 
A2-24(175)_B2-24(175) 11.4 24.53 0.404 77.89 1.00 0.46 0.1 
A2-24(185)_B2-24(185) 13.2 23.11 0.395 77.249 1.07 0.57 0.19 
A2-24(195)_B2-24(195) 15.2 37.52 0.219 78.202 4.04 0.41 0.07 
A6-24(195)_B2-24(195) 11.8 43.89 0.305 72.27 2.71 0.27 0.02 
A2-24(205)_B2-24(205) 19.4 44.63 0.265 77.77 5.55 0.43 0.08 
A6-24(195)_B4-24(195) 13.7 23.5 0.176 73.29 2.88 0.58 0.2 
A6-24(195)_B6-24(195) 14.9 26.19 0.231 75.10 2.58 0.57 0.18 
A4-24(195)_B2-24(195) 17 29.5 0.36 75.12 3.13 0.58 0.19 
A4-24(195)_B4-24(195) 14.6 31.94 0.121 76.56 4.48 0.46 0.1 
A4-24(195)_B6-24(195) 16.1 26.6 0.112 76.09 3.43 0.61 0.22 
A4-24(205)_B6-24(205) 14.4 28.2 0.14 84.57 4.19 0.51 0.13 
A4-24(205)_B4-24(205) 14.1 26.67 0.146 73.76 2.74 0.53 0.15 
A2-24(205)_B2-24(205) 17.8 43.92 0.19 75.59 5.36 0.41 0.07 
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Table 3.10. Effect screening of crystallite size, hydrodynamic diameter, PDI, magnetization 
saturation, and volume CS/HS on RF heating.  
 
 
 
Figure 3.15. The actual vs predicted RF heating fit of the model of crystallite size, PDI, and 
volume CS/HS on RF heating. 
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Table 3.11. ANOVA results for the predicted model effect of significant nanoparticle properties 
on RF heating.  
Source DF Sum of 
Squares 
Mean 
Square 
F 
Ratio 
Model 3 22.58684 7.52895 62.4514 
Error 9 1.085012 0.12056 
Prob > 
F 
C. Total 12 23.67185 
 
<.0001 
 
Table 3.12. Parameter estimates for the model fit least squares of significant nanoparticle 
properties effecting RF heating. 
Term Estimate 
Std 
Error t Ratio Prob>|t| 
Intercept -0.26799 0.816764 -0.33 0.7503 
Crystallite Size 0.423428 0.04583 9.24 <.0001 
VOLUME CS/HS -9.93554 1.614326 -6.15 0.0002 
PDI -6.01891 1.016722 -5.92 0.0002 
 
RF=-0.26799+(0.423428*CS)+(-9.93554*Volume CS/HS)+(-6.01891*PDI)   (17) 
 
Table 3.13. Predicted and actual RF heating values. 
 RF Heating 
Synthesis Predicted Actual 
A3-24(205)_B3-24(205) 4.025245 3.037383 
A2.5-24(205)_B2.5-24(205) 2.387036 2.481686 
A2-24_B2-24 1.224124 1.092966 
 
 Using the properties of reactions A3-24(205)_B3-24(205), A2.5-24(205)_B2.5-24(205), 
and A2-24_B2-24 the RF heating values were predicted using Equation 17 as shown in Table 
3.13. The predicted RF heating values were in close agreement with measured RF heating values 
for reactions A2.5-24(205)_B2.5-24(205), and A2-24_B2-24. The A3-24(205)_B3-24(205) 
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predicted RF heating values were larger than the actual RF heating values (4.025245 
(oC/min)/mg vs. 3.037383 (oC/min)/mg). It is speculated that the model is a good predictor of 
the actual measured RF heating considering the large amount of compounding measurement 
errors. Further reactions would increase the validity of the model and increase the efficiency in 
predicting RF heating values.  
 Next, the reaction pararmeters of temperature, first addition, and second addition were 
investigated to screen for effects on resulting nanoparticle properties. Only crystallite size, PDI, 
and volume CS/HS were investigated as they were found to be the only significant predictors of 
RF heating. The effect screening was unable to predict crystallite size, PDI, or volume CS/HS 
with an acceptable R
2
 value. The effect screening identified a ‘null term’ indicating that there is 
some additional factor influencing the nanoparticle properties besides temperature, first addition 
amount, and second addition amount. Further investigation is needed to determine this additional 
effect. However, it is speculated that this could be due to the reaction concentration affecting the 
heating rate. Another possible explanation is that there is insufficient data regarding the 
nanoparticle properties at 24 hours after the first addition to accurately determine how the second 
addition affects the final resulting properties. Further analysis using the nanoparticle properties 
after 24 hours of reaction as a starting point for predicting increase in crystallite size could reveal 
the important parameter. 
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Chapter 4: Surface Functionalization of Benzyl Alcohol 
Synthesized Iron Oxide Nanoparticles 
 
 
 
4.1 Experimental Section 
 4.1.1 Reagents, Materials, and Equipment 
All chemicals and materials were used as received.  Water (H2O) (Fisher Scientific, Optima ® 
LC/MS grade), Tetramethylammonium hydroxide (TMAOH) solution (Alfa Aesar, 25% w/w 
aq.), poly (vinyl alcohol) (Polysciences, Inc., MW ~6000, 80 mol% hydrolyzed), bromoacetic 
acid (Alfa Aesar, 98+%), sodium hydroxide (NaOH) (Alfa Aesar, pearl, 97%), 70% ethanol 
(EtOH) (Sigma Aldrich, 200 proof for molecular biology), ethanol (Pharmco-AAPER, 190 proof 
ACS/USP grade), (3-Aminopropyl)trimethoxysilane (APTS) (Alfa Aesar, 97%), (3-
aminominopropyl)triethoxysilane (APTES) (Alfa Aesar, 98%), (3-Glycidyloxypropyl)
trimethoxysilane (GLYMO) (Acros Organics,98%), L-cysteine (Cys) (Alfa Aesar, 98+%), DL-
serine (Ser) (Alfa Aesar, 99%), DL-arginine (Arg) (Alfa Aesar, 98%), DL-lysine 
monohydrochloride (Lys) (Alfa Aesar, 99%), DL-Threonine (Thr) (Alfa Aesar, 99%), glycine 
(Gly) (Alfa Aesar, 99%), L-glutamine (Gln) (Sigma, ≥99%), L-(+)-asparagine (Asn) (Alfa Aesar, 
99%), hydroxylamine HCl, citric acid, anhydrous (BDH, 99.5-100.5%), (S)-(-)-4-Amino-2-
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hydroxybutyric acid (SAHBA) (Aldrich Chemistry, 96%), γ-aminobutryic acid (ABA) (Sigma 
Life Science ≥99%), ethylenediamine (EDA) (Acros Organics, 99+%, extra pure), 
tetraethylenepentamine (TEPA) (Acros Organics, technical grade), hydrochloric acid (HCl) 
(Fischer, Optima
TM
, 32-35%), 0.2 μm filter (PALL Life Sciences, Acrodisc® Syringe Filter 0.2 
μm Supor® Membrane Low Protein Binding), 30k, and 100k molecular weight cutoff (MWCO) 
centrifuge filter (PALL Life Sciences, Macrosep® Advance Device), PD-10 desalting column 
(GE Healthcare, Sephadex® G-25 medium), Fe inductively coupled plasma (ICP) standard (Alfa 
Aesar, Iron, plasma standard solution, Specpure®, Fe 1000 µg/mL), hydrochloric acid solution 
(HCl) (Electron Microscopy Sciences, 20%), potassium ferrocyanide aqueous solution (Prussian 
Blue) (Electron Microscopy Sciences, 20%), S-2-(4-Aminobenzyl)-1,4,7,10-
tetraazacyclododecane tetraacetic acid (DOTA) (Macrocyclics), 
177
LuCl3 (Perkin Elmer), 1-
Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) (Thermo Scientific),  N-
hydroxysulfosuccinimide (S-NHS) (Thermo Scientific), β–mercaptoethanol (Sigma Aldrich), 
ammonium hydroxide (Fisher Scientific, Optima grade), 0.25 M ammonium acetate , and 0.1 M 
2-(N-morpholino)ethanesulfonic acid (MES) buffer containing 0.9% NaCl (Optima grade 
NH4OH adjusted pH =6.4). 
 
 4.1.2 Synthesis of Carboxymethylated Polyvinyl Alcohol (CMPVA)  
 Polyvinyl alcohol (PVA) can be reacted with bromoacetic acid and base to synthesize 
carboxymethylated polyvinyl alcohol (CMPVA) as previously reported.
94,130
 First, three different 
solutions were made including: Solution A – 5 g of PVA dissolved in 50 mL of H2O, Solution B 
– 5.324 g of sodium hydroxide (NaOH) dissolved in 25 mL of H2O, and Solution C – 11.575 g of 
bromoacetic acid dissolved in 200 mL of 70% ethanol (EtOH). To Solution C 3.33 g of NaOH 
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was added slowly and stirred to dissolve. Solution A was set on a stirring hot plate and heated to 
50°C with constant stirring prior to slow addition of Solution B. Next, a drop wise addition of 
Solution C, to the mixed Solution A and B was carried out and reacted under a reflux condenser 
for five hours to carboxymethylate the PVA. After carboxymethylation, the pH of the CMPVA 
was measured and adjusted to approximately 6.0 with a 1 M solution of hydrochloric acid. The 
CMPVA was then precipitated out of solution by addition of cold EtOH. The precipitated 
CMPVA in cold EtOH was centrifuged at 3,000×g for 15 minutes (Thermo Scientific, Sorvall 
Legend X1R centrifuge) to remove any unreacted chemicals. This process was repeated 3-6 
times to fully wash the CMPVA. The washed CMPVA was then dried using a vacuum oven set 
at 50°C for one week.  
  
 4.1.3 Surface Functionalization with CMPVA 
 To modify the surface with CMPVA, 40 mg of dry FeOx nanoparticles were sonicated 
for 180 minutes in 2 mL of 0.0625%, 0.125%, 0.25%, or 0.5% w/w aqueous tetramethyl 
ammonium hydroxide (TMAOH) solution. Dispersing the nanoparticles prior to addition of 
surface functionalization ligands is crucial to efficiently surface functionalize individual 
nanoparticles. During the entire surface functionalization procedure the nanoparticles were not 
magnetically stirred to prevent possible aggregation due to magnetic fields causing additional 
interparticle attraction. A 40 mg/mL CMPVA solution was made by dissolving dry CMPVA in 
water with low heating and stirring. Next, 10 mL of the 40 mg/mL CMPVA solution was diluted 
with 9.5 mL of H2O immediately prior to addition of 0.5 mL of the nanoparticle TMAOH 
solution. This solution was sonicated for 180 minutes. The initial dilution of CMPVA was found 
to aid in the nanoparticle surface functionalization. It is thought that surface functionalization is 
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more efficient at lower concentrations of nanoparticles, which reduces the distance between 
nanoparticles during CMPVA surface functionalization. The nanoparticle CMPVA solution was 
allowed to sit for one week. In first attempts at surface functionalization with CMPVA the 
nanoparticle CMPVA solution was allowed to sit for 2 weeks, however the particles initially 
became clear at 1 week. Therefore, 1 week was chosen as the minimal amount of time, since 
nanoparticles in CMPVA were still turbid at 24-48 hours.  
 Next, CMPVA-FeOx nanoparticles were washed using a 30k molecular weight cut-off 
(MWCO) centrifugal filter spun at 4,000×g to remove excess CMPVA and any residual 
TMAOH. This centrifuge process also concentrated the nanoparticle solution. This concentrated 
solution was transferred to a clean vial and sonicated briefly (15 minutes) to aid in proper re-
dispersion. Further clean-up was carried out using a disposable PD-10 desalting column that was 
equilibrated with H2O. This step was used to remove non-functionalized or aggregated 
nanoparticles as well as any remaining TMAOH. The desalting column diluted the sample 
slightly, so an additional 30k centrifuge filter was spun at 4,000×g for one hour. A 0.2 µm sterile 
filter was used in a biosafety laminar flow hood to sterilize the CMPVA-FeOx nanoparticles and 
remove any CMPVA-FeOx clusters larger than 200 nm.  
 
 4.1.4 Surface Functionalization with APTS or APTES  
 Surface functionalization with APTS or APTES was performed by adding 10 mg of dry 
FeOx nanoparticles to a 0.125% TMAOH solution. This was sonicated for 30 minutes to disperse 
the nanoparticles. Prior to addition of APTS or APTES the nanoparticle TMAOH solution was 
diluted with 8 mL of H2O and vortexed briefly (10 seconds). Immediately after dilution, either 
1.78 mL of (3-Aminopropyl)trimethoxysilane (APTS) or 2.38 mL (3-
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aminominopropyl)triethoxysilane (APTES) was added dropwise followed by a quick  10 second 
vortex spin. The surface modification reaction was magnetically stirred at 60°C for one hour. 
The solution pH was adjusted to about 7.4 with 32-35% hydrochloric acid (HCl) solution. 
Magnetic separation for 1 hour was used to pull out partially, incompletely, or aggregated 
surface functionalized nanoparticles. The remaining clear honey colored top solution was 0.2 μm 
filtered to remove any large APTS or APTES nanoparticles as well as any excess reacted APTS 
or APTES that may clog up the centrifuge filter. This solution was then washed 3-5 times with 
H2O in a 30k MWCO centrifuge filter spun at 4,000rpm for 10 minutes in a swing bucket 
centrifuge. In the final wash step the solution was concentrated to 1.5 mL and the pH was 
readjusted to about 7.4.  Sterile filtration with a 0.2 μm filter in a biosafety laminar flow hood 
was used to obtain the final sterile surface functionalized product. 
 
 4.1.5 Surface Functionalization with GLYMO and Base Catalyzed 
Epoxide Ring Opening with Nucleophiles 
 The surface functionalization process with GLYMO started with adding 10 mg of dry 
FeOx nanoparticles to 10 mL of 0.125% TMAOH solution. The nanoparticle TMAOH solution 
was sonicated for 30 minutes to fully disperse the nanoparticles. This solution was then further 
diluted upon addition of 8 mL of H2O prior to addition of 2.25 mL of 3-Glycidyloxypropyl 
trimethoxysilane (GLYMO) (0.0114 mol). It is essential that the GLYMO be added all at once 
rather than dropwise to facilitate efficient surface modification. Following the GLYMO addition, 
the solution was vortexed for 10 seconds and then magnetically stirred and heated at 60°C for 1 
hour. After approximately 15 minutes of reaction the solution changed colors from a clear brown 
solution to a muddy brown solution. This indicated surface modification with GLYMO, as the 
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terminal epoxy groups should render the nanoparticles unstable at the high pH. The three 
membered epoxy ring was opened through a base catalyzed reaction with addition of a 
nucleophile. This reaction could have been acid-catalyzed, but this was not done as low pH could 
start to dissolve the surface of the FeOx nanoparticles. Additional base (1.6 mL of 25% 
TMAOH) was added immediately prior to addition of 1:1 molar ratio of the following 
nucleophiles: glycine (Gly) (0.86 g), DL-serine (Ser) (1.2g), γ-aminobutyric acid (ABA) (1.18 
g), or (S)-(-)-4-amino-2hydroxybutyric acid (SAHBA) (1.36 g), L-cysteine (Cys) (1.38 g), DL-
lysine-monohydrochloride (Lys) (2.08 g), L-glutamine (Gln) (1.67 g), DL-arginine (Arg) (1.86 
g), L-(+)-asparagine (Asn) (1.51 g), DL-Threonine (Thr) (1.36 g), hydroxylamine (0.79 g) or 
citric acid, anhydrous (2.19 g). Ethylenediamine (EDA) (0.763 mL) or tetraethylenepentamine 
(TEPA) (2.18 mL) were also used, but no additional TMAOH base was added as these chemical 
compounds are inherently basic. The reaction was continued at 60°C with magnetic stirring for 1 
hour. At this point the reaction was removed from heat and the pH was adjusted with 32-35% 
HCl to a pH of about 7.4. As a first cleanup step any nanoparticles that were not stable were 
magnetically separated for 1 hour. Only the top clear honey colored stable solution of 
nanoparticles was removed and subjected to a 0.2 μm filter. Next, the particles were washed with 
water 3-5 times in a 30k molecular weight cutoff (MWCO) centrifuge filter spinning at 4,000 
rpm for 10 minutes. The final wash was spun down to approximately 3 mL and the solution was 
then subjected to a disposable PD-10 desalting column equilibrated with water or PBS. As a final 
step the nanoparticles pH was checked and adjusted to 7.4 and then sterilized with a 0.2 μm filter 
in a biosafety laminar flow hood to obtain the final product. 
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4.1.6 EDC Coupling DOTA Chelate and Radiolabeling 
 The SAHBA-FeOx and CMPVA-FeOx nanoparticles were linked to DOTA metal chelate 
by EDC coupling reaction. First, 500 µL of SAHBA-FeOx or CMPVA-FeOx were mixed with 
500 µL of 0.1 M MES buffer (NH4OH adjusted pH=6.4). Next, 100 mg of EDC was dissolved in 
500 µL Ultra H2O and 100 mg of S-NHS was dissolved in 500 µL Ultra H2O. Activation of the 
carboxyl groups was performed by addition of 100 µL of EDC solution. The activated carboxyl 
groups were stabilized by addition of 100 µL of the S-NHS solution. After 10 mins 2 µL of β–
mercaptoethanol was added. In 100 µL of Ultra grade H2O 2 mg of DOTA was dissolved and 
then added to the FeOx in MES buffer to form an amide bond between the terminal amine on the 
DOTA chelate and the activated carboxyl groups of SAHBA-FeOx or CMPVA-FeOx. The 
reaction was allowed to react for 1.5 hours, before quenching with 100 µL of 0.275 M 
hydroxylamine. The resultant DOTA-SAHBA-FeOx or DOTA-CMPVA-FeOx were buffered 
exchange with a PD-10 column equilibrated with ammonium acetate.  
 Radiolabeling with 
177
Lu was performed by adding 40 µL of 
177
LuCl3 (~10 mCi) and 20 
µL of NH4OH to the DOTA-SAHBA-FeOx or DOTA-CMPVA-FeOx in ammonium acetate. 
The maximum beta energy of 
177
Lu is 0.497 MeV (79%), but the average beta energy is 0.13 
MeV. The 
177
Lu also has two gamma energies at 208 keV (11%) and 113 keV (6.4%). The 
chelation of 
177
Lu by DOTA was carried out at 40°C in a silicon oil bath overnight. The silicon 
oil bath was magnetically stirred. An MCX column was used to remove any free 
177
Lu from 
177
Lu-DOTA-SAHBA-FeOx or 
177
Lu-DOTA-CMPVA-FeOx. A PD-10 column was used to 
buffer exchange 
177
Lu-DOTA-SAHBA-FeOx or 
177
Lu-DOTA-CMPVA-FeOx into non-sterile 
DPBS and to remove any free 
177
Lu-DOTA or DOTA chelate. The ‘washed’ 177Lu-DOTA-
SAHBA-FeOx or 
177
Lu-DOTA-CMPVA-FeOx were then concentrated using a 3k MWCO 
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centrifuge filter spinning at 4,000 rpm in a swing bucket centrifuge for 10 minutes. The final 
product was obtained by 0.2 µm filtering in a sterile laminar flow hood.  
 
4.2 Characterization Techniques 
 4.2.1 Fourier Transform Infrared (FTIR) Attenuated Total Reflectance 
(ATR) Spectroscopy  
 Fourier transform infrared (FTIR) attenuated total reflectance (ATR) spectroscopy is 
paramount when analyzing the chemistry of colloid surfaces such as surface functionalized FeOx 
nanoparticles.
214
 The ability to analyze the surface functionalization in the aqueous environment 
is advantageous as it prevents the possibility of altering the surface functionalization during 
drying steps or removal from the aqueous environment.
214
 The attenuated total reflectance 
utilizes the properties of an internal reflectance element (IRE) with a high refractive index. These 
properties allow for the interface between the IRE and sample to be probed with infrared 
radiation. When the infrared radiation interacts with the interface an evanescent wave will 
penetrate slightly into the sample and absorb resulting in an absorption spectrum.
214
 The depth of 
penetration (dp) depends on the incident wavelength (λ), refractive index of IRE (n1), refractive 
index of sample (n2), and angle of incidence (θ) (Equation 18).
214
  
 d𝑝 =
𝜆
2𝜋𝑛1√sin2 𝜃−(
𝑛2
𝑛1
)
2
    (18) 
When the infrared light interacts with the surface of the sample, after passing through the IRE, 
the created perpendicular standing wave becomes ‘attenuated’ if the sample absorbs the infrared 
light.
214
 The refractive wave will lose some energy and is termed ‘attenuated total reflectance’.214  
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 FTIR-ATR spectroscopy was performed on a Thermo Scientific Nicolet 6700 equipped 
with a smart iTR for ATR to analyze liquid or dry samples. Single bounce ATR was used to 
examine all samples placed on the diamond crystal. The ATR system used has a penetration 
depth of 2.03 μm at an incident wavelength of 1000 cm-1, an incident wavelength angle of 42º, 
and a refractive index of 2.4.    
  
 4.2.2 X-ray Photoelectron Spectroscopy (XPS) 
X-ray photoelectron spectroscopy (XPS) was performed on a Thermo Scientific 
ESCALAB 250 spectrometer using a monochromatic Al Kα X-ray source (1486.6 eV).  External 
and internal flood guns were utilized to account for the organic coatings with charge 
composition. Sample preparation involved pressing nitrogen dried samples onto a strip of indium 
foil and attachment to the sample holder with double-sided adhesive carbon tape. CasaXPS 
software was used to analyze all data. Adventitious carbon at 284.8 eV was used to correct the 
observed binding energies.  
4.2.3 High-Performance Liquid Chromatography (HPLC) 
High-performance liquid chromatography (HPLC) was performed using a Waters isocratic 
HPLC system, equipped with UV-VIS absorbance and radioactivity (Bioscan) detectors to 
determine the radiochemical purity of radiolabeled FeOx nanoparticles eluted from a size 
exclusion-gel permeation chromatography column. The buffer used was 90% 50 mM ammonium 
acetate and 10% methanol. Aqueous samples were loaded before DOTA coupling to FeOx, after 
radiolabeling and MCX column, and after PD-10 column wash steps. 
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4.3 CMPVA Discussion 
 4.3.1 Surface Functionalization and Optimization for Biostability 
 The following naming system was used to keep track of the different types of surface 
functionalizations. The abbreviation of the respective surface functionalization precedes ‘FeOx’ 
and is separated by a hyphen. For example, carboxymethylated polyvinyl alcohol surface 
functionalized FeOx nanoparticles are referred to as ‘CMPVA-FeOx’. Any additional 
modifications to the surface functionalization will precede the surface functionalization 
abbreviation and will also be separated by a hyphen. 
Carboxymethylated polyvinyl alcohol (CMPVA) was used to provide colloidal and 
biological stability as well as providing terminal carboxyl groups for future conjugation. 
Optimization of this process is beneficial to facilitate higher yield, better biological stability, and 
increased biofunctionalization potential. The carboxyl groups on CMPVA polymer interact 
strongly with the surface iron atoms of FeOx nanoparticles and create a hydrophilic surface due 
to terminal carboxyl and hydroxyl groups.
94
 Therefore, it is important to optimize the surface 
functionalization process to ensure that an adequate number of carboxyl groups interact with the 
FeOx surface and a sufficient number of carboxyl groups are oriented outward to provide 
solution stability and sites for further conjugation. Optimization is especially important to 
determine how to effectively surface functionalize differently sized nanoparticles as even small 
changes in nanoparticle size will have drastic differences in surface area to volume ratio for a 
given gram amount of material. Several parameters were investigated to determine how to best 
adjust reaction parameters to functionalize varying nanoparticle sizes.  
 First, the carboxymethylation of polyvinyl alcohol was confirmed by FTIR-ATR 
spectroscopy of CMPVA. The spectrum from FTIR-ATR of CMPVA is shown in Figure 4.1.  
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Figure 4.1. The FTIR spectra shown as % transmittance vs wavenumber is shown with polyvinyl 
alcohol in blue, and carboxymethylated polyvinyl alcohol in red. Peaks at 1640, 1583 and 1417 
indicate the presence of carboxylate anion and the peak at 1089 cm
-1
 indicates the ether group. 
Polyvinyl acetate presence was indicated by peak at 1730 cm
-1
. The disappearance of the 1730 
cm
-1
 peak and appearance of peaks at 1600 and 1417 cm
-1
 are indicative of acetate groups being 
replaced by carboxylate ion groups in CMPVA.  
 
Peaks at 1640 and 1417 cm
-1
 are indicative of asymmetrical C=O stretching mode for 
carboxylate ion and the peak at 1089 cm
-1
 indicates asymmetrical stretching of C-O-C 
respectively.
215
 Typically the surface functionalization of FeOx nanoparticles with CMPVA 
involves a difficult phase transfer process to establish aqueous colloidal stability. The as 
synthesized nanoparticles were stable in organic solutions such as chloroform and were 
transferred to an aqueous 1.5% TMAOH solution by mixing overnight. The dry FeOx 
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nanoparticles produced by the modified seed growth method in benzyl alcohol were uniquely 
able to be dispersed in TMAOH directly and without the use of organic solutions such as 
chloroform. This is one large advantage to using the benzyl alcohol synthesized nanoparticles. 
The previously reported CMPVA surface functionalization methods did not provide long term 
colloidal stability in PBS, tissue culture medium, or other biologically relevant medium. It was 
thought that the previous methods had been optimized for their particular FeOx nanoparticle 
synthesis and certain factors may influence the efficiency of surface modification including pH, 
nanoparticle diameter, base concentration, and number of polymer per nanoparticle. These 
factors were investigated in an attempt to improve surface functionalization efficiency. 
 The concentration of TMAOH used was first investigated as the initial step is to disperse 
the nanoparticles in a TMAOH solution. It is advantageous to have well dispersed nanoparticles 
to properly surface functionalize individual nanoparticles and thus limit the amount of bridging 
or coating of aggregated nanoparticles. Low and high concentrations of base can lead to 
insufficient nanoparticle separation. Several concentrations (0.0625%, 0.125%, 0.25%, and 0.5% 
w/w TMAOH) were used to disperse the nanoparticles (20 mg/mL; 40:1 CMPVA to FeOx mass 
ratio). FeOx nanoparticles in these TMAOH solutions were analyzed with DLS to determine 
differences in hydrodynamic diameter and dispersion of nanoparticles. The hydrodynamic 
diameters were similar (26.42 ± 1.31 nm) as well as the PDI values throughout the different 
TMAOH concentrations as shown in Table 4.1. At each step in the surface functionalization 
procedure and wash steps DLS was performed. This provided an easy way to analyze the initial 
base concentration effect on efficiency of surface functionalization.  
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Table 4.1. Initial hydrodynamic diameters and PDI values for various v/v % concentration of 
TMAOH. 
% TMAOH 
Hydrodynamic 
Diameter (nm) 
PDI
a
 
0.0625 25.99 0.38 
0.125 29.96 0.363 
0.25 23.61 0.39 
0.5 26.12 0.41 
a
Polydispersity Index (PDI) determined by DLS. 
 
The results from the DLS investigation are shown in Figure 4.2. Aliquots were taken from four 
time points throughout the surface functionalization procedure and were labelled steps 1-4. 
Aliquots were taken before 30k MWCO centrifuge filter (step 1), after 30k MWCO centrifuge 
filter (step 2), and first (step 3) and second (step 4) fractions of elution from disposable PD-10 
desalting column. Large hydrodynamic diameters indicate possible bridging between 
nanoparticles and/or functionalizing an aggregation of nanoparticles. Large PDI values indicate 
large size distributions which are indicative of multiple size populations and/or aggregation. As 
can be seen with the 0.0625% TMAOH nanoparticle solution the PDI value was 0.51 and only 
5% of nanoparticles were not above 1000 nm (Figure 4.2 A). This is in accordance with the 
visual observation that the solution became turbid and had visible aggregation and precipitation 
after CMPVA was introduced. It was not surprising that subsequent steps 2-4 also contained 
large hydrodynamic diameters and PDI values.  
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Figure 4.2. DLS hydrodynamic size measurements at 4 steps throughout the surface 
functionalization process with CMPVA based on several TMAOH concentrations. The 
concentrations of TMAOH used were (A) 0.0625% TMAOH, (B) 0.125% TMAOH, (C) 0.25% 
TMAOH, and (D) 0.5%. The four steps when aliquots were taken are listed in order: before and 
after a 30k MWCO centrifuge filter and 1
st
 and 2
nd
 elution fractions from a PD-10 desalting 
column. Small, medium, and large hydrodynamic diameters correspond to inadequately 
functionalized (red), adequately functionalized (blue), or aggregated nanoparticles (green). 
 
To investigate if the pH after addition of CMPVA was sufficient in maintaining dispersion, 
samples of CMPVA only and FeOx nanoparticles containing CMPVA were titrated with 
TMAOH. The pH changes upon addition of 6.25% TMAOH to solutions of CMPVA only and 
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FeOx nanoparticles containing CMPVA are shown in Figure 4.3. Identical reaction 
concentrations of CMPVA and nanoparticles were used when titrating with 6.25% TMAOH. 
 
 
Figure 4.3. Solutions of CMPVA (blue) and FeOx nanoparticles with CMPVA (red) titrated 
with 6.25% TMAOH. Several markers indicate solution pH when TMAOH concentrations used 
in the DLS study were reached. 
 
A pH above 8.5 was deemed necessary to maintain a dispersion of nanoparticles for efficient 
surface functionalization with CMPVA. It was concluded that 0.0625% TMAOH offered a 
sufficiently high pH to initially disperse the nanoparticles, but the nanoparticles quickly 
aggregated due to a pH drop upon addition of CMPVA. As can be seen in Figure 4.3 the pH of 
nanoparticles with CMPVA at 0.0625% drops below 8.5 to a pH of 6.89. Next, the pH changes at 
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the 0.5% TMAOH solution in Figure 4.3 revealed that the 0.5% TMAOH concentration 
provided dispersion for the functionalization with CMPVA (steps 1 and 2 in Figure 4.2 D), 
however after elution from the PD-10 desalting column (steps 3 and 4 in Figure 4.2 D) it is 
apparent that removal of TMAOH by the desalting column resulted in the nanoparticles 
aggregating and crashing out of solution. This instability was further confirmed by a large 
amount of crashed nanoparticles on the PD-10 column and the large percentage by volume 
(>90%) with hydrodynamic diameters exceeding 1000 nm. The crashed nanoparticles on the PD-
10 column were most likely stabilized by TMAOH only since nanoparticles dispersed in 
TMAOH only completely crashed when loaded on to a PD-10 desalting column. All of these 
observations and results leads to the interpretation that the high concentration of TMAOH 
prevented an adequate exchange of TMAOH with CMPVA. A high concentration gradient of 
TMAOH results in retention of more TMAOH than CMPVA resulting in TMAOH molecules 
being more likely to re-interact with the FeOx surface. While the 0.5% TMAOH solution 
resulted in mainly unstable nanoparticles there was a small population of 188.8 and 173.7 nm 
hydrodynamic diameter nanoparticles that were attributed to ‘inadequately functionalized’ 
CMPVA surface functionalized nanoparticles. They were termed this because they displayed 
aggregation and loss of colloidal stability over time. It is thought that the removal of TMAOH 
led to reordering of the CMPVA on FeOx nanoparticles leading to bridging and aggregation. 
This exemplifies the importance of the PD-10 desalting column step to increase the long term 
stability and separate a stable population. While the 0.5% TMAOH solution resulted in surface 
functionalization of a small population of nanoparticles, this concentration did not produce the 
desired long term stability.  
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 The 0.125% and 0.25% TMAOH FeOx nanoparticle solutions resulted in stable CMPVA 
surface functionalized nanoparticles. There were crucial differences that can be seen after elution 
from the PD-10 desalting column (step 3- Figure 4.2 C). It can be seen that 20% of the 
population of the 0.25% TMAOH nanoparticle solution is inadequately functionalized. Similar to 
the 0.5% TMAOH step 3 and 4, the removal of TMAOH from the 0.25% TMAOH nanoparticle 
solution revealed that there was a population that was not fully functionalized and would lead to 
aggregation through bridging and/or reordering of CMPVA polymers. Interestingly, when the 
TMAOH was removed in steps 3 and 4 for the 0.125% TMAOH nanoparticles solution the 
population shifted from a 50:50 population of adequately to inadequately functionalized 
nanoparticles to 100% adequately surface functionalized nanoparticles. Additionally, the PDI 
values for 0.125% and 0.25% TMAOH nanoparticles solutions were 0.169 and 0.163 
respectively indicating small size distributions and minimal aggregation or crashing. Since, 
0.125% TMAOH nanoparticle solution had a larger initial population of adequately CMPVA 
surface functionalized nanoparticles (step 1) it resulted in a higher overall yield. Of the four 
TMAOH concentrations tested the 0.125% was chosen as the best concentration for CMPVA 
surface functionalization. 
 Subsequently, the above conditions were tested on a different size of nanoparticles to 
determine the methods applicability. Reaction A2-24_B2-24 nanoparticles (used in TMAOH 
concentration study) had a crystallite size of 12.8 nm and a hydrodynamic diameter of 28.9 nm. 
Nanoparticles produced by reaction A2-24(195)_B2-24(195) were chosen as they had a 
crystallite size of 15.2 nm and a hydrodynamic diameter of 37.5 nm. First, the same surface 
functionalization conditions and methods as above were tested on the larger nanoparticles (20 
mg/mL CMPVA, 0.125% TMAOH, and same mass ratio of CMPVA to nanoparticles). This 
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method did indeed functionalize the surface with CMPVA; however the final product’s 
hydrodynamic size was 310.97 ± 51 nm which resulted in aggregation and precipitation. 
Additionally, this size is too large to be sterile filtered and is therefore less applicable regardless 
of stability. The large resultant hydrodynamic diameter was thought to be a result of excessive 
CMPVA concentration leading to higher chances of crosslinking or bridging of multiple 
nanoparticles. The same mass amount of smaller nanoparticles contains a greater number of total 
nanoparticles and a larger total surface area which greatly offsets the ratio of CMPVA to 
nanoparticles. An approximate ratio of number of CMPVA molecules to number of FeOx 
nanoparticles or total surface area was calculated. The nanoparticles were treated as spheres as 
TEM confirmed spherical nanoparticle morphology. The surface area and volume of a sphere 
were used to simplify the calculations. The density of magnetite (5.17 g/cm
3
) was used when 
determining the number of nanoparticles in 10 mg of sample by mass. The total number of 
nanoparticles and surface area of one nanoparticle were used to determine the total surface area 
of 10 mg of nanoparticles. The 400 mg of CMPVA, used to functionalize the surface of A2-
24_B2-24 nanoparticles, equates to 66.67 μmoles or 4.015×1019 of 6,000 molecular weight 
CMPVA. The surface area, volume and mass of one nanoparticle are shown in Table 4.2 to 
illustrate the large differences of particle properties with small changes in the diameter of 
nanoparticles.  
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Table 4.2. Values of nanoparticle properties calculated using crystallite and hydrodynamic 
diameter. 
Crystallite 
diameter (nm) 
Volume 
(m^3) 
SA 
(m^2) SA/V 
Mass of 
1 NP (g) 
12.8 1.10E-24 5.15E-16 0.47 5.68E-18 
15.2 1.84E-24 7.26E-16 0.39 9.51E-18 
Hydrodynamic 
Diameter (nm)         
28.9 1.26E-23 2.62E-15 0.21 6.53E-17 
37.5 2.76E-23 4.42E-15 0.16 1.43E-16 
 
The total number and total surface area of nanoparticles in 10 mg sample are shown in Table 
4.3. These ratios were used to determine the amount of CMPVA to use for the investigation of 
surface functionalizing larger nanoparticles by matching the ratios used in the TMAOH 
optimization for CMPVA surface functionalization. 
 
Table 4.3. Total number and surface area of nanoparticles in 10 mg are shown based on different 
crystallite and hydrodynamic diameters. The ratio of the number of CMPVA molecules to both 
nanoparticles and total surface area are also shown. 
Crystallite 
diameter (nm) 
# of NP in 
10 mg 
SA in 10 mg 
(m^2) 
#of 
CMPVA:NP 
# of 
CMPVA:SA 
12.8 1.76E+15 9.07E-01 2.28E+04 4.43E+19 
15.2 1.05E+15 7.64E-01 3.82E+04 5.26E+19 
Hydrodynamic 
Diameter (nm)         
28.9 1.53E+14 4.02E-01 2.62E+05 1.00E+20 
37.5 7.01E+13 3.09E-01 5.73E+05 1.30E+20 
 
Based on the ratios calculated it was determined that when the crystallite size increased from 
12.8 to 15.2 nm the CMPVA concentration should be 11.9 mg/mL. Likewise, based on 
hydrodynamic diameter increase from 28.9 to 37.5 nm the CMPVA concentration should be 9.15 
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mg/mL. When the CMPVA concentration was adjusted based on surface area it was determined 
that 16.8 mg/mL and 15.4 mg/mL be used respective of calculations using crystallite or 
hydrodynamic diameter. It should be noted that the original article
94
 used slightly different 
crystallite (15 nm instead of 15.2 nm) and hydrodynamic diameter (30 nm instead of 28.9 nm 
and 37 nm instead of 37.5 nm) values which resulted in calculating 12.4 mg/mL and 10.7 mg/mL 
CMPVA concentration based on total number of particles for crystallite and hydrodynamic size 
respectively and 17.1 mg/mL and 16.2 mg/mL based on total surface area for crystallite and 
hydrodynamic size respectively. Since, hydrodynamic diameter is larger than the particle size 
and crystallite size is smaller than the particle size the values were averaged. Optimally 2.28×10
4
 
CMPVA molecules should be used for every one nanoparticle or 4.43×10
19
 CMPVA molecules 
should be used based on the total surface area of 10 mg. Using the same mass amount of A2-
24(195)_B2-24(195) nanoparticles the above averaged values were used to determine if 
calculations based on total number or total surface area is more accurate. Two surface 
functionalization attempts with 11.6 mg/mL and 16.7 mg/mL of CMPVA (values from original 
article that were tested) were used in place of 20 mg/mL CMPVA originally used. Aliquots of 
the two surface functionalizations were taken before and after a 30k MWCO centrifuge filter and 
from 3 elution fractions from a PD-10 desalting column to compare the efficiency (Figure 4.4). 
It was determined that adjusting the CMPVA concentration based on number of nanoparticles 
(11.6 mg/mL of CMPVA) lead to more efficient functionalization of nanoparticles.  
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Figure 4.4. DLS hydrodynamic size measurements based on volume for different CMPVA 
concentrations based on total number of nanoparticles (A) (11.5 mg/mL CMPVA) or surface 
area (B) (16.6 mg/mL) in 10 mg of FeOx nanoparticles at various steps in the clean-up process. 
Depending on the hydrodynamic size the volume population of nanoparticles was labelled as 
either functionalized (blue), partially functionalized (red), or aggregated (green) nanoparticles. 
The four steps when aliquots were taken are listed in order: before and after a 30k MWCO 
centrifuge filter and 1
st
 and 2
nd
 elution fractions from a PD-10 desalting column. 
 
The resultant CMPVA nanoparticles had an average hydrodynamic size of 199.97 ± 34.04 nm 
(50%) and 54.79 ± 24.53 nm (50%) with a PDI of 0.206 (Figure 4.4).  The hydrodynamic size of 
A2-24(195)_B2-24(195) CMPVA nanoparticles is slightly larger than the A2-24_B2-24 
CMPVA nanoparticles, but they were stable in various media. This was expected since A2-
24(195)_B2-24(195) nanoparticles had a larger crystallite and hydrodynamic size before 
CMPVA surface functionalization. The CMPVA surface functionalization based on surface area 
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had a majority of nanoparticles with large hydrodynamic diameters (approaching 1000 nm). This 
suggests that the nanoparticles were aggregating due to a high concentration of CMPVA. 
 CMPVA surface functionalization of A4-24(195)_B6-24(195) nanoparticles for broad 
stability assessment was carried out with some minor modifications to the CMPVA surface 
functionalization method. These modifications were used as they more closely resemble the 
surface modification procedure of APTS, APTES, and GLYMO that were used in the stability 
assessment. The initial dispersion of nanoparticles in TMAOH solution was only sonicated for 
30 minutes prior to addition of CMPVA solution. The time allotted for CMPVA modification of 
the surface was 24 hours instead of 1 week. FTIR-ATR was used to confirm successful surface 
functionalization with CMPVA. Figure 4.5 displays the FTIR-ATR spectra of bare FeOx 
nanoparticles and water. The normalized FTIR-ATR spectra of CMPVA nanoparticles with 
water subtracted out is shown in Figure 4.6. FTIR-ATR was carried out on CMPVA-FeOx in 
solution to discern the functional groups without potentially altering the functional groups which 
may have occurred by drying nanoparticles to a fine powder prior to FTIR characterization. In 
Figure 4.6 the C-H stretching vibrations, asymmetrical C=O stretching mode for dimerized 
saturated carboxylic acids, and asymmetrical stretching of C-O-C are indicated respectively by 
the existence of peaks at 2940, 1716, and 1092 cm
-1
. The 2940 cm
-1 
peak can be attributed to C-
H stretching vibrations of the carbon chain in CMPVA instead of the very strong and broad O-H 
stretching vibrations due to subtraction of water from the spectra.   
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Figure 4.5. FTIR-ATR spectra of A) FeOx nanoparticles and B) water. 
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Figure 4.6. Normalized FTIR-ATR spectra of CMPVA-FeOx aqueous solution with water 
subtracted. 
  
DLS was also used to confirm modification of FeOx nanoparticles with CMPVA (Figure 
4.7). Interestingly, the shorter sonication time used to disperse nanoparticles and shorter 
CMPVA reaction time reduced the resultant hydrodynamic size to 91.6±20.53 (100%) with a 
PDI value of 0.148±0.015.  This is important as this is the upper limit of the “optimal size” of 
nanoparticles to avoid opsoinzation and clearance from the body, and to facilitate more passive 
targeting. Zeta potential further corroborated the presence of CMPVA on FeOx nanoparticles. A 
negative zeta potential indicated carboxylic acid groups at pH=7.4 (Figure 4.8). 
 
Figure 4.7. DLS hydrodynamic diameter by volume percentage for CMPVA-FeOx. 
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Figure 4.8. Zeta potential measurement of CMPVA -FeOx. 
 
4.4 Silane Surface Functionalization of Iron Oxide Nanoparticles 
 FeOx nanoparticles (A4-24(195)_B6-24(195)) were surface functionalized with three 
silane ligands including GLYMO, APTS, and APTES. These silane surface functionalizations 
are used in many applications including corrosion protection,
216-218
 adhesive durability,
219
 
semiconductor coatings,
220-223
 and surface passivation
224
 and are well characterized and 
understood for bulk materials. GLYMO was chosen because the epoxy ring can be easily opened 
with a base catalyzed reaction involving nucleophilic ligands to provide a multitude of surface 
functionalizations with different properties. This epoxy ring opening can be base or acid 
catalyzed allowing for rapid alterations in the surface chemistry such as charge and terminal 
functional groups present. These alterations however will have significant effects on the stability 
in different buffers and medium. Therefore investigate how different ligands affect the stability 
in different aqueous stability will provide a better understanding of how the stability can be 
tailored by choice of ligands. APTS-FeOx and APTES-FeOx were used as comparison surface 
functionalizations in the stability assessment as they are a commonly used in literature to surface 
functionalize nanoparticles for aqueous stability.
225,226
 Hydrolysis and condensation of APTS, 
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APTES, and GLYMO to the surface of FeOx nanoparticle results in a silica-like shell or network 
surrounding the FeOx nanoparticle. However, the inherent solubility and rate of hydrolysis of 
each silane notably affects the resultant surface functionalization efficiency.
150
 The solubility 
difference of APTS and APTES compared to GLYMO determined how the silanes were added to 
the nanoparticle solution. A slow drop-wise addition of APTS and APTES was required for 
efficient surface functionalization. APTS and APTES are most soluble at pH~10 in water. 
Therefore when adding these silanes to the TMAOH nanoparticle solution (high pH), a quick 
addition could lead to a high local concentration of the silanes and a nucleation event preventing 
efficient condensation on the surface of the FeOx nanoparticles. Upon titration to pH 7.4 with 
HCl the terminal amine groups of APTS-FeOx and APTES-FeOx provided sufficient colloidal 
stability and were ready for subsequent wash and purification steps. 
 In contrast, GLYMO is highly soluble at pH=5.3. The complete and rapid addition of 
GLYMO facilitates the generation of an emulsion-like suspension where the GLYMO ligands 
will interact with the FeOx and condense to the surface in the proper orientation. The 
condensation can be visibly seen as the clear brown TMAOH nanoparticle solution changes to a 
“muddy brown” color after 10-15 minutes of reaction. This color change is the result of the 
alteration of solubility of the nanoparticles due to the terminal epoxy groups of the GLYMO 
shifting the nanoparticle stability to lower pH. At this point addition of extra TMAOH base and 
nucleophiles were used to open the epoxy ring to provide aqueous stability. Addition of a 
nucleophile at the high pH resulted in an immediate color change from “muddy brown” to clear 
brown indicating the successful base-catalyzed epoxy ring opening. This color change was not 
always indicative of aqueous stability as the addition of Lys, Arg, Cys, Thr, Asn, Gln, 
hydroxylamine, or citric acid did not result in colloidal stability once the pH was adjusted to 7.4. 
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Only Gly, Ser, EDA, TEPA, ABA or SAHBA proved to provide sufficient colloidal stability at 
pH=7.4. Figure 4.9 is a visual comparison of sufficient colloidal stability provided by Gly and 
Ser at pH=7.4, even in the presence of a rare earth magnet, and the unstable and precipitated 
solutions of Lys, Gln, Arg, and Cys.  
 
 
Figure 4.9. Visual aqueous stability assessment at pH=7.4 in presence of a magnet of several 
nucleophilic ligands used to open the GLYMO epoxy ring. Aqueous stability was indicated by a 
clear brown top solution as seen in Gly-FeOx and Ser-FeOx. From left to right: Lys-FeOx, Gln-
FeOx, Gly-FeOx, Ser-FeOx, Arg-FeOx, and Cys-FeOx.  
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The instability in a magnetic field is critical in identifying unstable nanoparticles and is used as 
the first step in the washing and purification process. Bridging and aggregation due to inefficient 
electrostatic repulsion or steric hindrance is the most likely cause of the aggregation seen in 
GLYMO-FeOx nanoparticles modified with Lys, Arg, Cys, Thr, Asn, Gln, hydroxylamine, or 
citric acid. 
The APTS-FeOx, APTES-FeOx, and GLYMO-FeOx nanoparticles were all washed, 
purified, and sterilized after pH titration and magnetic separation of unstable nanoparticles. This 
process was also used for CMPVA nanoparticles used in the stability investigation. The PD-10 
desalting column was not used for additional cleanup of APTS-FeOx or APTES-FeOx 
nanoparticles as these nanoparticles crashed on the column during the elution step. The reasoning 
behind this is that APTS and APTES surface functionalizations require specific counter-ion salts 
for stability and the size exclusion PD-10 column swiftly separates the ions from the much larger 
nanoparticles. The rapid removal of the counter-ions required for stability results in aggregation 
and instability as the nanoparticles move through the PD-10 column. Additional 30k MWCO 
centrifuge filter wash steps were applied in lieu of the PD-10 column to further remove excess 
APTS and APTES and as a buffer exchange step. The sterilization with a 0.2 μm sterile filter in a 
sterile bio-safety laminar flow hood was the last step of the wash, purification, and sterilization 
process. 
Characterization with FTIR, XPS, and DLS was used to confirm the addition of APTS, 
APTES, and GLYMO to the surface of FeOx nanoparticles. The normalized FTIR-ATR spectra 
for APTS-FeOx and APTES-FeOx with water removed are displayed in Figure 4.10. The 
normalized FTIR-ATR spectra for GLYMO-FeOx and further modified with Gly, Ser, EDA, 
TEPA, ABA, and SAHBA with water removed are shown in Figure 4.11-13. When the 
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GLYMO-FeOx terminal epoxy ring is opened and modified with a nucleophile the nanoparticle 
is named without the GLYMO. For example, ‘Ser-FeOx’ refers to the terminal epoxy ring 
opening of GLYMO-FeOx with Ser. The primary identifying peaks of respective surface 
functionalizations are listed in Table 4.4. There are several silane containing peaks 
corresponding to SiO-H, Si-O-Si, and Si-O-H stretches that were present at approximately 1100 
cm-1, 1058 cm-1, and 918 cm-1 respectively.
227-230
 Each of the silanes contained a C-H 
stretching doublet from the propyl group that absorbs at 2930 cm
-1
 and 2860 cm
-1
.
227,228
 The 
terminal amine group of APTS-FeOx and APTES-FeOx nanoparticles had peaks indicative of N-
H stretching vibration, weak asymmetrical NH3
+
 bending, and symmetrical NH3
+ 
bending at 
3420 cm
-1
, 1660-1610 and 1550-1485 cm
-1
 respectively.
215,227,228
 A combined asymmetric NH
3+
 
bending vibration and torsional oscillation was present in APTS-FeOx, APTES-FeOx, EDA-
FeOx, and TEPA-FeOx nanoparticles at peaks of 2222-2000 cm
-1
.
215
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Figure 4.10. FTIR-ATR spectra with normalized percent transmittance for A) APTS-FeOx and 
B) APTES-FeOx with water subtracted. 
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Figure 4.11. FTIR-ATR spectra with normalized percent transmittance for A) Gly-FeOx and B) 
Ser-FeOx with water subtracted. 
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Figure 4.12. FTIR-ATR spectra with normalized percent transmittance for A) EDA-FeOx and 
B) TEPA-FeOx with water subtracted. 
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Figure 4.13. FTIR-ATR spectra with normalized percent transmittance for A) ABA-FeOx and 
B) SAHBA-FeOx with water subtracted. 
 
Epoxy ring opening by respective nucleophiles was confirmed by the absence of the “12 micron 
band” peak at 750-840 cm-1 and ring breathing frequency for the epoxide group at 1250 cm-1.215 
FTIR-ATR spectra comparison of GLYMO-FeOx and SAHBA-FeOx demonstrate the epoxy 
ring opening (Figure 4.14). The epoxy ring peaks are absence in all GLYMO nanoparticle 
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functionalizations after the addition of the nucleophilic ligand (Figure 4.11-13 and Table 4.4). 
In Figure 4.14 it is important to note the appearance of peaks at 1581 and 1416 cm
-1
 
corresponding to the terminal carboxylate anion which indicates that the amine group of SAHBA 
opened the epoxy ring.
215
 
 
Figure 4.14. Normalized FTIR-ATR spectrum of GLYMO-FeOx (blue line) and SAHBA-FeOx 
(red line). Epoxy ring opening with SAHBA is indicated by disappearance of peaks at 1250 and 
740-850 cm
-1
 and appearance of peaks at 1581 and 1416 cm
-1
.  
Table 4.4. List of identifying FTIR-ATR peaks surface functionalized FeOx nanoparticles.  
Peak Description and 
Wavenumber (cm
-1
) 
APTS-
FeOx 
APTES-
FeOx 
EDA-
FeOx 
TEPA-
FeOx 
Gly-
FeOx 
Ser-
FeOx 
ABA-
FeOx 
SAHBA-
FeOx 
N-H stretching 3420 3455 3422 3422 3421 3422 3421 3422 3421 
C-H stretching 
doublet, propyl 
group 
2930 
2860 
2965 
2892 
2930 
2846 
2964 
2898 
2964 
2864 
2916 
2870 
2939 
2858 
2920 
2879 
2941 
2880 
Asymmetric 
NH3
+
 bending 
vibration and 
torsional 
oscillation 
2222-2000 
 
2100 2095 2205 2152     
Carboxylate 
Anion 
1650-1550 
1400 
    1614 
1400 
1616 
1400 
1558 
1405 
1581 
1416 
Epoxy Ring 
Breathing 
Frequency 
1250         
CO2 stretching/ 
C-O stretch 
1320-1000   1201 1201 1201 1201 1201 1201 
SiO-H 1100 1118  1101 1101 1110 1100 1100 1101 
Si-O-Si 1058   1057 1057 1057 1058 1058 1060 
Si-O-H 918 917 917 916 917 911 916 916 917 
12 micron band 840-750         
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XPS was first used to characterize the non-surface functionalized nanoparticles. High-
resolution Fe 3p XPS characterization of A4-24(195)_B6-24(195) nanoparticles (Figure 4.15) 
was used to determine the amount of magnetite and maghemite present. High-resolution Fe 2p 
XPS spectrum is not suitable to distinguish between magnetite and maghemite crystal structures 
due to multiple satellite peaks and broad line widths.
231,232
 The Fe 3p peak was deconvoluted into 
three peaks at 53.119 eV, 55.195 eV, and 56.279 eV. The 53.119 eV peak was attributed to Fe
2+
 
ions.
232
 The 55.195 and 56.279 eV were attributed to Fe
3+
 ions.
231,232
 Pure magnetite will consist 
of a 1:2 Fe
2+
 to Fe
3+
 ratio, but experimentally it was determined to be 0.52.
231,232
 Since the ratio 
of Fe
2+
 to Fe
3+
 was 3:96 it was concluded that the sample contained a mixture of magnetite and 
maghemite as maghemite contains no Fe
2+
 ions. Using the experimentally determined Fe
2+
 to 
Fe
3+
 ratio of 0.52 for pure magnetite it was estimated that the sample with a ratio of 3:96 
contained approximately 8.86% magnetite and 91.14% maghemite.  
 
Figure 4.15. High-resolution Fe 3p XPS spectrum of FeOx nanoparticles without surface 
modification.  
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XPS was also used to further verify surface functionalization and confirm epoxy ring opening. 
Non-surface functionalized FeOx nanoparticles are shown in Figure 4.16.The FeOx 
nanoparticles XPS N 1s and Si 2p spectra (not shown) revealed no peaks were present providing 
confirmation that peaks in these spectra of APTS-FeOx, Gly-FeOx, and Ser-FeOx are due to 
their respective surface functionalization’s.  
 
Figure 4.16. XPS survey spectrum, and high resolution Fe 2p, and O 1s spectra of FeOx 
nanoparticles without surface modification.  
 
Analyzing the XPS survey scan of the APTS-FeOx (Figure 4.17) revealed presence of 
iron, oxygen, carbon, silicon, and nitrogen as expected for successful surface functionalization. 
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Further analysis of the high-resolution Si 2p spectrum revealed the presence of Si-C and Si-O 
bonds from the deconvulted peaks positioned at 102.038 eV, and 104.732 eV.
233
 This confirms 
the presence of the APTS and the successful hydrolysis of the silane. However, to confirm 
successful silanization with the FeOx nanoparticles analysis of the high-resolution O 1s spectrum 
is required. The O 1s peak was deconvulted into four peaks at 529.803 eV, 530.424 eV, 531.573 
eV, and 532.573 eV binding energies. The peaks at 530.424 eV, 531.573 eV are most likely due 
to impurities from benzyl alcohol, benzaldehyde, or even acetylacetonate. The peaks at 529.803 
eV and 532.573 eV correspond to Fe-O and Si-O binding energies.
231,234 
These peaks confirm the 
successful silanization of APTS to FeOx nanoparticles. The high-resolution N 1s spectrum was 
next analyzed to further determine the APTS is modifying the surface as expected. Indeed, the N 
1s doublet peak was deconvulted into three peaks at 399.323 eV, 400.245 eV, and 401.328 eV 
binding energies indicating N-C, -NH2, and –NH3
+
 respectively.
234 
The high-resolution C 1s 
spectrum was used to further confirm that the attachment of the APTS to FeOx is occurring 
through the Si-O-Fe rather than a NHCO bond. A NHCO bond would appear in the C 1s 
spectrum with binding energy of 292 eV.
233
 The only peaks deconvulted from the C 1s spectrum 
were 284.988 eV, 286.197 eV, and 288.291 eV corresponding to C-C/C-H bonds, C-O/C-N, and 
carbon impurities.
233,235
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Figure 4.17. XPS high-resolution Si 2p, N 1s, and O 1s spectra of APTS-FeOx nanoparticles. 
 
Gly-FeOx and Ser-FeOx were investigated with XPS to confirm successful GLYMO 
silanization and attachment to FeOx and successful epoxy ring opening by the amine in Gly and 
Ser. Ser-FeOx had similar silane peaks to APTS as expected and are shown in the high-
resolution Si 2p, N 1s, and O 1s spectra (Figure 4.18). In the high-resolution Si 2p spectrum the 
peak can be deconvulted into 102.484 and 103.1781 eV binding energy peaks corresponding to 
Si-C and Si-O bonds in GLYMO. Next, the O 1s spectrum was analyzed and the main peak 
deconvoluted into four peaks at 529.617, 530.987, 532.067, and 532.651 eV binding energies. 
The 529.617 eV binding energy peak is attributed to the oxygen in Fe3O4.
231
 The 530.987 and 
532.651 eV binding energies are attributed to the carboxylic acid of Ser. The epoxy ring opening 
with Ser through the amine rather than the carboxylic acid is confirmed by absence of a 533.13 
eV binding energy peak.
236
 Analysis of the high-resolution N 1s spectrum revealed three 
deconvulted peaks at binding energies of 399.589 eV, 401.354 eV, and 402.851 eV 
 123 
 
corresponding to N-C, NH2, and NH2
+
, respectively.
237
 The N 1s spectrum further corroborates 
the amine opening of the epoxide ring as expected. 
 
 
Figure 4.18. XPS high-resolution Si 2p, N 1s, and O 1s spectra of Ser-FeOx nanoparticles. 
 
 
Figure 4.19. XPS high-resolution Si 2p, N 1s, and O 1s spectra of Ser-FeOx nanoparticles. 
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The Gly-FeOx high resolution XPS spectra (Figure 4.19) was in close agreement with 
the Ser-FeOx XPS spectra as expected. The high-resolution Si 2p spectrum revealed Si-O and 
SiO2 peaks at 102.412 and 102.98 eV binding energies from the GLYMO. The high-resolution O 
1s spectrum also revealed a Fe-O bond at 529.591 eV. The Si-O, and carboxylic acid oxygen 
bonds from glycine were observed at 532.42 eV, and 531.148 eV and 532.682 eV 
respectively.
238
 The high-resolution N 1s spectrum further established the amine group opened 
the GLYMO epoxy ring, indicated by 399.589, 401.354, and 402.851 eV binding energy 
corresponding to N-C, NH2, and NH2
+
.
237
 
 DLS is an invaluable characterization technique to determine the properties of the surface 
modified nanoparticles in solution. The efficiency of surface functionalization was assessed by 
hydrodynamic diameter, polydispersity index (PDI), and zeta potential (ζ), listed in Table 4.5. 
The DLS size measurements and zeta potential measurements for each surface functionalization 
are shown in Figures 4.21-23. The hydrodynamic diameter change for each surface 
functionalization as compared to TMAOH nanoparticles depends on the surface 
functionalization. Possible aggregation was revealed in some of the surface functionalizations 
which contained a small volume fraction of larger hydrodynamic diameters. The small 
hydrodynamic diameter of APTS-FeOx (17.83±7.628 (99.9%)) compared to the hydrodynamic 
diameters of APTES-FeOx (92.15±17.77 (71.4%) and 332.5±58.37 (28.6%)) suggests that APTS 
is most likely more stable than APTES. APTES has a 7 fold slower hydrolysis rate than APTS 
which most likely resulted in some incomplete or insufficient surface functionalization; this is 
supported by the second larger hydrodynamic diameter population for APTES. 
150
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Table 4.5. DLS measurements of hydrodynamic diameter, polydispersity index, and Zeta 
potential for surface functionalized FeOx nanoparticles.  
Surface 
Functionalization 
Hydrodynamic 
Diameter (nm) 
Polydispersity Index 
(PDI) 
Zeta Potential (ζ) 
(mV) 
TMAOH-FeOx 26.6±7.795 (100%) 0.112  
APTS-FeOx 17.83±7.628 (99.9%) 0.317 21.5±1.33 
APTES-FeOx 92.15±17.77 (71.4%) 
332.5±58.37 (28.6%) 
0.386 21.1±1.94 
EDA-FeOx 35.56±11.09 (99.9%) 
193.2±41.47 (0.1%) 
0.221 46.4±13.1 
TEPA-FeOx 38.12±9.959 (100%) 0.150 41.2±19.7 
Gly-FeOx 29.13±12.67 (100%) 0.228 -22.4±5.8 
Ser-FeOx 34.63±6.5 (82.3%) 
110.3±32.88 (17.7%) 
0.219 -20.2±11.2 
ABA-FeOx 29.56±5.713 (93) 
114.2±37.97 (7%) 
0.372 -21.8±5.09 
SAHBA-FeOx 25.59±6.269 (99.2%) 
126.7±36.98 (0.8%) 
0.269 -29.2±14 
CMPVA-FeOx 91.6±20.53 (100%) 0.148 -19.2±0.936 
 
 
Figure 4.20. DLS measurements based on volume percent for A) APTS-FeOx and B) APTES-
FeOx. 
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Remarkably, there was a range of hydrodynamic diameters and PDI values for GLYMO 
nanoparticles. While the differences are subtle they are more than likely due to small changes in 
size of the added nucleophile, formation of differing water solvation shell sizes, and/or magnetic 
separation selecting a particular size. Despite the differences in hydrodynamic size and PDI 
values these GLYMO functionalized nanoparticles produced a stable colloid at biologically 
relevant pH.  
 
 
 
 
Figure 4.21. DLS measurements based on volume percent for A) Gly-FeOx and B) Ser-FeOx. 
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Figure 4.22. DLS measurements based on volume percent for A) ABA-FeOx and B) SAHBA-
FeOx. 
  
 
 
Figure 4.23. DLS measurements based on volume percent for A) EDA-FeOx and B) TEPA-
FeOx. 
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DLS was next used to measure the zeta potential which can be useful in predicting cellular 
interactions. The zeta potential measurements are shown in Figures 4.24-27. The presence of 
terminal carboxylate groups in Gly-FeOx, Ser-FeOx, ABA-FeOx, SAHBA-FeOx and CMPVA 
nanoparticles resulted in negative zeta potentials. The negative zeta potentials due to terminal 
carboxyl groups is expected as the amine groups of these molecules are much better nucleophiles 
than alcohol groups or water and will open the epoxy ring much more efficiently.
239
 SAHBA-
FeOx had the most negative zeta potential of -29.2 mV. The chemically similar ligands SAHBA 
and Ser differ in the carbon chain length and position of the alcohol group in relation to the 
carboxylic acid group. This is important as the OH group in SAHBA is closer to the electron 
withdrawing group of the carboxylic acid thus lowering the pKa resulting in a more negative zeta 
potential at pH of 7.4. Large negative or positive zeta potentials have been reported as an 
indicator of colloidal stability, but may not always indicate stability in biologically relevant 
medium that cannot be easily measured using DLS.  
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Figure 4.24. Zeta potential measurement of A) Gly-FeOx and B) Ser-FeOx nanoparticles. 
 
 
 
Figure 4.25. Zeta potential measurement of A) ABA-FeOx and B) SAHBA-FeOx nanoparticles. 
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The APTS-FeOx, APTES-FeOx, EDA-FeOx, and TEPA-FeOx nanoparticles all had positive 
zeta potentials as expected (Figure 4.26 and 4.27). This was due to the terminal protonated 
amine groups at pH of 7.4. The APTS-FeOx and APTES-FeOx nanoparticles were expected to 
have the same final surface functionalization despite different starting ligands. This was further 
corroborated by the similar zeta potentials measured. The EDA-FeOx and TEPA-FeOx 
nanoparticles had zeta potentials twice as large as APTS-FeOx /APTES-FeOx which resulted 
from the larger amount of primary and secondary amines present in EDA-FeOx and TEPA-FeOx 
nanoparticles as compared to APTS-FeOx and APTES-FeOx nanoparticles. Additionally, the pH 
titration to 7.4 for EDA-FeOx and TEPA-FeOx nanoparticles required more HCl than the APTS-
FeOx and APTES-FeOx nanoparticles, further substantiating the zeta potential differences.  
 
 
 
Figure 4.26. Zeta potential measurement of A) APTS-FeOx and B) APTES-FeOx. 
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Figure 4.27. Zeta potential measurement of A) EDA-FeOx and B) TEPA-FeOx. 
 
4.5 Stability Assessment in Different Biologically Relevant Medium 
 The stability assessment of the surface functionalized FeOx nanoparticles is vital in 
predicting how efficiently they can be used in biological applications. By testing the stability in 
several biologically relevant medium a better understanding of biological effects such as cellular 
uptake, biodistribution, and retention can be accomplished. The surface functionalization 
methods were chosen to provide biological stability and allow for further conjugation potential 
via 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) coupling. More specifically, APTS 
and APTES were chosen as they are commonly used surface functionalizations with reported 
aqueous stability provided by terminal amines. The CMPVA surface functionalization was used 
as it was shown to have stability in a wide range of biological media. GLYMO surface 
functionalizations were chosen as they provided a convenient and rapid way to modify the 
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surface with a nucleophile. The benefit of the GLYMO method is that a variety of nucleophiles 
can be used to tailor the stability to specific applications. Several amino acids were used in 
attempts to provide a variety of terminal groups granting a “bio-stealth” like property and EDA 
and TEPA were chosen to produce an amine terminal functionalization that would be a good 
comparison to APTS and APTES functionalizations. While a variety of tested amino acids and 
compounds were unsuccessful in providing stability after magnetic extraction and purification 
steps, Gly-FeOx and Ser-FeOx had very promising initial stabilities. Thus, ABA and SAHBA 
were chosen as they are chemically and structurally similar to Gly and Ser respectively. In a 
recent study increasing chain length of multidentate block copolymers were shown to positively 
affect the stability of FeOx nanoparticles in PBS.
240
 ABA contains a slightly longer carbon chain 
than glycine. SAHBA differs from Ser as it contains a slightly longer carbon chain and the 
alcohol group is closer in proximity to the carboxylic acid group. With the alcohol closer to the 
carboxylic acid it is thought that stability would be improved by increasing the electrostatic 
repulsion between nanoparticles by producing a more negative zeta potential. 
 Water, 1x PBS, 0.5x PBS, 0.9% NaCl, CSF, CM, and HS were used to determine the 
stability and investigate potential causes of instability of the different surface functionalizations. 
Visual assessment of the surface functionalized FeOx nanoparticles at various time points were 
used in place of DLS measurements as not all solutions can be easily measured using DLS 
techniques. Visual assessment was broken into three categories: clear solution, cloudy solution, 
and precipitated/crashed solution representing stability, partial stability, and complete instability 
respectively. The stability was monitored at several time points from initial dispersion to 2 weeks 
in test medium. Table 4.6 summarizes the times at which each surface functionalized 
nanoparticle first showed signs of instability (cloudy or precipitation). Upon initial inspection all 
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surface functionalized nanoparticles were stable in all media except EDA-FeOx and TEPA-
FeOx. Both of these became cloudy in cell medium and HS immediately.  
 
Table 4.6. List of first signs of instability of various surface functionalized FeOx nanoparticles; 
indicated by a cloudy or precipitated solution.  
 H2O 1x PBS 0.5x PBS 0.9% 
NaCl 
CSF CM HS 
APTS-FeOx  2 hours 2 hours  2 hours 48 hours  
APTES-FeOx  2 hours 2 hours 2 hours 2 hours 24 hours 24 hours 
EDA-FeOx      2 hours 24 hours 
TEPA-FeOx     1 week 2 hours 2 hours 
Gly-FeOx      2 weeks* 24 hours 
Ser-FeOx      2 weeks** 2 weeks 
ABA-FeOx      2 weeks* 2 weeks 
SAHBA-FeOx      2 weeks**
 
 
CMPVA-FeOx      2 weeks**  
*Small amount of precipitation may be due to cell medium sitting at room temperature 
**Very small amount of precipitation which may be due to cell medium sitting at room 
temperature 
 
 Visual inspection of nanoparticles in water revealed that even at 1 month time (Figure 
4.28) all surface functionalizations were clear and stable. This is important to note as stability in 
water does not necessarily indicate stability in the biological media of interest. PBS was 
investigated as it is a very commonly used biological buffer. All nanoparticles except APTS-
FeOx and APTES-FeOx were soluble in 1x PBS at 2 weeks. APTS-FeOx and APTES-FeOx 
showed initial aggregation at 2 hours and were completely precipitated out of solution at 24 
hours.  
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Figure 4.28. Time study of surface functionalized FeOx nanoparticle stability in water (H2O) 
and 1x phosphate buffered saline (PBS). Clear, cloudy, or aggregated precipitations indicate 
stable, partially stable, or complete instability respectively. 
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 Assessment of stability in 0.5x PBS and 0.9% NaCl (Figure 4.29) solutions were chosen 
to ascertain if the phosphate ions or concentration of sodium and chloride counter ions caused 
the instability in 1x PBS for APTS-FeOx and APTES-FeOx. Interestingly, APTS-FeOx and 
APTES-FeOx had the same stability in 0.5x PBS, but APTES-FeOx was instable in 0.9% NaCl. 
This suggests that the phosphate ions are causing instability in APTS-FeOx. Analysis of the DLS 
data (Table 4.5) shows that APTES-FeOx has a much larger hydrodynamic size (92.15±17.77 
nm (71.4%) and 332.5±58.37 nm (28.6%)) as compared to APTS-FeOx (17.83±7.628 nm 
(99.9%)). This difference in size and the inability to 0.2 μm sterile filter APTS-FeOx or APTES-
FeOx solutions after several days prompted further investigation. To further investigate the 
difference in stability the hydrodynamic size was analyzed in water at two time points. The data 
(Figure 4.30) shows a hydrodynamic diameter increase over time for both APTS-FeOx and 
APTES-FeOx, but the extent of increase suggests that APTES-FeOx aggregates at a much faster 
rate than APTS-FeOx. This suggests that the APTES-FeOx may not have completely formed a 
silane shell and may be reorienting and forming a silane shell around multiple nanoparticles. 
Alternatively, a re-hydrolyzation process leading to improper silane shell reforming could also 
be occurring leading to larger hydrodynamic sizes and instability. The APTES-FeOx is able to 
maintain stability in water even with changes in hydrodynamic size, but the addition of salts 
causes complete precipitation. These results suggests that APTS-FeOx and APTES-FeOx may 
appear clear and stable in some solutions, but are susceptible to re-hydrolysis and aggregation 
over time.  
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Figure 4.29. Time study of surface functionalized FeOx nanoparticle stability in 0.5x PBS and 
0.9% sodium chloride (saline). Clear, cloudy, or aggregated precipitations indicate stable, 
partially stable, or complete instability respectively. 
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Figure 4.30. DLS hydrodynamic size measurements of APTS-FeOx (A) or APTES-FeOx (B) 
after 1 (Top) and 12 days (Bottom). 
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 CSF stability is important to investigate for the application of FeOx nanoparticles for the 
treatment of glioblastoma multiforme (GBM). CSF is a close representation of the environment 
that the nanoparticles would be subjected to in treatment of brain tumors. In Figure 4.31 it can 
be seen that APTS-FeOx and APTES-FeOx first show signs of instability at 2 hours and at 24 
hours are completely crashed out of solution. TEPA-FeOx showed a small amount of 
precipitation at 1 week indicating partial instability. Instability at these short time periods limits 
their applicability in delivering time sensitive brachytherapy. Additionally, the instability could 
prohibit blood circulation and/or uptake. 
 
 
Figure 4.31. Time study of surface functionalized FeOx nanoparticle stability in artificial 
cerebral spinal fluid (CSF). Clear, cloudy, or aggregated precipitations indicate stable, partially 
stable, or complete instability respectively. 
 
 In vitro investigations of FeOx nanoparticles are often performed using complete cell 
medium containing FBS. Similarly, in vivo administered FeOx nanoparticles in humans will 
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have some degree of interaction with HS. The proteins contained in the respective serum can 
have varying degrees of interaction with the nanoparticles and therefore affect the stability. Thus, 
stability assessments in these media are imperative and are shown in Figure 4.32. Protein 
coronas can form around nanoparticles when introduced to media containing serum which will 
directly and substantially affect cellular interactions.241 Interestingly, EDA-FeOx and TEPA-
FeOx nanoparticles instantaneously became cloudy upon introduction to CM or HS and were 
approaching complete precipitation at 2 hours. The other positive zeta potential surface 
functionalizations, APTS-FeOx and APTES-FeOx, also displayed aggregation signs early. At 48 
hours for APTS-FeOx and 24 hours for APTES-FeOx aggregation and precipitation began. The 
negative surface functionalized nanoparticles showed small amounts of precipitation for Gly-
FeOx and Ser-FeOx and very small amounts of precipitation for ABA-FeOx, SAHBA-FeOx, and 
FeOx at 2 weeks.  Analyzing the HS stability revealed that only APTS-FeOx, SAHBA-FeOx, 
and CMPVA-FeOx retained stability at 2 weeks. The stability was very similar in CM and HS 
for APTES-FeOx, EDA-FeOx, TEPA-FeOx, and Ser-FeOx suggesting that the FBS in CM was 
the cause of instability. Gly-FeOx was instable at 24 hours in HS and only showed small 
amounts of instability at 2 weeks in CM suggesting that the higher concentration of serum in HS 
as compared to CM resulted in the different stabilities. 
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Figure 4.32. Time study of surface functionalized FeOx nanoparticle stability in cell medium 
(CM) and human serum (HS). Clear, cloudy, or aggregated precipitations indicate stable, 
partially stable, or complete instability respectively. 
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 Interesting stability information can be established when comparing the differences of 
stability in PBS, CM, and HS. With regards to APTS-FeOx the instability can be attributed to 
phosphate ions rather than serum proteins as the APTS-FeOx nanoparticles remained stable in 
HS at 2 weeks. The differences between positive and negative zeta potential surface 
functionalizations are striking. The larger degree of instability of positive surface 
functionalizations as compared to negative surface functionalizations seen in CM and HS offers 
some substantiation to claims of higher cellular uptake values recorded for cationic amine group 
functionalizations. However, the increased uptake recorded may be due to crashed cationic 
surface functionalizations and not true uptake or internalization. 
DLS investigation of APTS-FeOx, APTES-FeOx, EDA-FeOx, and TEPA-FeOx in water 
was assessed after 12 days to determine if any changes were occurring that were not visually 
seen. The hydrodynamic size after twelve days in water for APTS-FeOx and APTES-FeOx is 
shown in Figures 4.30; EDA-FeOx and TEPA-FeOx is shown in Figure 4.33 and 4.34. APTS-
FeOx nanoparticles increased from 17.83±7.628 nm (99.9%) to 122.1±37.45 nm (95.7%) and 
5326±699.2 nm (4.3%) where APTES increased to 674.7±85.2 nm (100%) (Figure 4.30). EDA-
FeOx and TEPA-FeOx surface functionalized nanoparticles measured hydrodynamic diameters 
were 35.56 ±11.09 nm (99.9%) and 38.12±9.959 nm (100%) respectively. After 12 days EDA-
FeOx and TEPA-FeOx surface functionalized nanoparticles measured hydrodynamic diameters 
were 27.82±11.01 nm (100%) and 29.52±9.047nm (100%). This is crucial as it clearly shows 
that the silane on the EDA-FeOx and TEPA-FeOx nanoparticles does not alter overtime whereas 
the APTS silane does alter over time resulting in larger hydrodynamic diameters. 
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Figure 4.33.  Dynamic light scattering hydrodynamic diameter measurement by volume for 
EDA-FeOx nanoparticles (A) and EDA-FeOx nanoparticles 12 days later (B). 
 
 
Figure 4.34.  Dynamic light scattering hydrodynamic diameter measurement by volume for 
TEPA-FeOx nanoparticles (A) and TEPA-FeOx nanoparticles 12 days later (B). 
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 The long term stability was analyzed at 3 weeks, 1 month and 5 months (Figure 4.35 and 
4.36). The stability at 1 month was deemed sufficient for initial stability assessment. The 5 
month time point may not be an accurate representation of long term stability as there was some 
volume changes observed in a few of the microcentrifuge tubes most likely due to evaporation. 
The volume changes do not seem to be related to media and are considered an effect of random 
inefficient sealing of microcentrifuge tubes which resulted in only some of the samples 
evaporating. Regardless, the 5 month analysis is helpful in visualizing instability that may have 
been present and unseen at earlier time points. For water the first signs of instability were seen at 
5 months for APTES-FeOx and very small amounts of precipitation in Gly-FeOx, and Ser-FeOx. 
There was some small amount of precipitation at 5 months in 1x PBS for Gly-FeOx, and Ser-
FeOx, but not 0.5x PBS. At 5 months the first and small signs of instability in CSF were 
observed for Gly-FeOx, Ser-FeOx, ABA-FeOx, and CMPVA-FeOx. 
In conclusion, CMPVA-FeOx, Ser-FeOx, ABA-FeOx, and SAHBA-FeOx demonstrated 
broad stability at 1 week. The CMPVA-FeOx and SAHBA-FeOx nanoparticles only had 
minimal precipitation in CM at 2 weeks, but were otherwise stable up to 5 months with the 
exception of some CMPVA-FeOx precipitation in CSF. Overall, SAHBA-FeOx had the best and 
broadest solution stability even at 5 months. It is thought that the longer carbon chain and the 
alcohol being in closer proximity to the carboxylate group in SAHBA provided the best 
electrosteric stability of the surface functionalizations tested. Furthermore, this investigation 
suggests that the presence of both hydroxyl and carboxyl groups appear to provide the best and 
broadest stability as seen in CMPVA-FeOx and SAHBA-FeOx. The different media revealed 
that the concentration of salt, sugar, and protein can have dramatic effects on the stability. More 
specifically, water or PBS stability is not indicative of stability in all biologically relevant media. 
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These two surface functionalizations have relatively large differences in hydrodynamic size, but 
similar broad stability and zeta potentials. They will potentially be very useful in determining 
differences in biological effects based on size. 
 
 
 
 
Figure 4.35. Time study of surface functionalized FeOx nanoparticle stability in water, 1x PBS, 
and 0.5x PBS at 3 weeks, 4 weeks, and 5 months. Clear, cloudy, or aggregated precipitations 
indicate stable, partially stable, or complete instability respectively. 
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Figure 4.36. Time study of surface functionalized FeOx nanoparticle stability in 0.9% NaCl, 
CSF, CM, and HS at 3 weeks, 4 weeks, and 5 months. Clear, cloudy, or aggregated precipitations 
indicate stable, partially stable, or complete instability respectively. 
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4.6 Iron Oxide Nanoplatform: Confirming Conjugation Potential 
with a Radiotherapeutic 
 The surface functionalizations were chosen not only to provide biological stability, but to 
also provide additional conjugation potential. To demonstrate their conjugation potential a metal 
chelate, DOTA, was conjugated to SAHBA-FeOx and CMPVA-FeOx nanoparticles. DOTA can 
chelate Lutetium-177 (
177
Lu), primarily a beta emitter that has been used to treat GBM in 
preclinical murine orthotopic xenograft models.48 It can also be easily monitored due to a 
relatively small amount of gamma emmision.48 Successful attachment of the DOTA chelate and 
radiolabeling with 
177
Lu will demonstrate these FeOx surface functionalized nanoparticles ability 
to act as a nanoplatform for additional radiotherapeutics. SAHBA-FeOx and CMPVA-FeOx 
were chosen as they showed the best stability results. 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) is a water soluble carbodiimide used for the coupling 
reaction of carboxyl and amine groups to form an amide bond.93 N-hydroxysulfosuccinimide (S-
NHS) is used to increase the efficiency of the carboxyl and primary amine coupling reaction.93  
 High-performance liquid chromatography (HPLC) was used to confirm successful EDC 
coupling of the DOTA chelate and determine the radiochemical purity of radiolabeled 
177
Lu-
DOTA-SAHBA-FeOx. The HPLC elution profiles of SAHBA-FeOx measured by UV-VIS 
absorbance at 254 nm and radioactivity detectors are shown in Figure 4.37. This was done to 
establish the time at which SAHBA-FeOx nanoparticles elute and confirm no radioactivity is 
present. Next, EDC coupling of the DOTA chelate to the SAHBA-FeOx was performed and then 
radiolabeled with 
177
Lu. HPLC was used after removal of free metal cations with an MCX 
column, specifically 
177
Lu. Dose calibrator measurements of 
177
Lu-DOTA-SAHBA-FeOx after 
MCX column indicated a 52.4% chelation yield. The absorbance results in Figure 4.38 show 
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additional peaks at approximately 12.05 and 21.9 mins corresponding to free 
177
Lu-DOTA, and 
ammonium hydroxide buffer, respectively. The radioactivity peak (Figure 4.38) centered at 
approximately 9.18 mins overlaps with the absorbance at 254 nm peak (~8.49 mins) indicating 
successful radiolabeling of DOTA-SAHBA-FeOx nanoparticles with 
177
Lu. It should be noted 
that the HPLC radioactivity elution time is slightly delayed due to the time required for the 
elution to reach the radioactivity counter. The radioactivity peak at 12.33 mins represents free 
177
Lu-DOTA.  
 
 
Figure 4.37.  HPLC elution profiles of SAHBA-FeOx nanoparticles. The absorbance at 254 nm 
(top) and radioactivity counts (bottom) are shown. 
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Figure 4.38.  HPLC elution profiles of 
177
Lu-DOTA-SAHBA-FeOx post MCX column elution. 
The normalized absorbance at 254 nm (top) and radioactivity counts (bottom) are shown.  
 
To remove the remaining free 
177
Lu-DOTA, and DOTA, a PD-10 size exclusion column was 
used. Dose calibrator measurements of 
177
Lu-DOTA-SAHBA-FeOx after PD-10 column 
indicated a 14.5% synthetic radiochemical yield. The absorbance at 254 nm in Figure 4.39 only 
contains one peak centered at approximately 8.6 mins confirming the successful removal of 
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remaining free 
177
Lu-DOTA, and DOTA chelate by the PD-10 column. Furthermore, the 
presence of only one radioactivity peak at 8.79 mins confirms the removal of free 
177
Lu-DOTA. 
 
 
 
Figure 4.39.  HPLC elution profiles of 
177
Lu-DOTA-SAHBA-FeOx post MCX and PD-10 
column elution. The absorbance at 254 nm (top) and radioactivity counts (bottom) are shown.  
 
 Next, an HPLC study was used to determine the radiochemical stability of the 
nanoplatform when subjected to RF hyperthermia. This investigation is essential in determining 
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the ability of the nanoparticles to deliver both hyperthermia and brachytherapy. The 
radiochemical stability was assessed for 
177
Lu-DOTA-SAHBA-FeOx after 0, 15, and 45 minutes 
of RF heating. If the 
177
Lu is released from the DOTA chelate or 
177
Lu-DOTA is released from 
the nanoparticle after RF heating there could be a reduction in the treatment dose in the region of 
interest and potential radiation damage to normal tissue in other regions. Additionally, free 
177
Lu 
has been shown to incorporate in bone which could limit the amount of activity that can be safely 
used in treatment, due to radiation sensitivity of bone marrow.242,243 The HPLC separated 
absorbance spectrum for 0, 10, and 15 minutes of RF heating is shown in Figure 4.40. The 
HPLC integrated peak areas at approximately 8.3-11.4 mins and 12.03-14.01 mins correspond to 
177
Lu-DOTA-SAHBA-FeOx and 
177
Lu-DOTA respectively. Changes in integrated peak areas 
were used to assess the heat stability after 15 and 45 minutes of RF heating (Figure 4.41). The 
integrated peak ratios of 
177
Lu-DOTA-SAHBA-FeOx to 
177
Lu-DOTA were 97.2% to 2.8%, 
97.2% to 2.8%, and 97.6% to 2.4% for 0, 10 and 15 minutes of RF heating.  No significant 
increases in integrated peak areas for radioactivity were observed after 15 or 45 minutes of RF 
heating, confirming the heat stability of 
177
Lu-DOTA-SAHBA-FeOx.  
Furthermore, gamma counting was used to determine if any 
177
Lu was released after 
heating. To accomplish this, the 
177
Lu-DOTA-SAHBA-FeOx nanoparticles were passed through 
a MCX column after RF heating and the MCX column was gamma counted after elution of the 
177
Lu-DOTA-SAHBA-FeOx. The gamma counts per minute of the MCX columns for RF heating 
177
Lu-DOTA-SAHBA-FeOx 0, 10, and 15 mins were 120,686 cpm, 117,373 cpm, and 118,275 
cpm respectively. The MCX column can remove 
177
Lu from the stable 
177
Lu-DOTA-SAHBA-
FeOx as the MCX column more strongly binds 
177
Lu. This result shows clearly that no 
significant amount of 
177
Lu was released upon RF heating.  
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Figure 4.40.  HPLC elution profiles absorbance at 245 nm of 
177
Lu-DOTA-SAHBA-FeOx final 
product after T0, T15, and T45 minutes of RF heating.  
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Figure 4.41.  HPLC elution profiles radioactivity counts of 
177
Lu-DOTA-SAHBA-FeOx final 
product after T0, T15, and T45 minutes of RF heating. 
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 HPLC absorbance and radioactivity analysis confirmed the successful conjugation of 
DOTA metal chelate and radiolabeling with 
177
Lu to SAHBA-FeOx and CMPVA-FeOx. Greater 
than 97% radiochemical purity was obtainable with the cleanup methods used. Additionally, no 
significant amount of 
177
Lu or 
177
Lu-DOTA was released from 
177
Lu-DOTA-SAHBA-FeOx 
nanoparticles after RF heating. These results demonstrate the possibility of expanding the 
conjugation to include combinations of other radiotherapeutics, chemotherapeutics, and/or 
diagnostic agents by utilizing EDC coupling. 
 In this chapter the synthesized nanoparticles were easily surface functionalized without 
the need for difficult phase transfer methods. For surface functionalization with CMPVA, an 
optimal 0.125% TMAOH concentration was determined. Furthermore, it was determined that for 
different nanoparticle sizes the methods are best modified by changing the amount of surface 
functionalization ligand relative to the number of nanoparticles. The CMPVA surface 
functionalization methods were successfully used to produce APTS-FeOx, APTES-FeOx, and 
GLYMO-FeOx. The GLYMO-FeOx nanoparticles proved to be very beneficial as the terminal 
epoxy ring could be modified with a variety of nucleophiles to provide different biological 
stability properties. FeOx nanoparticle surface functionalizations were verified through FTIR-
ATR, XPS, and/or DLS characterization. Stability investigations revealed that SAHBA-FeOx 
had the best and broadest stability in different biologically relevant media. The SAHBA-FeOx 
and CMPVA-FeOx demonstrated further conjugation potential via the EDC coupling of DOTA 
metal chelate and radiolabeling with 
177
Lu. This produces a theranostic FeOx nanoparticle that 
can potentially provide radiotherapy and hyperthermia, with MRI capability.      
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Chapter 5: Biological Testing of Surface Functionalized Iron 
Oxide Nanoparticles 
 
 
 
5.1 Experimental Section 
 5.1.1 Reagents, Materials, and Equipment 
T75 flask (Greiner Bio-One, CELLSTAR®, red filter cap, sterile), Dulbecco’s phosphate 
buffered saline (DPBS) (Corning, cellgro, without calcium and magnesium, sterile), 0.25% 
trypsin solution (Hyclone), handheld automated cell counter (Millipore, Scepter™), 6-well plate 
(Greiner Gio-One, Cellstar®), 96-well plates (Greiner Bio-One, Cellstar®), artificial cerebral 
spinal fluid (CSF) (Harvard Apparatus, artificial), human serum (HS) (Bioreclamation, LLC), 
modified DMEM/F-12 medium (Hyclone, 0.1 µm sterile filtered) containing 10% fetal bovine 
serum (FBS) (Seradigm, ultimate grade, triple 0.1 µm sterile filtered), 1% antibiotic/antimycotic 
solution (Hyclone, 10,000 U/mL Penicillin G, 10,000 µg/mL Streptomycin, 25 µg/mL 
Amphotericin B, 0.2 µm filtered), Cell Lytic
TM
 M lysis buffer (Sigma), cell proliferation reagent 
WST-1 (Roche) 
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5.1.2 Tissue Culture and Cellular Uptake Studies 
 For biological testing, M059K, GBM-6, or U87MG (AmericanType Culture Collection) 
cell lines were incubated at 37°C and 5% CO2 in either T75 or T25 flasks containing complete 
cell medium. Upon reaching ~80% confluence the cells were washed with Dulbecco’s phosphate 
buffered saline (DPBS) and trypsinised with 0.25% trypsin solution to passage or split the cells 
into additional culture flasks. A handheld automated cell counter was used to determine the 
concentration of cells. Cells were diluted to a concentration of 75,000 cells/mL of culture 
medium prior to plating 2 mL in each well of a 6-well plate. The cells were allowed to attach 
overnight (~16 hours). Cellular uptake was determined by adding 200 μL of surface 
functionalized nanoparticles (250 μg/mL). After 4 hours of uptake the cell medium was aliquoted 
(500 μL), followed by aspiration of the remaining medium. Next, cells were washed three times 
with DPBS. Cells were lifted in approximately 1.5 mL of DPBS and transferred to a 
microcentrifuge tube. Cells were centrifuged at 13,000 rpm for 7 minutes to pellet the cells. The 
supernatant was discarded and 30 μL of Cell LyticTM M lysis buffer was added and sonicated for 
15 minutes. To dissolve the nanoparticles and cells 2.14 μL of 70% nitric acid was added and 
heated in a heat block at 90°C for 1 hour. A 30 μL aliquot of the collected cell media with 2.14 
μL of 70% nitric acid was also heated at 90°C for 1 hour. Prussian blue assay was used to 
determine the amount of iron. The concentration of cells and amount of iron were used to 
calculate the cell uptake in units of iron per cell. 
 
5.1.3 WST-1 Cell Proliferation Assays 
Cytotoxicity was assessed by a WST-1 cell proliferation assay in a 96-well format. The 
cells were diluted to a concentration of 25,000 cells/mL of cell medium and 100 μL (2,500 cells) 
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were plated in each well (n=7). After attaching overnight, 10 μL of PBS control or surface 
functionalized nanoparticles (250 μg/mL) was added to each well on two 96-wells plates to 
assess proliferation at 24 and 48 hours. Cell medium was aspirated at 24 or 48 hours and 110 μL 
of cell proliferation reagent WST-1 in cell medium (500 μL in 5 mL of cell media) was added to 
each well. The cells were incubated at 37°C and 5% CO2. At 30, 60, 90, and 120 minutes the 96-
well plate was shaken for 60 seconds in a plate reader equipped with UV-VIS. UV-VIS was 
measured at 440 nm with a reference at 620 nm. 
A half maximal inhibitory concentration (IC50) was also determined using a WST-1 assay 
similar to the cytotoxicity methods above. A 10x DMEM-FBS solution was created by 
dissolving 1.56 g of DMEM powder (HyClone Laboratories Inc., DME/F -12 1:1+2.5 mM L 
glutamine, +15 mM HEPES buffer, -sodium bicarbonate) and 0.2438 g of sodium bicarbonate 
(NaHCO3) (Sigma, 99.5%) in 10 mL of Ultra H2O. This solution was 0.1 µm sterile filtered in a 
sterile biological laminar flow hood. Next, 9 mL of the 10x DMEM solution was mixed with 9 
mL of sterile 10x FBS to obtain a 5x DMEM-FBS solution. To 120 µL of the 5x DMEM-FBS 
solution a total of 540 µL of SAHBA-FeOx nanoparticles (~2,200 µg of Fe/mL) and water was 
added to create 81.81%, 75%, 65.909%, 50%,40%, 20%, 10%, and 0% (1769, 1555, 1179, 944, 
472, and 236 µg of Fe/mL) treatment concentrations. After plating 2,500 cells in 100 μL in each 
well of a 96-well plate the cells were allowed to attach overnight, the medium was then aspirated 
and then treated with 110 μL of SAHBA-FeOx DMEM-FBS solutions. After 24 hours of 
treatment, the WST-1 cell proliferation assay was completed as stated above. The resulting cell 
proliferation values were analyzed in Microsoft Excel with Solver add-in to fit a non-linear IC50 
curve. Solver was used to minimize the sum of squares of the predicted y-values from Equation 
19, where A, B, C and D constants are the maximum point, slope of the middle section of the 
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curve, point of inflection, and minimum point respectively. The IC50 was determined by 
rearranging Equation 19 to formulate Equation 20. 
 𝑦 = 𝐷 +  
(𝐴−𝐷)
1+(
𝑥
𝐶
)
𝐵         (19) 
 𝑥 = 𝐶 × [
(𝐴−𝑦)
(𝑦−𝐷)
]
(
1
𝐵
)
          (20) 
 
5.1.4 Colony Forming Cell Assay of RF Hyperthermia treated M059K Cells  
M059K cells were harvested from a T75 culture flask and counted. Next, 800,000 cells 
were transferred to a 15 mL conical tube and centrifuged at 1,500 rpm for 5 minutes to pellet the 
cells. The cells were re-dispersed in 1 mL of cell medium and added to 4 mL of cell medium in a 
T25 culture flask. Overnight incubation allowed time for the cells to attach. CMPVA 
nanoparticle treatment or PBS control (250 μL) was added to respective T25 flask and placed 
back in the incubator for 24 hours. After 24 hour incubation the cells were harvested with 1 mL 
of trypsin and quenching with 3 mL of cell medium. Next, three 500 μL aliquots of PBS control 
and six 500 μL CMPVA nanoparticle treatments were added to microcentrifuge tubes. For the 
PBS control an additional 150 μL of cell medium was added (no particle control group). Three of 
the CMPVA nanoparticle treatment aliquots received 150 μL of cell medium (particle group) and 
three received 150 μL of extra CMPVA nanoparticles (~325 µg of iron) in cell medium (extra 
particle group). Each treatment group was then heated in a water bath at 37°C for one minute 
prior to RF heating for 0, 10 or 15 minutes at 200.2 A, and 1287 W, in a coil tuned to ~270 kHz. 
The colony assay performed by diluting each treatment to 150 cells/mL and plating 300 cells (2 
mL) on 6-well plates in triplicate. Cell colonies were stained with crystal violet dye and counted 
at 2 weeks. 
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5.1.5 U87MG Glioblastoma Tumor Implantation  
The in vivo mice investigations were conducted according to protocols sanctioned by the 
McGuire VAMC institutional animal care and use committee (IACUC# 01748). For tumor 
implantation, female athymic nude-Foxn1nu mice (Harlan Laboratories) were first anesthetized 
with isoflurane (3% knockdown, 2% maintenance in oxygen). Next, the mice were positioned in 
a stereotactic frame (David Kopf Instruments). A drill was positioned after a midline incision to 
drill a 0.7 mm burr hole at a position 0.5 mm anterior to the bregma and 2 mm laterally to the 
right. Next, a microinjection pump (Bioanalytical Systems) equipped with a 25 µL Hamilton 
syringe and a 28 gauge removable needle was positioned at a depth of 4.0 mm into the brain 
(measured from the surface of the skull). The syringe was loaded with 5 µL of PBS containing 5 
x 10
4
 U87MG cells per µL. The cell suspension was infused at a constant rate of 0.2 µL per 
minute for a period of 10 minutes resulting in deposition of 1 x 10
5
 cells. After infusion, sterile 
bone wax was utilized to seal the burr hole and the midline incision was sutured. After sufficient 
recovery time, the animals were returned to the vivarium. 
  
 5.1.6 Radioactivity Dose Preparation and Survival Study 
 CMPVA-FeOx or SAHBA-FeOx were further conjugated to DOTA chelate via EDC 
coupling, radiolabeled with 
177
Lu, washed, purified, and sterilized as described in section 4.1.6. 
Additionally, DOTA chelate only was also radiolabeled to serve as a treatment group. The 
radioactivity was measured by gamma well counting and dose calibrator. The radioactivity was 
matched for 
177
Lu-DOTA, 
177
Lu-DOTA-SAHBA-FeOx, and 
177
Lu-DOTA-CMPVA-FeOx by 
dilution with PBS, SAHBA-FeOx, and CMPVA-FeOx respectively. SAHBA-FeOx and 
CMPVA-FeOx nanoparticles were used for dilution in order to retain a similar concentration of 
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nanoparticles to the SAHBA-FeOx treatment group. Additionally, three radioactivity 
concentrations were prepared for each treatment in sterile microcentrifgue tubes to account for 
177
Lu radioactive decay (half-life= 6.7 days) over the three days required for surgical procedures 
and infusion of 40 mice (15, 15, 10 mice for days 1, 2, and 3 respectively). More specifically, the 
three concentrations were required to allow for a constant infusion volume of 10 µL in order to 
deliver the same radioactive dosage to the mice. The U87MG survival study consisted of 40 mice 
randomized into five treatment groups (n=8) including PBS control, SAHBA FeOx, 
177
Lu-
DOTA, 
177
Lu-DOTA-SAHBA-FeOx, and 
177
Lu-DOTA-CMPVA-FeOx. All radiolabeled 
treatment groups were planned to receive approximately 10 µCi of 
177
Lu-DOTA, 
177
Lu-DOTA-
SAHBA-FeOx, or 
177
Lu-DOTA-CMPVA-FeOx.  For CED the mice were placed into a 
stereotactic frame and a midline incision was made to reveal the burr hole. After removal of bone 
wax the microinjection needle was centered stereotactically on the burr hole and lowered to a 
depth of 4 mm to hit the center of the tumor. Next, CED of the treatment groups was performed 
at 0.2 µL/min flow rate for 50 minutes to deliver a total volume of 10 µL.  A rodent study of 
CED with aqueous infusion using a 28-gauge needle was proven to provide effective CED.
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For further verification a 0.6% agarose gel (1.5 mL in microcentrifuge tube) was also infused 
with 10 µL of each treatment to determine average activity delivered at time of infusion. 
Survival studies were conducted by weight measurements of mice daily in order to follow the 
disease progression. Mice were weighed on the day of infusion and a loss of body weight was 
used as a surrogate end point for death. Mice were euthanized when body weight was reduced to 
80% of maximum weight. Euthanasia was performed by CO2 asphyxiation. 
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 5.1.7 Statistical Analysis 
Where appropriate, values are mean ± standard error. Cell survival and cell uptake 
treatment groups are compared to the control group using analysis of variance (ANOVA) and 
Dunnett two-sided post hoc test with a 0.05 significance level. ANOVA Tukey honest significant 
difference (HSD) post hoc test with a 0.05 significance level was used to compare between 
individual treatment groups. The in vivo survival study data was analyzed using a Mantel-Cox 
log rank test for pair-wise comparisons. IBM SPSS Statistics 22 software was used to perform all 
statistical analysis. 
 
5.2 Cellular Uptake, Proliferation, and IC50 Investigations 
The cellular uptake of APTS-FeOx, APTES-FeOx, CMPVA-FeOx, and Gly-FeOx, Ser-
FeOx, EDA-FeOx, TEPA-FeOx, ABA-FeOx, and SAHBA-FeOx at 4 hours is shown in Figure 
5.1 as percent uptake and picograms (pg) of iron per cell. The cellular uptake method used in this 
study was not able to discern between internalized nanoparticles or surface adsorbed 
nanoparticles, but did allow for comparison between differences in surface functionalized 
nanoparticles. Upon first analysis the uptake of EDA-FeOx and TEPA-FeOx appear to have by 
far the best cellular uptake with uptake calculated to be 96.2 ± 8.8 pg of iron/cell and 71.7 ± 20.6 
% uptake for EDA-FeOx and 99.2 ± 32.7 pg of iron/cell and 41.3 ± 9.0 % uptake for TEPA-
FeOx. ANOVA Tukey HDC post-hoc test revealed that both EDA-FeOx and TEPA-FeOx were 
statistically different than the PBS control (p<0.001) (Appendix - Tables A1-5). Positive zeta 
charge may indeed increase interaction with the surface of the cells, but it was determined that 
the high cellular uptake is a false indication of the true cellular uptake for two reasons. First, 
there is a known cell medium instability that could lead to precipitation on the surface of cells. 
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Second, visual clumping of EDA-FeOx and TEPA-FeOx could be seen during incubation with 
cells in the cell uptake study. This result is important as it illustrates, rather dramatically, the 
potential for artificially high cellular uptake due to instability upon introduction into cell 
medium. Both of these GLYMO surface functionalizations appeared stable in water, 1x PBS, 
0.5x PBS, and 0.9% NaCl for more than 2 weeks, but were significantly precipitated after only 2 
hours in cell medium. Therefore, the stability of nanoparticles to be used in biological 
applications must be carefully evaluated and considered when reporting high cell uptake. The 
other positive zeta potential surface functionalizations, APTS-FeOx and APTES-FeOx, resulted 
in higher cell uptake values compared to the negative surface functionalizations. However, 
ANOVA Tukey HSD post hoc test revealed only significant differences between APTS-FeOx or 
APTES-FeOx and either EDA-FeOx or TEPA-FeOx.  
Cellular uptake studies with APTS-FeOx or APTES-FeOx that was not prepared 
immediately prior to testing resulted in larger cellular uptakes further corroborating the 
connection between instability/size and cellular uptake seen in EDA-FeOx and TEPA-FeOx 
uptake. More specifically given time the APTS-FeOx and APTES-FeOx formed larger 
aggregates due to rehydrolyzing or restructuring causing increased instability and cellular uptake. 
Examining the negative zeta potential surface functionalizations reveals similar uptake values 
within the range of 0.19-0.46% uptake or 0.65-1.41 pg of iron per cell. All five of the tested 
anionic surface functionalizations had strikingly similar stabilities. The similar stability and 
terminal group chemistry results in similar measured cellular uptake values. Remarkably, the 
SAHBA-FeOx nanoparticles, which were stable in a wide array of media, had the lowest uptake 
(0.65±0.06 pg of iron per cell, 0.19±0.03% uptake). However, ANOVA Tukey HSD post-hoc 
tests (Appendix – Tables 1-5) CMPVA-FeOx, Gly-FeOx, Ser-FeOx, ABA-FeOx, and SAHBA-
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FeOx SAHBA-FeOx were only statistically different when compared to EDA-FeOx or TEPA-
FeOx. More studies may reveal a significant link between better stability and lower cellular 
uptake. Future reports linking only positive zeta potential to higher cellular uptake may need to 
be reported as lower stability resulting in higher cell uptake.  
 
 
Figure 5.1. GBM-6 cellular uptake results for surface functionalized FeOx nanoparticles; 
reported in units of percent uptake (purple) or pg of iron/cell (blue). EDA-FeOx and TEPA-FeOx 
uptake values are included in the inset figure with a larger y-axis. 
 
Initial toxicity was investigated in terms of proliferation using a WST-1 cell proliferation 
assay at 24 and 48 hours. The results are shown in Figure 5.2. TEPA-FeOx had significant 
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(ANOVA Tukey HSD post-hoc test) difference in proliferation as compared to the control at 
both 24 and 48 hours (Appendix – Tables A6-12). This was expected due to the high degree of 
instability in cell medium at short time points and the large amount of cell uptake. Larger 
amounts of cell uptake may be preventing essential cellular processes leading to  the observed 
toxicity and decreased proliferation rates. Interestingly the EDA-FeOx only showed decreases in 
cell proliferation at 48 hours even though the nanoparticles were instable in cell medium and had 
large amounts of cell uptake. Further analysis of WST-1 with ANOVA Tukey and Dunnett two-
sided post-hoc tests (Appendix – Table A6-12) only indicated a significant reduction in cell 
proliferation, compared to the PBS control, at 24 hours for TEPA-FeOx nanoparticles and at 48 
hours for EDA-FeOx and TEPA-FeOx nanoparticles.  
 
 
Figure 5.2. Effect of surface functionalized nanoparticles on cell proliferation at 24 (blue) and 
48 (purple) hours. 
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  The half maximal inhibitory concentration (IC50) of SAHBA-FeOx was determined by 
WST-1 and cell titer blue cell proliferation assays at 24 hours using several concentrations of 
SAHBA-FeOx in U87 cells. The results from both assays are shown in Figure 5.3. The non-
linear curve was fitted using Microsoft Excel Solver add-in by minimizing the sum of squares of 
Equation 19 predicted y-values. Due to increased cell proliferation at the lowest concentration 
of SAHBA-FeOx the curve was solved without the 0 SAHBA-FeOx concentration data point. 
The A, B, C, and D constant values were found to be 120.0642, 5.838533, 53.19202, and 
24.84344 respectively when minimizing the sum of squares. The sum of squares was minimized 
to 12.59 or 112.77 for WST-1 and cell titer blue respectively. Using Equation 20 it was found 
that the IC50 at 24 hours of treatment with SAHBA-FeOx was 1495.91 or 1320.38 µg/mL for 
2,500 U87 cells plated 24 hours prior to treatment based on WST-1 and cell titer blue 
respectively. The difference in percent control of cell viability for the two cell proliferation 
assays is thought to be due to determination via absorbance (WST-1) or fluorescence (cell titer 
blue) measurements. Due to the color of the iron oxide solutions it is thought that there could be 
some overlap in the WST-1 UV-VIS absorbance measurements resulting in higher cell viability 
as compared to the PBS control. Therefore, the cell titer blue fluorescent based assay is more 
likely indicative of the true cell viability. However, we also see an increase in cell viability as 
compared to the PBS control for both assays at low concentrations suggesting that the FeOx 
nanoparticle treatment may be increasing cell viability. Further investigation is needed to 
comment further. 
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Figure 5.3. Effect of varying concentrations of SAHBA-FeOx on cell proliferation at 24 hours 
based on WST-1 (green) and cell titer blue (blue) assays used to determine IC50. The IC50 trend 
line is shown in black with open circles representing estimated y-values. 
 
5.3 Effect of Hyperthermia on Cell Proliferation 
WST-1 cell proliferation assay was also used to investigate potential differences of RF 
induced hyperthermia. M059K glioblastoma cells were selected for initial in vitro hyperthermia 
studies to verify the FeOx nanoparticles could be used to kill glioblastoma cells by delivering 
sufficient hyperthermia. The CMPVA surface functionalized A2-24_B2-24 nanoparticles were 
used due to their well-studied surface functionalization and low polydispersity. The cellular 
uptake (Figure 5.4) revealed that the M059K cells had an uptake value of 0.2 µg of Fe per 
100,000 cells when treated with 2.18 mg/mL iron concentration of CMPVA nanoparticles. Extra 
CMPVA nanoparticles were added after 24 hours of uptake prior to cell heating as a positive 
control and to ensure an adequate concentration of nanoparticles to demonstrate RF 
hyperthermia. An additional ~325 µg of iron was added for the extra nanoparticles group 
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resulting in 99.94% of ‘external’ and 0.06% ‘internal’ nanoparticles (0.2 µg/325.2 µg). With 
such a large excess of ‘external’ nanoparticles the extra nanoparticles group was considered a 
mixture with a dominant percent of ‘external’ heating and the particle group was considered only 
‘internal’ heating.245,246  
 
 
Figure 5.4. M059J cell uptake of CMPVA-FeOx (red) and PBS control (Blue) at 24 hours in 
terms of µg of iron (A), percent uptake (B), and pg of Fe/cell (C). 
 
 The results of the in vitro hyperthermia experiment are shown in Figure 5.5. Analysis of 
the ‘no heat’ treatment (Figure 5.5. top (blue)) for PBS control, nanoparticles, and extra 
nanoparticles, revealed no significant differences in cell proliferation further corroborating no 
significant toxicity of CMPVA nanoparticles (Appendix –Tables A13-16 statistical analysis 
results).  
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Figure 5.5. RF hyperthermia effect on M059K survival as determined by colony assay. (Top) No 
particle (blue), particle (red), and extra particle (green) treatment groups survival are shown at 0, 
10 and 15 minutes with a * indicating a significant difference determined by ANOVA and 
Dunnett two-sided post-hoc tests with a 0.05 significance level. (Bottom) The corresponding 
treatments measured RF hyperthermia over 15 minutes with dashed lines indicating 10 and 15 
minutes of heating. 
 
The PBS control showed no changes in cell proliferation after exposure to RF AC magnetic field 
for 10 and 15 minutes. The RF heating of the PBS control (Figure 5.5. bottom, blue line) was 
measured and did not have significant deviation from 37°C. The RF hyperthermia of the 
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nanoparticle and extra nanoparticle treatments had measurable and significant lowering of cell 
proliferation at 10 minutes. Interestingly, the decreases of cell proliferation were seen in both 
treatments with different temperature measurements (Figure 5.5, bottom). Even though the 
temperature only reached 38.5°C after ten minutes of RF heating (red line) it had similar cell 
killing as compared to the extra particle group (green line) with a temperature increase to 47.1°C. 
Analyzing the 15 minutes heating revealed that both nanoparticle and extra nanoparticle 
treatments had significant cell killing when compared to the PBS control treatment. At first 
glance, the extra nanoparticle group at 15 minutes appears to have additional cell killing, but was 
not found to be significant based on ANOVA Tukey HSD post hoc test (Appendix – Tables 
A13-16). At 15 minutes the extra nanoparticle group temperatures entered the thermal ablation 
range at 48.4°C, where the nanoparticle group only reached 39.1°C. It should be noted that 
repeating the experiment with additional replicates (higher N) could elucidate significant 
differences that is expected for the larger temperature differences. However, these results were 
sufficient to demonstrate glioblastoma cell killing via RF induced hyperthermia and revealed 
potential vast differences based on ‘internal’ and ‘external’ hyperthermia. 
 
5.4 Survival Study- Iron Oxide nanoparticle 
177
Lu Brachytherapy 
Investigation 
 The efficacy of FeOx nanoparticles in providing brachytherapy was investigated for 
177
Lu-DOTA-SAHBA-FeOx and 
177
Lu-DOTA-CMPVA-FeOx nanoparticles. These two surface 
functionalized nanoparticles were chosen due to their similar broad and long term stability 
characteristics, and differences in surface functionalization size. It was hypothesized that the 
smaller size of 
177
Lu-DOTA-SAHBA-FeOx could facilitate better distribution within the tumor. 
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In order to test this hypothesis an in vivo survival study using a murine orthotopic xenograft 
model of glioblastoma multiforme (U87MG) was used. Radiolabeling SAHBA-FeOx and 
CMPVA-FeOx nanoparticles with 
177
Lu was confirmed with HPLC absorbance and radioactivity 
measurements (Figures 5.6 and 5.7). The overlap of peaks in the 254 nm absorbance and 
radioactivity spectra at the same elution time confirms the successful radiolabel chelation 
product for both 
177
Lu-DOTA-SAHBA-FeOx and 
177
Lu-DOTA-CMPVA-FeOx nanoparticles. 
The radioactivity counts are shifted slightly to longer elution times due to delay in time required 
to travel from elution to the eSatin radioactivity counter. Dose calibrator measurements were 
used to determine the chelation yield, and synthetic radiochemical yield. After washing with the 
MCX column the chelation yield was estimated to be 64%, 54.9%, and 83.6% yield for 
177
Lu-
DOTA-SAHBA-FeOx, 
177
Lu-DOTA-CMPVA-FeOx, and 
177
Lu-DOTA respectively. The 
synthetic radiochemical yield, after PD-10 wash, was estimated to be 23.6% for 
177
Lu-DOTA-
SAHBA-FeOx and 14.2% for 
177
Lu-DOTA-CMPVA-FeOx. The 
177
Lu-DOTA was not run on the 
PD-10 column due to inability to visualize the progression through the PD-10 column and collect 
only the 
177
Lu-DOTA. 
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Figure 5.6.  HPLC of 
177
Lu-DOTA-SAHBA-FeOx final product. The absorbance at 254 nm 
(top) and radioactivity counts (bottom) are shown. 
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Figure 5.7.  HPLC of 
177
Lu-DOTA-CMPVA-FeOx final product. The absorbance at 254 nm 
(top) and radioactivity counts (bottom) are shown. 
 
Agarose gels were also infused with 
177
Lu-DOTA, 
177
Lu-DOTA-SAHBA-FeOx, or 
177
Lu-
DOTA-CMPVA-FeOx in order to determine the average infused 
177
Lu activity. Gamma well 
counting and back decaying of agarose gels revealed an average infused 
177
Lu activity of 9.72 ± 
0.03, 8.59 ± 0.20, and 9.10 ± 0.37 µCi for 
177
Lu-DOTA, 
177
Lu-DOTA-SAHBA-FeOx, or 
177
Lu-
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DOTA-CMPVA-FeOx respectively. The survival curves for PBS, SAHBA-FeOx, 
177
Lu-DOTA,
 
177
Lu-DOTA-SAHBA-FeOx and 
177
Lu-DOTA-CMPVA-FeOx in vivo treatments are shown in 
Figure 5.8. The pair-wise comparison of a log rank Mantel-Cox test revealed differences in 
survival between the five treatment groups (Appendix - Tables A17 and A18). The FeOx 
control treatment was significantly different than 
177
Lu-DOTA control (significance = 0.000), but 
was not significantly different from the PBS control (significance = 0.058). A larger survival 
study may elucidate a significant difference between the SAHBA-FeOx and PBS and 
177
Lu-
DOTA control groups. The difference between SAHBA-FeOx and 
177
Lu-DOTA is speculated to 
be a combination of two factors. First, there is evidence from WST-1 cell proliferation assays 
that SAHBA-FeOx may potentially increase cell proliferation which could translate to increased 
tumor growth rate and reduced survival time. Second, 
177
Lu-DOTA may possibly have a small 
positive effect on survival, however no significant difference was found between 
177
Lu-DOTA 
and PBS treatment at this dose level. A significant difference was revealed between the three 
controls and 
177
Lu-DOTA-SAHBA-FeOx (significance 0.000), as well as between the three 
controls and 
177
Lu-DOTA-CMPVA-FeOx (significance 0.000). These results confirm the 
effective brachytherapy deliver by 
177
Lu-DOTA-SAHBA-FeOx and 
177
Lu-DOTA-CMPVA-
FeOx. There was no significant difference between 
177
Lu-DOTA-SAHBA-FeOx and 
177
Lu-
DOTA-SAHBA-FeOx. This is not surprising as only one mouse in the 
177
Lu-DOTA-SAHBA-
FeOx lived 37 more days than the last surviving 
177
Lu-DOTA-CMPVA-FeOx mouse. Since one 
mouse is representative of 12.5% of the population, a larger study will be necessary to determine 
if this is a real effect on number of long term survivors between 
177
Lu-DOTA-SAHBA-FeOx and 
177
Lu-DOTA-CMPVA-FeOx nanoparticle treatments due to differences in hydrodynamic 
diameters or surface chemistry. Additionally, further studies such as biodistribution and retention 
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investigations are needed to confirm no biological differences between 
177
Lu-DOTA-SAHBA-
FeOx and 
177
Lu-DOTA-CMPVA-FeOx.  
 
 
Figure 5.8. Survival study using murine orthotopic xenograft model of glioblastoma multiforme 
(U87MG) treated with PBS (Black), FeOx (Blue), 
177
Lu-DOTA (Purple), 
177
Lu-DOTA-SAHBA-
FeOx (Red), and 
177
Lu-DOTA-CMPVA-FeOx (Green). Significantly different treatment groups 
from control are indicated by a * as determined by ANOVA and Dunnett two-sided post hoc test 
at a 0.05 significance level. 
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Chapter 6: Conclusion 
 
 
 
6.1 Conclusion 
 The first goal of this dissertation was to synthesize FeOx nanoparticles via an innovative 
and optimizable benzyl alcohol modified seed growth to obtain ideal nanoparticle properties for 
increased RF induced magnetic hyperthermia treatment of cancer. This was achieved by 
investigating reaction environment, precursor concentration, and temperature effects on resultant 
nanoparticle properties. 
1.  Carrying out the reaction in the presence of air instead of under nitrogen flow provided 
an additional mechanism of nucleation and growth besides the thermal decomposition. 
This added oxidation of benzyl alcohol to benzaldehyde mechanism allowed for 
reduction of Fe(acac)3 facilitating possible synthesis of magnetite and synthesizing 
nanoparticles with larger crystallite sizes by better separation of nucleation and growth. 
This was in accordance with reflux occurring just above benzaldehyde’s boiling point 
(178.1°C).  
2. Increasing the Fe(acac)3 concentration and/or temperature results were explained by the 
LaMer growth and Ostwald ripening methods. These increases result in increased 
monomer generation leading to faster burst nucleation events (reaching higher rates of 
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nucleation) and a better separation of nucleation and growth leading to larger crystallite 
sizes and smaller size distributions. The mixed reaction-diffusion limited growth 
processes and Ostwald ripening were used to explain the differences in amorphous vs. 
crystallite growth and increasing or decreasing size distributions respectively. There 
appears to be a limit of monomer generation based on increasing concentration and 
temperature that result in a prolonged nucleation event leading to larger size distributions, 
amorphous growth, and smaller crystallite sizes. 
3. The modified seed growth aided in obtaining larger crystallite sizes that were more 
crystalline and had a lower size distribution. Nanoparticles produced by the modified 
seed growth methods resulted in some of the largest RF heating values. 
4. The best RF magnetic heating values were obtained for reaction A2-24(205)_B2-24(205) 
which has a crystallite size of 19.5 ± 1.06 nm and a PDI of 0.265. The SAR and ILP 
values (SAR = 1,175.56 W/g and ILP = 3.113 
𝑛𝐻𝑚2
𝑘𝑔
) are comparable to some of the best 
commercially available ferrofluids.  
5. JMP software was able to model the nanoparticle properties effect on RF heating. The 
determined equation for predicting RF heating could reasonably predict the RF heating 
properties based on the significant nanoparticle properties of crystallite size, PDI, and 
volume CS/HS. 
 
 The second goal was to design a surface functionalization method that can provide true 
colloidal and biological stability and is easily conjugated with additional targeting ligands, 
chemotherapeutics, or radiotherapeutics.  
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1. The GLYMO surface functionalization process provided a simple method that could be 
tuned with a wide array of nucleophiles to obtain broad biological stability.  
2. SAHBA-FeOx and CMPVA-FeOx had the best and broadest stability of the surface 
functionalizations tested. Both surface functionalizations proved stable in water, PBS, 
saline, CSF, complete cell medium, and human serum. SAHBA-FeOx had the best 
overall stability even at 5 months. 
3. Further conjugation potential was proven by EDC coupling a DOTA chelate and 
radiolabeling with 
177
Lu. HPLC verified the EDC coupling and radiolabeling process was 
successful. The EDC coupling can be used to attach chemotherapeutics, 
radiotherapeutics, and/or diagnostics containing a primary amine or carboxyl group. 
 
The final goal was to initially investigate biological effects of iron oxide nanoparticles on cell 
proliferation and uptake, as well as investigate initial in vitro effect of hyperthermia and in vivo 
brachytherapy delivery.  
1. The surface functionalized iron oxide nanoparticles, with the exception of EDA-FeOx 
and TEPA-FeOx, were shown to not significantly affect the cell proliferation indicating 
no toxicity. 
2. Cellular uptake measurements revealed that proper stability in water or PBS and cell 
medium or other relevant medium is essential to measuring accurate cellular uptake. The 
EDA-FeOx and TEPA-FeOx nanoparticles were not stable in cell medium which resulted 
in false indication of high cellular uptake values. Furthermore, statistical analysis 
between positive (APTS-FeOx and APTES-FeOx) and negative (CMPVA-FeOx, Gly-
FeOx, Ser-FeOx, ABA-FeOx, and SAHBA-FeOx) nanoparticles revealed no statistically 
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significant differences in cellular uptake. This finding is not in agreement with literature 
reporting’s of increased cellular uptake for positive surface charged nanoparticles. 
3. Cell colony assay revealed that RF heating with surface functionalized FeOx 
nanoparticles could be used to effectively kill cells. Furthermore, there is evidence 
suggesting that cell killing can be obtained without large increases in solution 
temperature which would be highly beneficial for RF hyperthermia applications. 
4. Survival studies of murine orthotopic xenograft model of glioblastoma multiforme 
(U87MG) treated with PBS, FeOx, 
177
Lu-DOTA, 
177
Lu-DOTA-SAHBA-FeOx, and 
177
Lu-DOTA-CMPVA-FeOx showed that SAHBA-FeOx and CMPVA-FeOx 
nanoparticles can be effectively used to delivery brachytherapy via CED. 
 
The investigation into the benzyl alcohol modified seed growth synthetic parameters and 
JMP analysis revealed important nucleation and growth mechanism. This lead to the ability to 
optimize synthesis to produce optimal nanoparticle characteristics for RF induced magnetic 
hyperthermia. The GLYMO surface functionalization process proved to be a facile method with 
tunable colloidal/biological stability and is directly applicable to biomedical applications 
including hyperthermia and brachytherapy delivery. Researching the material synthesis, surface 
functionalization, and biological testing proved to be a more directly applicable approach to 
furthering iron oxide nanoparticles to the clinic for RF induced magnetic hyperthermia. 
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Appendix 
 
 
 
 
Table A1. Descriptives for cell uptake study based on pg of Fe per cell values. 
 N Mean Std. 
Deviation 
Std. Error 95% Confidence Interval for 
Mean 
Minimum Maximum 
Lower Bound Upper Bound 
Gly-FeOx 9 1.2770 .67894 .22631 .7551 1.7989 .55 2.50 
Ser-FeOx 9 1.3263 .23690 .07897 1.1442 1.5084 .92 1.66 
EDA-FeOx 9 96.1587 10.06934 3.35645 88.4187 103.8987 79.92 107.98 
TEPA-FeOx 9 99.2303 35.11813 11.70604 72.2361 126.2245 62.38 153.77 
ABA-FeOx 9 1.4106 .53743 .17914 .9975 1.8237 .83 2.50 
SAHBA-FeOx 9 .6539 .12100 .04033 .5609 .7469 .52 .88 
CMPVA-FeOx 9 1.3357 1.09110 .36370 .4970 2.1744 .34 3.05 
APTS-FeOx 9 3.4168 .87460 .29153 2.7445 4.0891 2.10 4.60 
APTES-FeOx 9 2.3539 .54045 .18015 1.9385 2.7694 1.45 3.05 
Total 81 23.0181 41.81012 4.64557 13.7732 32.2631 .34 153.77 
 
Table A2. Descriptives for cell uptake study based on percent uptake values. 
 N Mean Std. 
Deviation 
Std. Error 95% Confidence Interval for 
Mean 
Minimum Maximum 
Lower Bound Upper Bound 
Gly-FeOx 9 .4615 .14989 .04996 .3463 .5767 .24 .67 
Ser-FeOx 9 .3511 .06166 .02055 .3037 .3985 .25 .44 
EDA-FeOx 9 71.7294 21.95533 7.31844 54.8531 88.6058 42.23 95.81 
TEPA-FeOx 9 41.2559 9.61316 3.20439 33.8666 48.6452 33.31 55.85 
ABA-FeOx 9 .4271 .14410 .04803 .3164 .5379 .28 .70 
SAHBA-FeOx 9 .1937 .04216 .01405 .1613 .2261 .14 .27 
CMPVA-FeOx 9 .4079 .32337 .10779 .1593 .6565 .11 .91 
APTS-FeOx 9 .9150 .16723 .05574 .7865 1.0436 .63 1.08 
APTES-FeOx 9 .5237 .13339 .04446 .4212 .6263 .38 .79 
Total 81 12.9184 25.67111 2.85235 7.2420 18.5947 .11 95.81 
 
 200 
 
Table A3. ANOVA values for cell uptake studies.  
 Sum of Squares df Mean Square F Sig. 
pg 
Between Groups 129144.970 8 16143.121 108.607 .000 
Within Groups 10701.945 72 148.638   
Total 139846.915 80    
Percent 
Between Groups 48123.297 8 6015.412 94.212 .000 
Within Groups 4597.189 72 63.850   
Total 52720.486 80    
 
Table A4. Tukey HSD post-hoc tests results for cell uptake study based on pg of Fe per cell 
values. 
(I) Treatment (J) Treatment Mean Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
Gly-FeOx 
Ser-FeOx -.04928 5.74723 1.000 -18.4292 18.3306 
EDA-FeOx -94.88166* 5.74723 .000 -113.2615 -76.5018 
TEPA-FeOx -97.95332* 5.74723 .000 -116.3332 -79.5734 
ABA-FeOx -.13355 5.74723 1.000 -18.5134 18.2463 
SAHBA-FeOx .62308 5.74723 1.000 -17.7568 19.0030 
CMPVA-FeOx -.05872 5.74723 1.000 -18.4386 18.3212 
APTS-FeOx -2.13980 5.74723 1.000 -20.5197 16.2401 
APTES-FeOx -1.07693 5.74723 1.000 -19.4568 17.3030 
Ser-FeOx 
Gly-FeOx .04928 5.74723 1.000 -18.3306 18.4292 
EDA-FeOx -94.83238* 5.74723 .000 -113.2123 -76.4525 
TEPA-FeOx -97.90404* 5.74723 .000 -116.2839 -79.5242 
ABA-FeOx -.08427 5.74723 1.000 -18.4642 18.2956 
SAHBA-FeOx .67236 5.74723 1.000 -17.7075 19.0522 
CMPVA-FeOx -.00944 5.74723 1.000 -18.3893 18.3704 
APTS-FeOx -2.09053 5.74723 1.000 -20.4704 16.2894 
APTES-FeOx -1.02765 5.74723 1.000 -19.4075 17.3522 
EDA-FeOx 
Gly-FeOx 94.88166* 5.74723 .000 76.5018 113.2615 
Ser-FeOx 94.83238* 5.74723 .000 76.4525 113.2123 
TEPA-FeOx -3.07166 5.74723 1.000 -21.4516 15.3082 
ABA-FeOx 94.74811* 5.74723 .000 76.3682 113.1280 
SAHBA-FeOx 95.50474* 5.74723 .000 77.1248 113.8846 
CMPVA-FeOx 94.82294* 5.74723 .000 76.4430 113.2028 
APTS-FeOx 92.74185* 5.74723 .000 74.3620 111.1217 
APTES-FeOx 93.80473* 5.74723 .000 75.4248 112.1846 
TEPA-FeOx 
Gly-FeOx 97.95332* 5.74723 .000 79.5734 116.3332 
Ser-FeOx 97.90404* 5.74723 .000 79.5242 116.2839 
EDA-FeOx 3.07166 5.74723 1.000 -15.3082 21.4516 
ABA-FeOx 97.81977* 5.74723 .000 79.4399 116.1997 
SAHBA-FeOx 98.57640* 5.74723 .000 80.1965 116.9563 
CMPVA-FeOx 97.89460* 5.74723 .000 79.5147 116.2745 
APTS-FeOx 95.81351* 5.74723 .000 77.4336 114.1934 
APTES-FeOx 96.87639* 5.74723 .000 78.4965 115.2563 
ABA-FeOx 
Gly-FeOx .13355 5.74723 1.000 -18.2463 18.5134 
Ser-FeOx .08427 5.74723 1.000 -18.2956 18.4642 
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EDA-FeOx -94.74811* 5.74723 .000 -113.1280 -76.3682 
TEPA-FeOx -97.81977* 5.74723 .000 -116.1997 -79.4399 
SAHBA-FeOx .75663 5.74723 1.000 -17.6233 19.1365 
CMPVA-FeOx .07483 5.74723 1.000 -18.3051 18.4547 
APTS-FeOx -2.00625 5.74723 1.000 -20.3861 16.3736 
APTES-FeOx -.94338 5.74723 1.000 -19.3233 17.4365 
SAHBA-FeOx 
Gly-FeOx -.62308 5.74723 1.000 -19.0030 17.7568 
Ser-FeOx -.67236 5.74723 1.000 -19.0522 17.7075 
EDA-FeOx -95.50474* 5.74723 .000 -113.8846 -77.1248 
TEPA-FeOx -98.57640* 5.74723 .000 -116.9563 -80.1965 
ABA-FeOx -.75663 5.74723 1.000 -19.1365 17.6233 
CMPVA-FeOx -.68180 5.74723 1.000 -19.0617 17.6981 
APTS-FeOx -2.76289 5.74723 1.000 -21.1428 15.6170 
APTES-FeOx -1.70001 5.74723 1.000 -20.0799 16.6799 
CMPVA-FeOx 
Gly-FeOx .05872 5.74723 1.000 -18.3212 18.4386 
Ser-FeOx .00944 5.74723 1.000 -18.3704 18.3893 
EDA-FeOx -94.82294* 5.74723 .000 -113.2028 -76.4430 
TEPA-FeOx -97.89460* 5.74723 .000 -116.2745 -79.5147 
ABA-FeOx -.07483 5.74723 1.000 -18.4547 18.3051 
SAHBA-FeOx .68180 5.74723 1.000 -17.6981 19.0617 
APTS-FeOx -2.08109 5.74723 1.000 -20.4610 16.2988 
APTES-FeOx -1.01821 5.74723 1.000 -19.3981 17.3617 
APTS-FeOx 
Gly-FeOx 2.13980 5.74723 1.000 -16.2401 20.5197 
Ser-FeOx 2.09053 5.74723 1.000 -16.2894 20.4704 
EDA-FeOx -92.74185* 5.74723 .000 -111.1217 -74.3620 
TEPA-FeOx -95.81351* 5.74723 .000 -114.1934 -77.4336 
ABA-FeOx 2.00625 5.74723 1.000 -16.3736 20.3861 
SAHBA-FeOx 2.76289 5.74723 1.000 -15.6170 21.1428 
CMPVA-FeOx 2.08109 5.74723 1.000 -16.2988 20.4610 
APTES-FeOx 1.06288 5.74723 1.000 -17.3170 19.4428 
APTES-FeOx 
Gly-FeOx 1.07693 5.74723 1.000 -17.3030 19.4568 
Ser-FeOx 1.02765 5.74723 1.000 -17.3522 19.4075 
EDA-FeOx -93.80473* 5.74723 .000 -112.1846 -75.4248 
TEPA-FeOx -96.87639* 5.74723 .000 -115.2563 -78.4965 
ABA-FeOx .94338 5.74723 1.000 -17.4365 19.3233 
SAHBA-FeOx 1.70001 5.74723 1.000 -16.6799 20.0799 
CMPVA-FeOx 1.01821 5.74723 1.000 -17.3617 19.3981 
APTS-FeOx -1.06288 5.74723 1.000 -19.4428 17.3170 
*. The mean difference is significant at the 0.05 level. 
 
Table A5. Tukey HSD post-hoc tests results for cell uptake study based on percent uptake 
values. 
(I) Treatment (J) Treatment Mean Difference 
(I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
Gly-FeOx 
Ser-FeOx .11041 3.76681 1.000 -11.9360 12.1568 
EDA-FeOx -71.26792* 3.76681 .000 -83.3143 -59.2215 
TEPA-FeOx -40.79442* 3.76681 .000 -52.8408 -28.7480 
ABA-FeOx .03437 3.76681 1.000 -12.0120 12.0808 
SAHBA-FeOx .26779 3.76681 1.000 -11.7786 12.3142 
CMPVA-FeOx .05358 3.76681 1.000 -11.9928 12.1000 
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APTS-FeOx -.45355 3.76681 1.000 -12.5000 11.5929 
APTES-FeOx -.06224 3.76681 1.000 -12.1086 11.9842 
Ser-FeOx 
Gly-FeOx -.11041 3.76681 1.000 -12.1568 11.9360 
EDA-FeOx -71.37834* 3.76681 .000 -83.4247 -59.3319 
TEPA-FeOx -40.90483* 3.76681 .000 -52.9512 -28.8584 
ABA-FeOx -.07604 3.76681 1.000 -12.1225 11.9704 
SAHBA-FeOx .15738 3.76681 1.000 -11.8890 12.2038 
CMPVA-FeOx -.05683 3.76681 1.000 -12.1032 11.9896 
APTS-FeOx -.56396 3.76681 1.000 -12.6104 11.4825 
APTES-FeOx -.17265 3.76681 1.000 -12.2191 11.8738 
EDA-FeOx 
Gly-FeOx 71.26792* 3.76681 .000 59.2215 83.3143 
Ser-FeOx 71.37834* 3.76681 .000 59.3319 83.4247 
TEPA-FeOx 30.47351* 3.76681 .000 18.4271 42.5199 
ABA-FeOx 71.30229* 3.76681 .000 59.2559 83.3487 
SAHBA-FeOx 71.53571* 3.76681 .000 59.4893 83.5821 
CMPVA-FeOx 71.32151* 3.76681 .000 59.2751 83.3679 
APTS-FeOx 70.81438* 3.76681 .000 58.7680 82.8608 
APTES-FeOx 71.20569* 3.76681 .000 59.1593 83.2521 
TEPA-FeOx 
Gly-FeOx 40.79442* 3.76681 .000 28.7480 52.8408 
Ser-FeOx 40.90483* 3.76681 .000 28.8584 52.9512 
EDA-FeOx -30.47351* 3.76681 .000 -42.5199 -18.4271 
ABA-FeOx 40.82879* 3.76681 .000 28.7824 52.8752 
SAHBA-FeOx 41.06220* 3.76681 .000 29.0158 53.1086 
CMPVA-FeOx 40.84800* 3.76681 .000 28.8016 52.8944 
APTS-FeOx 40.34087* 3.76681 .000 28.2945 52.3873 
APTES-FeOx 40.73218* 3.76681 .000 28.6858 52.7786 
ABA-FeOx 
Gly-FeOx -.03437 3.76681 1.000 -12.0808 12.0120 
Ser-FeOx .07604 3.76681 1.000 -11.9704 12.1225 
EDA-FeOx -71.30229* 3.76681 .000 -83.3487 -59.2559 
TEPA-FeOx -40.82879* 3.76681 .000 -52.8752 -28.7824 
SAHBA-FeOx .23342 3.76681 1.000 -11.8130 12.2798 
CMPVA-FeOx .01921 3.76681 1.000 -12.0272 12.0656 
APTS-FeOx -.48792 3.76681 1.000 -12.5343 11.5585 
APTES-FeOx -.09661 3.76681 1.000 -12.1430 11.9498 
SAHBA-FeOx 
Gly-FeOx -.26779 3.76681 1.000 -12.3142 11.7786 
Ser-FeOx -.15738 3.76681 1.000 -12.2038 11.8890 
EDA-FeOx -71.53571* 3.76681 .000 -83.5821 -59.4893 
TEPA-FeOx -41.06220* 3.76681 .000 -53.1086 -29.0158 
ABA-FeOx -.23342 3.76681 1.000 -12.2798 11.8130 
CMPVA-FeOx -.21420 3.76681 1.000 -12.2606 11.8322 
APTS-FeOx -.72133 3.76681 1.000 -12.7677 11.3251 
APTES-FeOx -.33002 3.76681 1.000 -12.3764 11.7164 
CMPVA-FeOx 
Gly-FeOx -.05358 3.76681 1.000 -12.1000 11.9928 
Ser-FeOx .05683 3.76681 1.000 -11.9896 12.1032 
EDA-FeOx -71.32151* 3.76681 .000 -83.3679 -59.2751 
TEPA-FeOx -40.84800* 3.76681 .000 -52.8944 -28.8016 
ABA-FeOx -.01921 3.76681 1.000 -12.0656 12.0272 
SAHBA-FeOx .21420 3.76681 1.000 -11.8322 12.2606 
APTS-FeOx -.50713 3.76681 1.000 -12.5535 11.5393 
APTES-FeOx -.11582 3.76681 1.000 -12.1622 11.9306 
APTS-FeOx 
Gly-FeOx .45355 3.76681 1.000 -11.5929 12.5000 
Ser-FeOx .56396 3.76681 1.000 -11.4825 12.6104 
EDA-FeOx -70.81438* 3.76681 .000 -82.8608 -58.7680 
TEPA-FeOx -40.34087* 3.76681 .000 -52.3873 -28.2945 
ABA-FeOx .48792 3.76681 1.000 -11.5585 12.5343 
SAHBA-FeOx .72133 3.76681 1.000 -11.3251 12.7677 
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CMPVA-FeOx .50713 3.76681 1.000 -11.5393 12.5535 
APTES-FeOx .39131 3.76681 1.000 -11.6551 12.4377 
APTES-FeOx 
Gly-FeOx .06224 3.76681 1.000 -11.9842 12.1086 
Ser-FeOx .17265 3.76681 1.000 -11.8738 12.2191 
EDA-FeOx -71.20569* 3.76681 .000 -83.2521 -59.1593 
TEPA-FeOx -40.73218* 3.76681 .000 -52.7786 -28.6858 
ABA-FeOx .09661 3.76681 1.000 -11.9498 12.1430 
SAHBA-FeOx .33002 3.76681 1.000 -11.7164 12.3764 
CMPVA-FeOx .11582 3.76681 1.000 -11.9306 12.1622 
APTS-FeOx -.39131 3.76681 1.000 -12.4377 11.6551 
*. The mean difference is significant at the 0.05 level. 
 
Table A6. Descriptives for WST-1 cell proliferation assay at 24 hours. 
 N Mean Std. 
Deviation 
Std. Error 95% Confidence Interval for 
Mean 
Minimum Maximum 
Lower Bound Upper Bound 
PBS 6 100.0000 3.11791 1.27288 96.7280 103.2720 95.67 104.30 
Gly-FeOx 6 103.9668 2.43660 .99474 101.4097 106.5238 100.27 107.10 
Ser-FeOx 6 103.6124 4.09556 1.67200 99.3143 107.9104 98.29 109.01 
EDA-FeOx 6 104.1469 4.57737 1.86870 99.3432 108.9505 98.71 112.01 
TEPA-FeOx 6 7.4513 1.03709 .42339 6.3629 8.5397 6.27 9.16 
ABA-FeOx 6 102.0611 2.10804 .86061 99.8488 104.2733 98.78 104.45 
SAHBA-FeOx 5 109.1063 3.50315 1.56666 104.7565 113.4560 103.93 111.86 
CMPVA-FeOx 6 97.3286 3.54828 1.44858 93.6049 101.0523 92.98 102.38 
APTS-FeOx 4 96.1010 17.67964 8.83982 67.9688 124.2333 69.67 106.72 
APTES-FeOx 4 99.5506 35.46892 17.73446 43.1117 155.9896 47.06 122.74 
Total 55 91.6280 31.46880 4.24325 83.1208 100.1352 6.27 122.74 
 
Table A7. Descriptives for WST-1 cell proliferation assay at 48 hours. 
 N Mean Std. 
Deviation 
Std. 
Error 
95% Confidence Interval for 
Mean 
Minimum Maximum 
Lower Bound Upper Bound 
PBS 4 100.0000 17.95642 8.97821 71.4273 128.5727 74.86 114.99 
Gly-FeOx 4 101.8516 18.16914 9.08457 72.9404 130.7627 79.07 118.77 
Ser-FeOx 5 97.7795 20.18831 9.02849 72.7124 122.8466 67.57 123.76 
EDA-FeOx 6 65.8497 9.11565 3.72145 56.2834 75.4160 56.20 82.92 
TEPA-FeOx 6 8.4482 .97988 .40003 7.4198 9.4765 7.34 10.16 
ABA-FeOx 5 90.8483 18.15668 8.11991 68.3038 113.3928 73.24 114.86 
SAHBA-FeOx 4 94.9261 9.50615 4.75308 79.7997 110.0525 84.81 107.05 
CMPVA-FeOx 6 98.2567 3.55627 1.45184 94.5246 101.9888 92.62 102.96 
APTS-FeOx 6 108.2573 6.61101 2.69893 101.3194 115.1951 100.92 118.97 
APTES-FeOx 6 96.7339 8.62068 3.51938 87.6871 105.7808 80.71 103.41 
Total 52 84.5293 31.97574 4.43424 75.6272 93.4314 7.34 123.76 
 
Table A8. ANOVA values for cell proliferation WST-1 assay at 24 and 48 hours.  
 Sum of Squares df Mean Square F Sig. 
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Proliferation24 
Between Groups 48357.024 9 5373.003 47.238 .000 
Within Groups 5118.400 45 113.742   
Total 53475.424 54    
Proliferation48 
Between Groups 45893.541 9 5099.282 34.260 .000 
Within Groups 6251.304 42 148.841   
Total 52144.845 51    
 
Table A9. Tukey HSD post-hoc tests results for WST-1 cell proliferation assay at 24 hours. 
(I) Treatment (J) Treatment Mean 
Difference 
(I-J) 
Std. 
Error 
Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
PBS 
Gly-FeOx -3.96677 6.15744 1.000 -24.4520 16.5185 
Ser-FeOx -3.61236 6.15744 1.000 -24.0976 16.8729 
EDA-FeOx -4.14688 6.15744 1.000 -24.6321 16.3384 
TEPA-FeOx 92.54869* 6.15744 .000 72.0635 113.0339 
ABA-FeOx -2.06109 6.15744 1.000 -22.5463 18.4241 
SAHBA-FeOx -9.10628 6.45798 .918 -30.5914 12.3788 
CMPVA-FeOx 2.67141 6.15744 1.000 -17.8138 23.1567 
APTS-FeOx 3.89897 6.88423 1.000 -19.0042 26.8022 
APTES-FeOx .44937 6.88423 1.000 -22.4538 23.3526 
Gly-FeOx 
PBS 3.96677 6.15744 1.000 -16.5185 24.4520 
Ser-FeOx .35441 6.15744 1.000 -20.1308 20.8396 
EDA-FeOx -.18011 6.15744 1.000 -20.6653 20.3051 
TEPA-FeOx 96.51546* 6.15744 .000 76.0302 117.0007 
ABA-FeOx 1.90567 6.15744 1.000 -18.5796 22.3909 
SAHBA-FeOx -5.13951 6.45798 .998 -26.6246 16.3456 
CMPVA-FeOx 6.63818 6.15744 .984 -13.8471 27.1234 
APTS-FeOx 7.86573 6.88423 .977 -15.0375 30.7689 
APTES-FeOx 4.41613 6.88423 1.000 -18.4871 27.3193 
Ser-FeOx 
PBS 3.61236 6.15744 1.000 -16.8729 24.0976 
Gly-FeOx -.35441 6.15744 1.000 -20.8396 20.1308 
EDA-FeOx -.53452 6.15744 1.000 -21.0198 19.9507 
TEPA-FeOx 96.16105* 6.15744 .000 75.6758 116.6463 
ABA-FeOx 1.55127 6.15744 1.000 -18.9340 22.0365 
SAHBA-FeOx -5.49392 6.45798 .997 -26.9790 15.9912 
CMPVA-FeOx 6.28377 6.15744 .989 -14.2015 26.7690 
APTS-FeOx 7.51133 6.88423 .983 -15.3919 30.4145 
APTES-FeOx 4.06172 6.88423 1.000 -18.8415 26.9649 
EDA-FeOx 
PBS 4.14688 6.15744 1.000 -16.3384 24.6321 
Gly-FeOx .18011 6.15744 1.000 -20.3051 20.6653 
Ser-FeOx .53452 6.15744 1.000 -19.9507 21.0198 
TEPA-FeOx 96.69557* 6.15744 .000 76.2103 117.1808 
ABA-FeOx 2.08578 6.15744 1.000 -18.3995 22.5710 
SAHBA-FeOx -4.95940 6.45798 .999 -26.4445 16.5257 
CMPVA-FeOx 6.81829 6.15744 .981 -13.6670 27.3035 
APTS-FeOx 8.04584 6.88423 .973 -14.8573 30.9490 
APTES-FeOx 4.59624 6.88423 1.000 -18.3069 27.4994 
TEPA-FeOx 
PBS -92.54869* 6.15744 .000 -113.0339 -72.0635 
Gly-FeOx -96.51546* 6.15744 .000 -117.0007 -76.0302 
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Ser-FeOx -96.16105* 6.15744 .000 -116.6463 -75.6758 
EDA-FeOx -96.69557* 6.15744 .000 -117.1808 -76.2103 
ABA-FeOx -94.60979* 6.15744 .000 -115.0950 -74.1245 
SAHBA-FeOx -101.65497* 6.45798 .000 -123.1401 -80.1699 
CMPVA-FeOx -89.87728* 6.15744 .000 -110.3625 -69.3920 
APTS-FeOx -88.64973* 6.88423 .000 -111.5529 -65.7465 
APTES-FeOx -92.09933* 6.88423 .000 -115.0025 -69.1961 
ABA-FeOx 
PBS 2.06109 6.15744 1.000 -18.4241 22.5463 
Gly-FeOx -1.90567 6.15744 1.000 -22.3909 18.5796 
Ser-FeOx -1.55127 6.15744 1.000 -22.0365 18.9340 
EDA-FeOx -2.08578 6.15744 1.000 -22.5710 18.3995 
TEPA-FeOx 94.60979* 6.15744 .000 74.1245 115.0950 
SAHBA-FeOx -7.04519 6.45798 .983 -28.5303 14.4399 
CMPVA-FeOx 4.73250 6.15744 .999 -15.7527 25.2177 
APTS-FeOx 5.96006 6.88423 .997 -16.9431 28.8633 
APTES-FeOx 2.51046 6.88423 1.000 -20.3927 25.4137 
SAHBA-FeOx 
PBS 9.10628 6.45798 .918 -12.3788 30.5914 
Gly-FeOx 5.13951 6.45798 .998 -16.3456 26.6246 
Ser-FeOx 5.49392 6.45798 .997 -15.9912 26.9790 
EDA-FeOx 4.95940 6.45798 .999 -16.5257 26.4445 
TEPA-FeOx 101.65497* 6.45798 .000 80.1699 123.1401 
ABA-FeOx 7.04519 6.45798 .983 -14.4399 28.5303 
CMPVA-FeOx 11.77769 6.45798 .717 -9.7074 33.2628 
APTS-FeOx 13.00525 7.15430 .721 -10.7964 36.8069 
APTES-FeOx 9.55565 7.15430 .940 -14.2461 33.3573 
CMPVA-FeOx 
PBS -2.67141 6.15744 1.000 -23.1567 17.8138 
Gly-FeOx -6.63818 6.15744 .984 -27.1234 13.8471 
Ser-FeOx -6.28377 6.15744 .989 -26.7690 14.2015 
EDA-FeOx -6.81829 6.15744 .981 -27.3035 13.6670 
TEPA-FeOx 89.87728* 6.15744 .000 69.3920 110.3625 
ABA-FeOx -4.73250 6.15744 .999 -25.2177 15.7527 
SAHBA-FeOx -11.77769 6.45798 .717 -33.2628 9.7074 
APTS-FeOx 1.22756 6.88423 1.000 -21.6756 24.1307 
APTES-FeOx -2.22204 6.88423 1.000 -25.1252 20.6811 
APTS-FeOx 
PBS -3.89897 6.88423 1.000 -26.8022 19.0042 
Gly-FeOx -7.86573 6.88423 .977 -30.7689 15.0375 
Ser-FeOx -7.51133 6.88423 .983 -30.4145 15.3919 
EDA-FeOx -8.04584 6.88423 .973 -30.9490 14.8573 
TEPA-FeOx 88.64973* 6.88423 .000 65.7465 111.5529 
ABA-FeOx -5.96006 6.88423 .997 -28.8633 16.9431 
SAHBA-FeOx -13.00525 7.15430 .721 -36.8069 10.7964 
CMPVA-FeOx -1.22756 6.88423 1.000 -24.1307 21.6756 
APTES-FeOx -3.44960 7.54129 1.000 -28.5388 21.6396 
APTES-FeOx 
PBS -.44937 6.88423 1.000 -23.3526 22.4538 
Gly-FeOx -4.41613 6.88423 1.000 -27.3193 18.4871 
Ser-FeOx -4.06172 6.88423 1.000 -26.9649 18.8415 
EDA-FeOx -4.59624 6.88423 1.000 -27.4994 18.3069 
TEPA-FeOx 92.09933* 6.88423 .000 69.1961 115.0025 
ABA-FeOx -2.51046 6.88423 1.000 -25.4137 20.3927 
SAHBA-FeOx -9.55565 7.15430 .940 -33.3573 14.2461 
CMPVA-FeOx 2.22204 6.88423 1.000 -20.6811 25.1252 
APTS-FeOx 3.44960 7.54129 1.000 -21.6396 28.5388 
*. The mean difference is significant at the 0.05 level. 
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Table A10. Dunnett two-sided post-hoc tests results for WST-1 cell proliferation assay at 24 
hours. 
(I) Treatment (J) 
Treatment 
Mean 
Difference 
(I-J) 
Std. 
Error 
Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
Gly-FeOx PBS 3.96677 6.15744 .994 -13.3274 21.2609 
Ser-FeOx PBS 3.61236 6.15744 .997 -13.6818 20.9065 
EDA-FeOx PBS 4.14688 6.15744 .991 -13.1473 21.4410 
TEPA-FeOx PBS -92.54869* 6.15744 .000 -109.8428 -75.2546 
ABA-FeOx PBS 2.06109 6.15744 1.000 -15.2331 19.3552 
SAHBA-FeOx PBS 9.10628 6.45798 .658 -9.0320 27.2445 
CMPVA-FeOx PBS -2.67141 6.15744 1.000 -19.9656 14.6227 
APTS-FeOx PBS -3.89897 6.88423 .997 -23.2344 15.4365 
APTES-FeOx PBS -.44937 6.88423 1.000 -19.7848 18.8861 
b. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
 
Table A11. Tukey HSD post-hoc tests results for WST-1 cell proliferation assay at 48 hours. 
(I) Treatment (J) Treatment Mean 
Difference (I-
J) 
Std. Error Sig. 95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
PBS 
Gly-FeOx -1.85159 8.62672 1.000 -30.6548 26.9516 
Ser-FeOx 2.22047 8.18402 1.000 -25.1046 29.5456 
EDA-FeOx 34.15028* 7.87508 .003 7.8567 60.4439 
TEPA-FeOx 91.55184* 7.87508 .000 65.2582 117.8454 
ABA-FeOx 9.15172 8.18402 .980 -18.1734 36.4768 
SAHBA-FeOx 5.07392 8.62672 1.000 -23.7293 33.8771 
CMPVA-FeOx 1.74330 7.87508 1.000 -24.5503 28.0369 
APTS-FeOx -8.25726 7.87508 .987 -34.5509 18.0363 
APTES-FeOx 3.26608 7.87508 1.000 -23.0275 29.5597 
Gly-FeOx 
PBS 1.85159 8.62672 1.000 -26.9516 30.6548 
Ser-FeOx 4.07205 8.18402 1.000 -23.2531 31.3972 
EDA-FeOx 36.00187* 7.87508 .002 9.7083 62.2955 
TEPA-FeOx 93.40343* 7.87508 .000 67.1098 119.6970 
ABA-FeOx 11.00330 8.18402 .937 -16.3218 38.3284 
SAHBA-FeOx 6.92551 8.62672 .998 -21.8777 35.7287 
CMPVA-FeOx 3.59489 7.87508 1.000 -22.6987 29.8885 
APTS-FeOx -6.40567 7.87508 .998 -32.6993 19.8879 
APTES-FeOx 5.11766 7.87508 1.000 -21.1759 31.4113 
Ser-FeOx 
PBS -2.22047 8.18402 1.000 -29.5456 25.1046 
Gly-FeOx -4.07205 8.18402 1.000 -31.3972 23.2531 
EDA-FeOx 31.92981* 7.38748 .003 7.2642 56.5954 
TEPA-FeOx 89.33137* 7.38748 .000 64.6658 113.9970 
ABA-FeOx 6.93125 7.71597 .996 -18.8311 32.6936 
SAHBA-FeOx 2.85345 8.18402 1.000 -24.4717 30.1786 
CMPVA-FeOx -.47716 7.38748 1.000 -25.1428 24.1884 
APTS-FeOx -10.47773 7.38748 .915 -35.1433 14.1879 
APTES-FeOx 1.04561 7.38748 1.000 -23.6200 25.7112 
EDA-FeOx PBS -34.15028* 7.87508 .003 -60.4439 -7.8567 
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Gly-FeOx -36.00187* 7.87508 .002 -62.2955 -9.7083 
Ser-FeOx -31.92981* 7.38748 .003 -56.5954 -7.2642 
TEPA-FeOx 57.40156* 7.04369 .000 33.8838 80.9193 
ABA-FeOx -24.99856* 7.38748 .045 -49.6642 -.3330 
SAHBA-FeOx -29.07636* 7.87508 .020 -55.3700 -2.7828 
CMPVA-FeOx -32.40698* 7.04369 .001 -55.9247 -8.8893 
APTS-FeOx -42.40754* 7.04369 .000 -65.9253 -18.8898 
APTES-FeOx -30.88420* 7.04369 .003 -54.4019 -7.3665 
TEPA-FeOx 
PBS -91.55184* 7.87508 .000 -117.8454 -65.2582 
Gly-FeOx -93.40343* 7.87508 .000 -119.6970 -67.1098 
Ser-FeOx -89.33137* 7.38748 .000 -113.9970 -64.6658 
EDA-FeOx -57.40156* 7.04369 .000 -80.9193 -33.8838 
ABA-FeOx -82.40012* 7.38748 .000 -107.0657 -57.7345 
SAHBA-FeOx -86.47792* 7.87508 .000 -112.7715 -60.1843 
CMPVA-FeOx -89.80854* 7.04369 .000 -113.3263 -66.2908 
APTS-FeOx -99.80910* 7.04369 .000 -123.3268 -76.2914 
APTES-FeOx -88.28576* 7.04369 .000 -111.8035 -64.7680 
ABA-FeOx 
PBS -9.15172 8.18402 .980 -36.4768 18.1734 
Gly-FeOx -11.00330 8.18402 .937 -38.3284 16.3218 
Ser-FeOx -6.93125 7.71597 .996 -32.6936 18.8311 
EDA-FeOx 24.99856* 7.38748 .045 .3330 49.6642 
TEPA-FeOx 82.40012* 7.38748 .000 57.7345 107.0657 
SAHBA-FeOx -4.07780 8.18402 1.000 -31.4029 23.2473 
CMPVA-FeOx -7.40841 7.38748 .990 -32.0740 17.2572 
APTS-FeOx -17.40898 7.38748 .376 -42.0746 7.2566 
APTES-FeOx -5.88564 7.38748 .998 -30.5512 18.7799 
SAHBA-FeOx 
PBS -5.07392 8.62672 1.000 -33.8771 23.7293 
Gly-FeOx -6.92551 8.62672 .998 -35.7287 21.8777 
Ser-FeOx -2.85345 8.18402 1.000 -30.1786 24.4717 
EDA-FeOx 29.07636* 7.87508 .020 2.7828 55.3700 
TEPA-FeOx 86.47792* 7.87508 .000 60.1843 112.7715 
ABA-FeOx 4.07780 8.18402 1.000 -23.2473 31.4029 
CMPVA-FeOx -3.33062 7.87508 1.000 -29.6242 22.9630 
APTS-FeOx -13.33118 7.87508 .793 -39.6248 12.9624 
APTES-FeOx -1.80784 7.87508 1.000 -28.1014 24.4858 
CMPVA-FeOx 
PBS -1.74330 7.87508 1.000 -28.0369 24.5503 
Gly-FeOx -3.59489 7.87508 1.000 -29.8885 22.6987 
Ser-FeOx .47716 7.38748 1.000 -24.1884 25.1428 
EDA-FeOx 32.40698* 7.04369 .001 8.8893 55.9247 
TEPA-FeOx 89.80854* 7.04369 .000 66.2908 113.3263 
ABA-FeOx 7.40841 7.38748 .990 -17.2572 32.0740 
SAHBA-FeOx 3.33062 7.87508 1.000 -22.9630 29.6242 
APTS-FeOx -10.00056 7.04369 .914 -33.5183 13.5172 
APTES-FeOx 1.52277 7.04369 1.000 -21.9949 25.0405 
APTS-FeOx 
PBS 8.25726 7.87508 .987 -18.0363 34.5509 
Gly-FeOx 6.40567 7.87508 .998 -19.8879 32.6993 
Ser-FeOx 10.47773 7.38748 .915 -14.1879 35.1433 
EDA-FeOx 42.40754* 7.04369 .000 18.8898 65.9253 
TEPA-FeOx 99.80910* 7.04369 .000 76.2914 123.3268 
ABA-FeOx 17.40898 7.38748 .376 -7.2566 42.0746 
SAHBA-FeOx 13.33118 7.87508 .793 -12.9624 39.6248 
CMPVA-FeOx 10.00056 7.04369 .914 -13.5172 33.5183 
APTES-FeOx 11.52334 7.04369 .823 -11.9944 35.0411 
APTES-FeOx 
PBS -3.26608 7.87508 1.000 -29.5597 23.0275 
Gly-FeOx -5.11766 7.87508 1.000 -31.4113 21.1759 
Ser-FeOx -1.04561 7.38748 1.000 -25.7112 23.6200 
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EDA-FeOx 30.88420* 7.04369 .003 7.3665 54.4019 
TEPA-FeOx 88.28576* 7.04369 .000 64.7680 111.8035 
ABA-FeOx 5.88564 7.38748 .998 -18.7799 30.5512 
SAHBA-FeOx 1.80784 7.87508 1.000 -24.4858 28.1014 
CMPVA-FeOx -1.52277 7.04369 1.000 -25.0405 21.9949 
APTS-FeOx -11.52334 7.04369 .823 -35.0411 11.9944 
*. The mean difference is significant at the 0.05 level. 
 
Table A12. Dunnett two-sided post-hoc tests results for WST-1 cell proliferation assay at 48 
hours. 
(I) Treatment (J) 
Treatment 
Mean 
Difference 
(I-J) 
Std. 
Error 
Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
Gly-FeOx PBS 1.85159 8.62672 1.000 -22.0678 25.7710 
Ser-FeOx PBS -2.22047 8.18402 1.000 -24.9124 20.4715 
EDA-FeOx PBS -34.15028* 7.87508 .001 -55.9856 -12.3150 
TEPA-FeOx PBS -91.55184* 7.87508 .000 -113.3871 -69.7165 
ABA-FeOx PBS -9.15172 8.18402 .811 -31.8436 13.5402 
SAHBA-
FeOx 
PBS 
-5.07392 8.62672 .994 -28.9933 18.8455 
CMPVA-
FeOx 
PBS 
-1.74330 7.87508 1.000 -23.5786 20.0920 
APTS-FeOx PBS 8.25726 7.87508 .853 -13.5780 30.0926 
APTES-
FeOx 
PBS 
-3.26608 7.87508 1.000 -25.1014 18.5692 
b. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
 
Table A13.  Colony Assay Descriptive Statistics. 
 N Mean 
Std. 
Deviation 
Std. 
Error 
95% Confidence Interval 
for Mean 
Minimum Maximum 
Lower 
Bound Upper Bound 
No Particle - 0 
min 
6 100.017 26.4299 10.7899 72.280 127.753 66.1 137.6 
Particle - 0 min 6 87.167 14.2152 5.8033 72.249 102.085 68.8 110.1 
Extra Particle - 0 
min 
6 89.900 12.6366 5.1589 76.639 103.161 74.3 110.1 
No Particle - 10 
min 
6 100.450 19.2761 7.8694 80.221 120.679 77.1 132.1 
Particle - 10 min 6 62.850 13.4213 5.4792 48.765 76.935 44.0 85.3 
Extra Particle - 
10 min 
6 55.033 10.8971 4.4487 43.598 66.469 44.0 71.6 
No Particle - 15 
min 
6 107.333 22.4136 9.1503 83.812 130.855 71.6 137.6 
Particle - 15 min 6 53.667 9.9631 4.0674 43.211 64.122 35.8 63.3 
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Extra Particle - 
15 min 
6 26.600 7.0798 2.8903 19.170 34.030 13.8 33.0 
Total 54 75.891 30.1153 4.0982 67.671 84.111 13.8 137.6 
 
 
 
Table A14.  Colony Assay ANOVA Results. 
 Sum of Squares df Mean Square F Sig. 
Between Groups 36155.034 8 4519.379 17.072 .000 
Within Groups 11912.472 45 264.722   
Total 48067.505 53    
 
Table A15.  Colony Assay Dunnett (2-sided) Post Hoc Test Results. 
Multiple Comparisons 
Dependent Variable:   Survival   
Dunnett t (2-sided)
a
   
(I) Group (J) Group 
Mean Difference (I-
J) 
Std. 
Error Sig. 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
Particle - 0 min No Particle - 0 
min 
-12.8500 9.3936 .644 -38.778 13.078 
Extra Particle - 0 
min 
No Particle - 0 
min 
-10.1167 9.3936 .841 -36.045 15.811 
No Particle - 10 min No Particle - 0 
min 
.4333 9.3936 1.000 -25.495 26.361 
Particle - 10 min No Particle - 0 
min 
-37.1667
*
 9.3936 .002 -63.095 -11.239 
Extra Particle - 10 
min 
No Particle - 0 
min 
-44.9833
*
 9.3936 .000 -70.911 -19.055 
No Particle - 15 min No Particle - 0 
min 
7.3167 9.3936 .965 -18.611 33.245 
Particle - 15 min No Particle - 0 
min 
-46.3500
*
 9.3936 .000 -72.278 -20.422 
Extra Particle - 15 
min 
No Particle - 0 
min 
-73.4167
*
 9.3936 .000 -99.345 -47.489 
*. The mean difference is significant at the 0.05 level. 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
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Table A16.  Colony Assay Tukey HSD Post Hoc Test Results. 
Multiple Comparisons 
Dependent Variable:   Survival   
(I) Group (J) Group 
Mean Difference 
(I-J) 
Std. 
Error Sig. 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
No Particle - 
0 min 
Particle - 0 min 12.8500 9.3936 .904 -17.746 43.446 
Extra Particle - 0 min 10.1167 9.3936 .975 -20.480 40.713 
No Particle - 10 min -.4333 9.3936 1.000 -31.030 30.163 
Particle - 10 min 37.1667
*
 9.3936 .007 6.570 67.763 
Extra Particle - 10 min 44.9833
*
 9.3936 .001 14.387 75.580 
No Particle - 15 min -7.3167 9.3936 .997 -37.913 23.280 
Particle - 15 min 46.3500
*
 9.3936 .000 15.754 76.946 
Extra Particle - 15 min 73.4167
*
 9.3936 .000 42.820 104.013 
Particle - 0 
min 
No Particle - 0 min -12.8500 9.3936 .904 -43.446 17.746 
Extra Particle - 0 min -2.7333 9.3936 1.000 -33.330 27.863 
No Particle - 10 min -13.2833 9.3936 .886 -43.880 17.313 
Particle - 10 min 24.3167 9.3936 .220 -6.280 54.913 
Extra Particle - 10 min 32.1333
*
 9.3936 .033 1.537 62.730 
No Particle - 15 min -20.1667 9.3936 .456 -50.763 10.430 
Particle - 15 min 33.5000
*
 9.3936 .022 2.904 64.096 
Extra Particle - 15 min 60.5667
*
 9.3936 .000 29.970 91.163 
Extra Particle 
- 0 min 
No Particle - 0 min -10.1167 9.3936 .975 -40.713 20.480 
Particle - 0 min 2.7333 9.3936 1.000 -27.863 33.330 
No Particle - 10 min -10.5500 9.3936 .967 -41.146 20.046 
Particle - 10 min 27.0500 9.3936 .121 -3.546 57.646 
Extra Particle - 10 min 34.8667
*
 9.3936 .015 4.270 65.463 
No Particle - 15 min -17.4333 9.3936 .646 -48.030 13.163 
Particle - 15 min 36.2333
*
 9.3936 .010 5.637 66.830 
Extra Particle - 15 min 63.3000
*
 9.3936 .000 32.704 93.896 
No Particle - 
10 min 
No Particle - 0 min .4333 9.3936 1.000 -30.163 31.030 
Particle - 0 min 13.2833 9.3936 .886 -17.313 43.880 
Extra Particle - 0 min 10.5500 9.3936 .967 -20.046 41.146 
Particle - 10 min 37.6000
*
 9.3936 .007 7.004 68.196 
Extra Particle - 10 min 45.4167
*
 9.3936 .001 14.820 76.013 
No Particle - 15 min -6.8833 9.3936 .998 -37.480 23.713 
Particle - 15 min 46.7833
*
 9.3936 .000 16.187 77.380 
Extra Particle - 15 min 73.8500
*
 9.3936 .000 43.254 104.446 
Particle - 10 
min 
No Particle - 0 min -37.1667
*
 9.3936 .007 -67.763 -6.570 
Particle - 0 min -24.3167 9.3936 .220 -54.913 6.280 
Extra Particle - 0 min -27.0500 9.3936 .121 -57.646 3.546 
No Particle - 10 min -37.6000
*
 9.3936 .007 -68.196 -7.004 
Extra Particle - 10 min 7.8167 9.3936 .995 -22.780 38.413 
No Particle - 15 min -44.4833
*
 9.3936 .001 -75.080 -13.887 
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Particle - 15 min 9.1833 9.3936 .986 -21.413 39.780 
Extra Particle - 15 min 36.2500
*
 9.3936 .010 5.654 66.846 
Extra Particle 
- 10 min 
No Particle - 0 min -44.9833
*
 9.3936 .001 -75.580 -14.387 
Particle - 0 min -32.1333
*
 9.3936 .033 -62.730 -1.537 
Extra Particle - 0 min -34.8667
*
 9.3936 .015 -65.463 -4.270 
No Particle - 10 min -45.4167
*
 9.3936 .001 -76.013 -14.820 
Particle - 10 min -7.8167 9.3936 .995 -38.413 22.780 
No Particle - 15 min -52.3000
*
 9.3936 .000 -82.896 -21.704 
Particle - 15 min 1.3667 9.3936 1.000 -29.230 31.963 
Extra Particle - 15 min 28.4333 9.3936 .087 -2.163 59.030 
No Particle - 
15 min 
No Particle - 0 min 7.3167 9.3936 .997 -23.280 37.913 
Particle - 0 min 20.1667 9.3936 .456 -10.430 50.763 
Extra Particle - 0 min 17.4333 9.3936 .646 -13.163 48.030 
No Particle - 10 min 6.8833 9.3936 .998 -23.713 37.480 
Particle - 10 min 44.4833
*
 9.3936 .001 13.887 75.080 
Extra Particle - 10 min 52.3000
*
 9.3936 .000 21.704 82.896 
Particle - 15 min 53.6667
*
 9.3936 .000 23.070 84.263 
Extra Particle - 15 min 80.7333
*
 9.3936 .000 50.137 111.330 
Particle - 15 
min 
No Particle - 0 min -46.3500
*
 9.3936 .000 -76.946 -15.754 
Particle - 0 min -33.5000
*
 9.3936 .022 -64.096 -2.904 
Extra Particle - 0 min -36.2333
*
 9.3936 .010 -66.830 -5.637 
No Particle - 10 min -46.7833
*
 9.3936 .000 -77.380 -16.187 
Particle - 10 min -9.1833 9.3936 .986 -39.780 21.413 
Extra Particle - 10 min -1.3667 9.3936 1.000 -31.963 29.230 
No Particle - 15 min -53.6667
*
 9.3936 .000 -84.263 -23.070 
Extra Particle - 15 min 27.0667 9.3936 .121 -3.530 57.663 
Extra Particle 
- 15 min 
No Particle - 0 min -73.4167
*
 9.3936 .000 -104.013 -42.820 
Particle - 0 min -60.5667
*
 9.3936 .000 -91.163 -29.970 
Extra Particle - 0 min -63.3000
*
 9.3936 .000 -93.896 -32.704 
No Particle - 10 min -73.8500
*
 9.3936 .000 -104.446 -43.254 
Particle - 10 min -36.2500
*
 9.3936 .010 -66.846 -5.654 
Extra Particle - 10 min -28.4333 9.3936 .087 -59.030 2.163 
No Particle - 15 min -80.7333
*
 9.3936 .000 -111.330 -50.137 
Particle - 15 min -27.0667 9.3936 .121 -57.663 3.530 
*. The mean difference is significant at the 0.05 level. 
 
Table A17. The means and medians for survival time of each treatment group. 
Treatment 
 
Mean
a
 Median 
Estimate Std. 
Error 
95% Confidence 
Interval 
Estimate Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
PBS 29.375 1.085 27.249 31.501 28.000 .943 26.152 29.848 
FeOx 26.625 .844 24.971 28.279 26.000 1.414 23.228 28.772 
177Lu-DOTA 31.375 .905 29.601 33.149 31.000 .306 30.400 31.600 
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177Lu-D-SAHBA-FeOx 46.625 7.486 31.953 61.297 40.000 3.423 33.290 46.710 
177Lu-D-CMPVA-FeOx 43.250 2.724 37.911 48.589 42.000 1.369 39.316 44.684 
Overall 35.450 2.000 31.529 39.371 31.000 1.054 28.934 33.066 
a. Estimation is limited to the largest survival time if it is censored. 
 
Table A18. Results of pairwise comparison of log rank (Mantel-Cox) test for each treatment in 
the survival study. 
Treatment PBS FeOx 177Lu-DOTA 177Lu-D-
SAHBA-FeOx 
177Lu-D-
CMPVA-FeOx 
Chi-
Square 
Sig. Chi-
Square 
Sig. Chi-
Square 
Sig. Chi-
Square 
Sig. Chi-
Square 
Sig. 
PBS   3.586 .058 1.079 .299 12.479 .000 16.964 .000 
FeOx 3.586 .058   12.494 .000 16.897 .000 16.897 .000 
177Lu-DOTA 1.079 .299 12.494 .000   11.396 .001 13.327 .000 
177Lu-D-SAHBA-
FeOx 
12.479 .000 16.897 .000 11.396 .001   .007 .933 
177Lu-D-
CMPVA-FeOx 
16.964 .000 16.897 .000 13.327 .000 .007 .933   
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